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Abstract 
Single particle mass spectrometry techniques were applied to the analysis of aerosol 
particles originating from inhaler devices, used to deliver pharmaceuticals for the 
treatment of lung disease such as asthma. 
The inhalation products studied were Seretide® for which the formulated drug product 
is composed of a blend of fluticasone propionate (FP) which is a corticosteroid and 
salmeterol xinofoate (SX) which is a long acting f3- agonist. It has been suggested 
previously that the formation of particles that are composed of both FP and SX by co- 
association can give improved efficacy: however in the past it has been difficult to 
analyze this type of co- associated particle. Hence, the purpose of the work described 
in this thesis was to develop single particle mass spectrometry methods that could 
assess the degree of co- association between FP and SX in fine aerosolized particles 
emitted from the inhaler devices. 
Two types of inhaler device were investigated and these were pressurized metered 
dose inhalers ( pMDIs) and dry powder inhalers (DPIs). The formulated product for 
pMDIs was a blend of FP and SX held in a suspension of propellant in a pressurized 
canister. The formulated product for the DPIs is comprised of a blend of FP and SX 
and an excipient lactose. 
Two commercial single particle mass spectrometers were used in this work; an 
Aerosol Time -of- Flight Mass Spectrometer (TSI, Shoreview, MN, USA) and an 
Aerodyne Aerosol Mass Spectrometer (Aerodyne, Billerica, MA, USA). Although the 
general layout of these instruments was similar in that they are both comprised of an 
iv 
inlet, a particle sizing region and a mass spectrometer, there were some differences in 
their design. For example, the ionization source of the Aerosol Time -of- Flight Mass 
Spectrometer used a single step process involving laser ablation and ionization while 
the Aerodyne Aerosol Mass Spectrometer used a two step process involving thermal 
desorption from a hot plate followed by electron ionization. These instruments were 
compared and evaluated in terms of their design and the characteristics of the data 
acquired on aerosols of pharmaceutical materials. 
Data analysis methods for single particle mass spectrometry were developed based on 
the mass spectrometric fragmentation patterns indicative of either pure or co- 
associated particles. Data analysis was performed by either using representative ions 
from the mass spectrum taken from each particle or by using multivariate statistical 
analysis as a pattern recognition tool applied to the complete mass spectrum for each 
particle. 
High levels (above 50 %) of co- association were found in the emitted doses from both 
pMDI and DPI products. Although the design of each instrument was different, 
reasonable agreement in the levels of co- association was found as long as the size of 
particle that was analyzed by the mass spectrometer in each case was taken into 
account. 
Finally a comparison of the applicability of each of the commercial single particle 
mass spectrometers to the analysis of materials taken from pharmaceutical aerosols 
was made. Recommendations for future work on instrument development and further 
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Single particle mass spectrometry (SPMS) can give detailed information on aerosol 
particle size and composition in -situ, in near real -timer. In the past, SPMS has been 
predominantly used to investigate environmental aerosols; these studies are important 
as aerosol particles found in the environment, such as automobile emissions or 
industrial waste emissions, can potentially have a detrimental effect on human health2. 
The interaction of particles with lung tissue can also have a positive effect on human 
health3. Medicinal products composed of particles of drug material are designed, 
manufactured and incorporated in inhaler devices used for the treatment of lung 
disease such as asthma. A significant amount of the chemical analysis of these types 
of materials involves particle size measurement and composition determination, 
therefore the application of SPMS to the analysis of medicinal aerosols is an attractive 
concept. 
Information obtained on particle size and composition, in -situ in pharmaceutical 
aerosols, using SPMS equipment may give some real benefit in increasing the 
understanding of current inhalation products and improving future manufacturing 
processes and products. Hence the major objectives of this research were (i) to 
develop SPMS techniques for the analysis of inhalation products, (ii) to use SPMS to 
investigate co- association in particles taken from inhalation products and (iii) to 
evaluate the application of two commercially available SPMS instruments to the 
analysis of inhalation products. 
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1.2 The Drug Discovery and Development Process 
The pharmaceutical industry is a complex, expensive and time consuming business4. 
The process of drug discovery and development has an associated high risk (not least 
in financial terms), but with potentially high rewards in terms of the discovery of 
medicines for the treatment of life -threatening diseases. 
The classical process of drug discovery involved the synthesis of small molecules 
followed by biological testing to ascertain pharmacological activity. The active 
ingredients in GSK's "blockbuster" drug products (those which have made more than 
one billion dollars per year) such as Paxil® for depressions' 6, Tagamet® an anti -ulcer 
treatment's and Seretide® for lung disease9' 10' 11, were developed in this way. 
In the 1980s, many compounds were synthesized individually then submitted for 
biological testing, whereas during the 1990s, the drug discovery divisions of many of 
the larger pharmaceutical companies automated this process. Using this approach 
millions of compounds per year are screened in disease areas such as cancer, cardio- 
vascular disease, central nervous system disorders, infectious disease, HIV, and lung 
disease12'13 
At the time of writing, as the market is so competitive, many of the larger and well 
established Pharmaceutical companies (termed `Big Pharma') are undergoing a 
restructuring process. Moreover, it appears likely that the small biopharmaceutical 
companies of today will become the `Big Pharma' companies of the future. This is 
because, in recent years, the approach to drug discovery has changed; for example 
during the biotechnology boom of the late 1990s, drug discovery platforms based on 
monoclonal antibodies14, and on antisense or gene -therapy's' 16, produced drugs based 
on larger biological molecules rather than smaller synthetic ones, giving products that 
are easier to protect via intellectual property. 
Having identified an active drug compound, the development of an efficacious 
formulated drug product that can be successfully marketed can be a technically 
complex process. New drugs must be shown to be safe and to have an efficacy 
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advantage over currently marketed compounds. Hence, for compounds that show 
biological activity and reach early development there is still a high attrition rate 
typically because of safety issues, or because only minimal advantage over existing 
products can be shown. Moreover, during the course of the drug development process, 
the pharmaceutical company must fulfil the requirements of the regulatory authorities. 
Agencies such as the Food and Drug Administration (FDA)I7 in the USA and the 
Medicines and Healthcare Products Regulatory Agency (MHRA)'8 in Europe have a 
remit to ensure patient safety and enforce strict guidelines on drug development and 
marketing. 
The patent on a new chemical entity i.e. the drug compound per se, lasts for 20 
years19. Therefore the pharmaceutical company has a limited time to develop the 
compound into a formulated product, test it for safety and efficacy, and then to market 
it. 
The significance of the finite lifetime of the patent is that when the patent has lapsed, 
generic drug companies may start to produce the given product. The cost of research 
and development for the generic company is minimal so invariably generic companies 
can sell similar products at a discount compared with the price charged by the original 
company. This typically results in a reduction in sales for the company that invested 
in research and development to produce the original product and reduces (or finishes) 
their involvement with the given product. 
It is a challenging task to understand the biology and chemistry of the drug 
compound, produce a formulated product and establish the manufacturing process 
within a finite amount of time. Hence, within the pharmaceutical industry there is a 
constant search for new technologies that may aid the understanding of the processes 
and products involved, as well as methods for progressing compounds through 
development as fast as possible while retaining the quality of the process and product. 
Clearly, there would be some advantage in reducing the time taken for drug 
development in terms of (a) getting the product to the patient and (b) recouping the 
many millions of dollars that are invested to develop each drug from active compound 
to marketed product. 
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Chemical analysis is an important part of many of the stages of the drug development 
process and many of the chemical analyses performed in the drug discovery and 
development processes are based on high performance liquid chromatography 
(HPLC). For example, stability testing and accelerated degradation studies commonly 
rely on this technique. However, to be able to perform HPLC analysis the sample 
must be in the appropriate format. For example, to analyze the drug content of a 
tablet, the sample preparation might involve dissolution, filtration extraction and/or 
derivatization of the tablet materia120'21. This is resource- intensive and time - 
consuming especially as there may be a need to analyze many thousands of tablets 
every year. 
Hence within the pharmaceutical industry there is a constant evaluation of novel 
analytical technologies that may enable the faster chemical analysis and greater 
understanding of pharmaceutical related materials. For example, recently it has been 
shown that a tablet may be analyzed non -invasively and automatically with techniques 
such as near infra -red22 or Raman spectroscopy23. It may be possible to reduce the 
time and cost of each analysis in the future using this approach. 
1.3 Lung Disease 
One of the major disease areas targeted by GlaxoSmithKline (GSK) is that of lung 
disease of which the two major types are asthma and chronic obstructive pulmonary 
disease (COPD). 
Asthma is a chronic disease characterized by recurrent attacks of breathlessness and 
wheezing. During an asthma attack the lining of the bronchial tubes swells causing the 
airways to narrow, reducing the air flow into and out of the lungs. According to World 
Health Organisation (WHO) estimates, in 2007, 300 million people suffered from 
asthma and 210 million suffered from COPD24. The causes of asthma are not 
currently completely understood although allergens, tobacco smoke and chemical 
irritants such as air pollutants have been identified as triggers for the disease. Asthma 
can be controlled by avoidance of these triggers for example through life -style 
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changes such as smoking cessation24 and by treatment using inhalation products such 
as those described in Section 1.4. 
COPD is a more severe lung disease, which is characterised by chronic obstruction of 
lung airflow that interferes with normal breathing and is not fully reversible. The 
common terms `chronic bronchitis' and `emphysema' are included within the COPD 
term. The most common symptoms of COPD are breathlessness, excessive sputum 
production and a chronic cough. The causes of COPD include tobacco smoke 
(including passive exposure), air pollution and occupational aerosols, dusts and 
chemicals. COPD is controlled25 by the avoidance of tobacco smoke (and other 
irritating dust particles) and by treatment using inhalation products such as those 
described in the next section. 
1.4 Characteristics of Inhalation Products 
Medicines for the treatment of lung disease are typically based on drug particles 
delivered directly to the lung (for increased speed of response to the drug), via an 
aerosol produced by either a dry powder inhaler (DPI) or a pressurized metered dose 
inhaler (pMDI) and such devices are termed inhalation products. The analysis of 
material from this type of product is based on the particle size and the drug dose, and 
it is typically performed using an Anderson Cascade Impactor (ACI)26 which is 
discussed in more detail later in this section. Analyses to determine the particle size 
distribution can be performed on the formulated product using ACI but do not give 
speciation data, i.e. whether particles contain drug, excipient or both and in what ratio. 
Also, sample preparation and analysis of samples using an ACI can be both time 
consuming and complex. 
Asthma is typically treated with corticosteroids27, 13- agonists28 or a combination of 
both29. Examples of corticosteroids include fluticasone propionate (FP) and 
budesonide; examples of ß -agonists include salmeterol xinofoate (SX) and 
formeterol. The active pharmaceutical ingredients in the GSK inhaler devices 
investigated in the studies described in this thesis were FP and SX and the chemical 
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structures of these compounds are shown in Table 1.1. Some of the major products 
in 
the asthma/COPD market are shown in Table 1.2. 
Fluticasone propionate 
(FP) 




Salmeterol xinofoate (SX) 
Salmeterol (free base) 
Cas H37 N 04 
MW 415 
OH OH Xinofoate 
C11 H8 03 
MW 188 
Table 1.1. The chemical structure, chemical formulae and molecular weights for the 
inhaled corticosteroid (ICS) fluticasone propionate (FP) and the long acting ß- 
agonist (LABA) salmeterol xinofoate (SX), the active drugs in many GSK inhaler 
products. 
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Product Company Device* Active drug Used for Reference 



































Ventolin® GSK pMDI Salbutamol Asthma 34 
Table 1.2. Examples of marketed inhalation products used for the treatment of asthma 
and chronic obstructive pulmonary disorder (COPD). * DPI =Dry powder inhaler, 
pMDI= pressurized metered dose inhaler, see text for a more detailed description. 
f Note that the same product is marketed as Advair® in the US and Seretide® in 
Europe. 
The formulations in the dry powder inhalers produced by GSK use FP or /and SX as 
the active drugs. These are available as prescription medicines such as Flovent® a 
blend of FP and lactose30 or Serevent® a blend of SX and lactose31. DPIs are also 
available as a combination of both FP and SX blended with lactose and this type of 
inhaler is discussed in detail in Section 1.5. 
Lactose is used as an excipient in many of the GSK DPI products. Excipients are 
materials added to the formulation that have no therapeutic activity. In this case 
lactose provides bulk to the formulation and is used as a carrier for the active drug(s). 
The Diskus® DPI, consists of a strip of blisters as shown in Figure 1.1(b) held within 
the Diskus® device shown in Figure 1.1(a). On actuation of the device the blister is 
ruptured and the contents (a single dose) inhaled by the patient. 
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Figure 1.1. A photograph of (a) The Diskus® device and (b) the strip of blisters 
containing the formulated product. The formulated product is delivered to the patient 
as the blister is ruptured, by actuation of the device. Note that this product is 
marketed as Advair® in the US and Seretide ® in European 
Three formulations of Seretide® DPI of varying drug strength were investigated in the 
studies reported in this thesis; FP 500 jig /SX 50 µg, FP 250 µg /SX 50 µg and FP 125 
µg /SX 50 µg. The range of formulations covers adult and paediatric therapies. 
Throughout this thesis these formulations are referred to by the shortened term 
"FP /SX 500/50" etc. 
An alternative DPI device (Gemini ®) currently under development, was also 
investigated during the work reported in this thesis. This device allowed two blisters 
to be ruptured for each actuation and in this case FP and SX were separately blended 
with lactose so that the FP and SX were not mixed until the device was actuated. 
The pressurized metered dose inhaler (pMDI), is an alternative inhaler device which 
consists of a canister containing a suspension of the drug, in a propellant, together 
with a surfactant. A diagram of a pMDI canister is shown in Figure 1.2 together with 
a photograph of the device. When activated, the pMDI gives a short burst of the drug 
suspension which is released in the form of a polydisperse aerosol. The amount of 
material in the aerosol is metered by a valve in the device. 
The product range for the GSK pMDI devices is analogous to the DPI range in that 
the formulations are based on FP, SX or a combination of both. The combination 
products used in this thesis comprised the formulations FP 250 jig /SX 25 µg, FP 125 
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µg /SX 25 µg and FP 50 µg /SX 25 µg (as for the DPI devices these will be referred to 
by the shortened term "FP /SX 50/25" etc.). 










(b) Actuator body 
a a 
Mouthpiece 
Figure 1.2. (a) Photograph of metered dose inhaler device (b) diagram showing the 
internal components of the pMDI device35 
1.5 Synergy Between Drugs in Combination Inhalers 
Although corticosteroids and ß- agonists can be prescribed separately, in clinical 
practice it has been found that two drugs in combination give a significantly greater 
efficacy than the individual drugs, or the anticipated efficacy for the sum of the 
individual compounds36 
This study36 is summarized in the graph given in Figure 1.3, which shows the efficacy 
after dosing with (i) either FP or SX (shown as traces (d) and (e) )(ii) FP and SX 
concurrently (shown as trace (b)) and (iii) as a blend from the same inhaler 
(Seretide ®) (shown as trace (a)). The graph shows that the efficacy is lowest when the 
two materials are dosed separately and highest when dosed as a blend. The expected 
efficacy of the sum of FP and SX is exceeded by the two inhalers administered 
concurrently; however, a blend of FP and SX gives a much higher efficacy than 
anticipated. 
9 
Chapter 1- Introduction 
A synergistic effect may explain the higher than anticipated increase in efficacy for 
the blend of FP and SX (Seretide ®) and it could be derived from both compounds 
making contact with the same lung tissue cells simultaneously. Also, if the 
formulations contained individual particles that were comprised of both active 
ingredients (FP and SX), this would give an increased likelihood of the deposition of 
both drugs simultaneously on the same lung tissue, compared with the administration 
of both drugs via two separate inhalers36. Hence, an investigation of the composition 
of particles emitted from inhalation products was a major objective of the work 
described in this thesis. 
Pharmaceutical synergy 
Molecular synergy 
_ _ _ _ _ _ _ _ _ _ (c) Additive (expected) - (FP +SX) 
(a) Seretide (1 inhaler) 
(b) Concurrent FP +SX 
(2 inhalers) 
i t 
A - (d) SX alone 
(e) FP alone 
Time 
Figure 1.3. The relative efficacy of FP and SX dosed (a) as a blend in a single 
Seretide® inhaler (b) concurrently with two separate inhalers, (c) the expected 
additive effect and, (d) and (e) as SX or FP alone. The top curve (a) shows a much 
higher than expected efficacy for a blend of FP and SX than for the two drugs 
administered separately or concurrently suggesting a synergistic effect 36 
1.6 The Analysis of Inhalation Products 
There are several analytical tests that are performed on the pharmaceutical materials 
that originate from commercially available inhaler devices37. Most of the analytical 
work performed on inhalation products is centred on the determination of particle size 
and overall composition. 
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The size of the particles originating from inhalation products is an important aspect of 
their mode of action. Intuitively, it might be expected that if the particles are too small 
then they could be prone to the typical tidal effects seen during respiration, i.e. the 
particles might be inhaled but then rapidly exhaled without depositing and therefore 
have no pharmacological effect. In contrast, if the particles are too large they could be 
expected to lodge in the upper airways (typically the throat) and then be swallowed 
without reaching the lung. 
In practice when designing inhalation products, a number of factors are considered 
including the required target region of the lung, the deposition mechanism, the 
inhalation profile of the patient (e.g. adult, child etc.) and the dose strength required38. 
Conventional analysis of particles contained in aerosols involves the measurement of 
particle size. This type of measurement is usually derived from two different 
analytical approaches. These are either (i) microscopy -based measurements to 
determine large particles, foreign particles and agglomerates39 or (ii) aerodynamic 
measurements to measure the particle size of the drug particles4o 
Historically, it has been difficult to perform in -situ analysis of individual particles 
within the aerosol plume of the product. Instead, the contents of a pMDI or DPI would 
typically be analyzed using a Andersen Cascade Impactor (ACI) apparatus26' 
4i as 
shown in Figure 1.4. 
The ACI is effectively used as a surrogate in -vivo technique to mimic the penetration 
of particles into the lung. The depth of penetration of particles of different size is 
shown by the diagram to the right in Figure 1.4. For example, particles of diameters 
between 2.1 and 3.3 gm will be collected at Stage 4 which equates to particles 
reaching the secondary bronchi42. 
For the analysis of materials produced by an inhaler, the inhaler device is actuated and 
the contents swept into the ACI. A flow of air passes through the stack of plates and 
particles are deposited onto a particular plate depending on aerodynamic size and 
inertia. Hence if the particle has enough inertia it will be deposited onto the plate, 
which means that the larger particles are deposited onto the plates in the first stages of 
11 
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the ACI. As the jets get smaller with each stage, the air velocity becomes faster and 
the smaller particles collect sufficient inertia to be deposited on the plates of the final 
stages of the ACI. Each of the series of plates is then washed and the washings 
assayed off -line using HPLC. 
Andersen Cascade Impactor 
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C, Ot -'.' alveoli 
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0.43 -0.55 alveoli 
Cutoffs shown correspond to 28 L /min. 
Adjusted for other flow rates. 
Figure 1.4. The Andersen Cascade Impactor (ACI). The left side of panel shows the 7 
plates of the ACI device each of which will catch particles in different size ranges. 
The right side of the panel shows the significance of these particle size ranges in 
terms of the depth of penetration into the lungs(particle sizes given in ,um) 35 
The ACI effectively gives an averaged measurement of the composition of groups of 
particles; however, to be able to study co- association, further detail is required to the 
extent of an assessment of the composition of each of the individual particles within a 
given sample population. 
A previous study of individual particles taken from inhaler devices used Raman 
imaging of plates taken from the ACI to identify and classify the particles and to 
assess the co- association between FP and SX in pMDIs43. This work reported that co- 
association could be measured and the degree of co- association estimated based on 
statistical analysis. However, the Raman imaging technique used was relatively slow 
(a few hours per sample) and could measure only relatively small numbers of particles 
per experiment. 
12 
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The ACI and Raman techniques described above are both off -line techniques i.e. the 
sample is collected and then analyzed at a later time. Limitations for off -line 
techniques include the possibility of artefact formation due to a change in the physical 
and/or chemical constitution of the analyte, for example during transportation or 
storage. Also, off -line analysis can involve a complex and resource- intensive sample 
preparation step, typically to extract the drug from the matrix of excipients included in 
the formulation. 
Hence it would be of great benefit to develop and apply an analytical technique, 
applicable to inhalation products, that would allow analysis of particles directly from 
the aerosol plume and provide insight into the identity of the active pharmaceutical 
ingredients within each particle. 
A technique that could deliver information on particle size and give detailed 
information on the composition of particles found in pharmaceutical aerosols might 
help to improve our understanding of this type of product and improve the 
formulation of future medicines. 
1. 7 Single Particle Mass Spectrometry (SPMS) 
The single particle mass spectrometer is capable of measuring both particle size and 
composition in near real -time directly from the aerosol. The development of single 
particle mass spectrometry (SPMS) started in the early 1970s with a major driver 
being the analysis of atmospheric aerosols"' as 
A diagram to show the regions of a typical single particle mass spectrometer is given 
in Figure 1.5. The instrument comprises an inlet, a particle sizing region, a 
vaporization/ionization section and a mass spectrometer. Much of the development of 
this type of instrumentation has focussed on one or more of these areas. 
A more detailed account of the development of SPMS is given in Section 2.2 together 
with a detailed description of the two commercially available instruments used to 
acquire the data presented in this thesis. 
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Figure 1.5. The major components of a single particle mass spectrometer. The inlet 
system converts a cloud of particles from an aerosol into a particle beam; the size of 
each particle is then measured before it is vaporized and ionized prior to the analysis 
of composition using the mass spectrometer. 
In the past, the main application for this type of instrument has been in environmental 
monitoring. Atmospheric aerosols have been shown to consist of a variety of materials 
including pollutants46, cigarette smoke47, fibres", and biological material such as 
bacterial or fungal spores49. Hence, the technique of SPMS has been used to analyze 
particles found in atmospheric aerosols of the particle types listed above 
(pollutants50, 
50a,50ó, cigarette smoke51, fibres52, bio- aerosols53) as well as many other types of 
particle found in the atmosphere. These studies are important as it is well known that 
particulate matter can interact with lung tissue and result in lung disease54' 
55 
Some of the particles in atmospheric aerosols studied by SPMS are in a similar size 
range to the drug particles found in inhalation products. Although the application of 
this technique to pharmaceutical aerosols is an attractive concept, reports of such 
applications in the literature are rare. 
1.8 Application of Single Particle Mass Spectrometry to the 
Analysis of Pharmaceutical Aerosols 
The real time (or near real -time) acquisition of data on particle size and composition 
has the potential to give unique information on the particles within the aerosols 
produced by both DPIs and pMDIs. Previous reports of the application of SPMS to 
pharmaceutical analysis are discussed below. 
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The analysis of a Ventolin® pMDI using aerosol time -of -flight mass spectrometry 
showed that optimum results were obtained if the pMDI was actuated into a large 
glass vessel (19 L). In this case several thousand particles could be sampled over a 30 
to 40 minute period. The mass spectra showed fragmentation that could easily be 
interpreted in terms of the active pharmaceutical ingredients56 
The analysis of an MDI (Combivent ®) has also been reported without the use of a 
sampling vessel. This was sampled via a spacer tube and a flow of air at 1.5 L /min 
was used to sweep material into the AToFMS instrument. For these experiments 
indicative ions in the mass spectra were used as markers for specific compounds; for 
example the ions at m/z 79/81 from the Br ion were shown to be unique for one of the 
active pharmaceutical ingredients (ipratropium) and m/z 97/99 was shown to be 
unique to the sulphate counter- ion57' 58 
For some initial work on the study of co- association between active pharmaceutical 
ingredients in inhalation products, using an AToFMS instrument, a sampling chamber 
was used to introduce the sample to the instrument. In that study, unequivocal 
evidence of co- association between the active drugs in the Symbicort® Turbuhaler® 
(Budesonide/ Formeterol) DPI, was not obtained. In contrast, good evidence for the 
presence of co- association between the active pharmaceutical ingredients in a 
Seretide® (SX and FP) DPI was obtained59 
1.9 Data Analysis for Single Particle Mass Spectrometry. 
Inhalation products are well defined in terms of the pharmaceutical ingredients that 
are used in the formulation. Whereas for environmental aerosols many unknown 
compounds (perhaps lOs or 100s) need to be detected and identified, there are only a 
few (typically 3 or 4) components in the formulation of the inhalation products. 
Moreover samples of standards of the pharmaceutical ingredients and excipients are 
readily available, which is not always the case for environmental analysis. 
For pMDIs the materials in the formulation consist of drug compound(s) and 
propellant. If the aerosol is expanded into a glass vessel, the propellant evaporates and 
15 
Chapter 1- Introduction 
typically is not detected by the mass spectrometer. This means that for a pMDI 
containing two active drug compounds (e.g. FP and SX), there are three possible 
categories of particle composition. These are pure FP particles, pure SX particles and 
particles that consist of a mixture of FP and SX because of co- association between the 
two compounds. 
For DPIs the materials in the formulation consist of drug compound(s) and a carrier, 
typically lactose. This means that for a DPI containing two active drug compounds 
(e.g. FP and SX), there are seven possible categories of particle composition. These 
are pure FP, pure SX or pure lactose (La) and also FP /SX, FP/La, SX/La and 
FP /SX/La. 
In a typical data set obtained from a SPMS experiment, a mass spectrum is associated 
with an individual particle. The SPMS mass spectrum typically shows many ions 
across the m/z scale and there may commonly be a few hundred particles in every data 
set. Clearly there is potential for acquiring large amounts of data and a co- ordinated 
approach to the data analysis is required both in terms of interrogating individual 
samples and in comparison of different sample sets. 
Multivariate Statistical Analysis (MVA)60 can be extremely useful for the analysis of 
large complex data sets and has been applied to SPMS data as a pattern recognition 
tool. This can be useful for both single sample analysis and for comparing data sets. 
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In the first part of this chapter the historical development of single particle mass 
spectrometers, from the early 1970s to the present time, is discussed with an emphasis 
on the instruments and techniques used for the work described in this thesis. 
For the single particle mass spectrometry experiments on inhalation products no 
sample preparation was required. However because material is released from the 
inhaler device during a short period (less than 1 second) after actuation, it was 
necessary to condition the sample using the apparatus described in Section 2.4.1. 
In the latter part of this chapter (Sections 2.4.2 and 2.4.3) a detailed description is 
given of the operation of the commercially available Aerosol Time -of- Flight Mass 
Spectrometer (AToFMS) (TSI, Shoreview, MN, USA) and the Aerodyne Aerosol 
Mass Spectrometer (AAMS) (Aerodyne, Billerica, MA,USA). 
2.2 A Brief History of Single Particle Mass Spectrometry 
In the early 1970s a proposal was outlined for an instrument that could identify the 
chemical composition of aerosols in real -time (or near real -time). It was predicted that 
the linking the composition and size of each individual particle in a given aerosol 
would be very useful, but was difficult with the contemporary instrumentation'. 
Among the drivers for developing the single particle mass spectrometry technique, 
was the importance of measuring particle size and composition in relation to lung 
function. This aligned the analysis of particles with mass spectrometry and aerosols 
that could interact with the lungs; for example, cigarette smoker. 
22 
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The main features of single particle mass spectrometers are summarized in Section 
1.7. The history of some of the most significant advances of single particle mass 
spectrometry since the early 1970s is summarized in Table 2.13 
to 24 Several reviews 
of this area are available in the literature3'4'5 and only a brief overview is given here. 
Much of the development of this type of instrumentation has been focussed on the 
inlet system, the particle sizing region and the mass spectrometer, and these are 
described in more detail in Section 2.3. 
2.3 The Components of the Single Particle Mass Spectrometer 
2.3.1 Inlets 
The inlet device has a role in delivering the particles from the aerosol cloud into the 
mass spectrometer as a focussed beam25. The first SPMS instruments used a needle 
valve and a pinhole orifice to introduce the sample into the ionization source region. 
This type of inlet was not very efficient in terms of particle transmission (e.g. Davis6 
reported a particle transmission/detection efficiency of 0.2 to 0.3 %) as it was 
susceptible to errors because of beam divergence. Later a more controlled method for 
sample introduction was developed where the particles entered the instrument through 
a capillary- nozzle inlet8. 
A nozzle - skimmer inlet was used on a number of versions of the AToFMS 
instrument16. A diagram of a nozzle - skimmer inlet is shown in Figure 2.1. Using this 
device a particle beam is formed when the aerosol expands through the converging 
nozzle into the vacuum. For this inlet, the pressure differential between the 
atmosphere at -760 Torr and the inside of the inlet at -2 Torr (1 Ton = 133 Pa), 
causes the gas to undergo a supersonic expansion during which small particles are 
accelerated to higher terminal velocities than the larger particles26. The size -dependent 
velocity distribution is the basis for determining the aerodynamic diameter of particles 

































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 2- Instrumentation for Single Particle Mass Spectrometry 
Figure 2.1 shows that the inlet device consists of a nozzle and a skimmer; the function 
of the nozzle is as an interface between the atmosphere and the first stage of vacuum 
i.e. it allows a reduction in pressure (to -2 Torr ( -266 Pa)). The function of the 
skimmer, located prior to the particle sizing region, is primarily to collimate the 
particle beam. 
A limitation of the nozzle -skimmer interface is that not all of the particles are 
transmitted with equal efficiency. It has been shown that the larger particles are 
transmitted with a higher efficiency than smaller particles, and that a correction must 
be used to relate the transmission efficiency to the aerodynamic diameter of each 
particle27. This correction is effectively a calibration which is used to scale the 
AToFMS data to yield continuous mass concentrations as a function of particle size 
over the sampling time and has been applied in a number of environmental studies27. 
However the data presented in this thesis, acquired using the nozzle -skimmer inlet, 
was used only to determine the presence of co- association independently of the 
particle size measurement; hence a correction factor was not applied in this case. 
First stage 
pump 
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Figure 2.1. Diagram of the nozzle -skimmer inlet used for the AToFMS instrument. As 
there is a pressure drop across this inlet, particles are accelerated to different 
velocities depending on size before entry to the particle sizing region. 
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The aerodynamic lens is an alternative inlet currently employed by the two 
commercially available instruments28' 29. This device consists of a series of six lenses 
(discs) with orifices ranging from the largest at the entrance lens (typically 5 mm) to 
the smaller exit aperture (typically 3 mm) as shown in Figure 2.23°' 3' 
As the aerosol passes through the first lens the larger particles are focussed towards 
the central axis of the aperture. Conversely, smaller particles remain outside the centre 
line along the path of the expanding gas stream. This is also shown in Figure 2.2. 
The second lens focuses more of the smaller particles and refocuses some of the larger 
particles that may have drifted due to diffusion. So, as the particles pass through each 
of the orifices of decreasing size, the beam becomes progressively narrower, until at 
the exit orifice particles emerge as a highly focussed particle beam of low 
divergence23. 
The main advantage of the aerodynamic lens is that it gives higher particle 
transmission efficiency (especially for smaller particles) which results in improved 









Enlarged diagram of 
lens orifice showing 
gas flow focussing 
particle beam 
Particle sizing region 
Figure 2.2. Diagram of an aerodynamic lens inlet as used on the AToFMS and AAMS 
instruments. Particles in the aerosol are focussed into a narrow beam by the 
narrowing lens orifices, prior to the particle sizing region"' 
31 
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2.3.2 Particle Sizing Methods 
Early particle sizing methods were based on a comparison of the number of ions 
detected by the mass spectrometer and the number concentration measured with a 
condensation nuclei counter (an optical method used for counting particles). Using 
this method a range of sizes from 4 nm to 1.3 gm could be measured6' 7. 
Later SPMS instruments used optical detection so that the intensity of the light 
scattered as the particle crossed a laser beam could be correlated to particle size32' 33 
Further development of optical detection resulted in instruments equipped with two 
lasers in the particle sizing region, hence the time taken for particles to travel between 
the two laser beams (the transit time) could be measured34 . The transit time could 
then be converted into an aerodynamic particle size scale if the instrument was 
calibrated with particles of a known size, typically polymer beads35. This type of 
sizing technique relies on particles of different sizes having different terminal 
velocities as they are accelerated into the particle sizing region by the pressure 
differential between the inlet and particle sizing region. In this case the smaller 
particles experience the highest acceleration and gain the highest terminal velocity. 
The limitations of measuring particle size in this way include (i) there is a high 
dependence on the size measurement efficiency on the size and shape of the particle 
32, 36, (ii) the limit of particle detection is around 80 nm32 (iii) if particle densities are 
high then the large particles may catch up with the smaller particles during 
measurement of velocity which may lead to incorrect size determination36. 
The particle size measured using the technique described above is the aerodynamic 
diameter which is a measure of the aerodynamic behaviour as if it were a perfect 
sphere. Note that the particles analyzed from the inhalation products were not 
regularly shaped and are as described in Section 4.2. 
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2.3.3 Ionization Techniques 
The commercial instruments used for the work described in this thesis used either 
laser desorption ionization (as in the case of the AToFMS instrument) or electron 
ionization (as in the case of the AAMS instrument) and an overview of these 
techniques is given, together with a brief discussion of other ionization techniques 
used during the development of SPMS. 
2.3.3.1 Surface Desorption Ionization 
With the first instruments ionization was achieved when particles hit a heated metal 
(typically rhenium) filament or ribbon held at high temperature, (in the range 500 to 
2000 °C) resulting in formation of neutral and ionic species 6, 7' 8' 9 
2.3.3.2 Electron Ionization 
Electron ionization is a technique that is based on the interaction of a beam of 
electrons with analyte molecules in the gas phase. Hence, prior to electron ionization 
(EI), it is necessary to vaporize the particle and various methods for doing this in 
SPMS instruments have been reported. In the early 1980s an SPMS instrument was 
built that used a heated coiled wire to vaporize the samples which were then ionized 
using a beam of electrons10. The efficiency of the vaporization was later improved by 
using a V- shaped filament" or in the case of the Aerodyne instruments a hotplate as 
described in Section 2.4.3. 
By convention electron ionization mass spectra are acquired at 70 eV because this 
gives a yield of ions close to the maximum and also a yield that is near constant over a 
small voltage range37. The beam of energetic electrons (shown in Equation 2.1 as e") 
interact with the analyte molecules (M) in the gas phase by passing close to or through 
the molecule38. This can lead to electronic excitation in the molecule by promoting an 
electron from a lower to higher orbital or ejection from the molecule to leave a 
positive ion. In the latter case (as summarized in Equation 2.1), the ion formed is a 
radical cation or molecular ion which may initially exist in an excited energy state 
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(M+.) *. Relaxation from this higher energy state can result in fragmentation (as 
summarized, by Equation 2.2), which is unique to that particular molecule: 
M + é 4 (M+')* + 2e- 
04+-)* _ (M+') + A +, B +, etc. 
Equation 2.1 
Equation 2.2 
2.3.3.3 Laser Desorption and Ionization 
Laser ablation involves a short pulsed, high power laser beam focused onto a surface 
or, in the case of SPMS instruments, focussed onto a particle. The amount of ablation 
depends on the wavelength of the laser, pulse duration, fluence and laser beam 
profile39 
The ablation process involves the transfer of energy from the laser beam to the atomic 
lattice causing melting and vaporization. Following ablation of solid surfaces the laser 
beam can interact with the expanding plasma plume. The absorption of laser energy 
by the plasma depends strongly on the laser wavelength; typically plasma absorption 
is greater at longer wavelengths. Short UV wavelengths penetrate the plasma more 
efficiently and directly initiate bond breaking in the sample4o 
Ionization of organic compounds with a laser will only occur if the compound absorbs 
radiation at the wavelength of the laser41. With most instruments vaporization and 
ionization of particles is achieved in a single step12 to 15 In this case, for organic 
species extensive fragmentation can result in spectra that are difficult to interpret. 
However, if two lasers are used the ablation and ionization steps are decoupled and 
each may be separately adjusted specifically for the compound(s) of interest42' 
42a 
Clearly this results in a much more complex instrument and such systems are not yet 
commercially available. 
The ablation laser can be synchronized with the particle sizing lasers as in the case of 
the AToFMS instrument (This is described in more detail in Section 2.4.2). In this 
case, the transit time of the particle between the two sizing laser beams is measured 
and hence the time at which the ablation laser needs to fire to hit the particle can be 
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computed. The alternative to synchronizing the sizing and ablation lasers is to 
continuously fire the ablation laser; however, the probability of hitting a particle with 
the laser beam then becomes much lower41. Note that particles which are detected by 
both timing lasers are said to have been `sized' and those which are desorbed and 
ionized by the third laser to produce mass spectra are said to be `hit'27. 
2.3.3.4 Soft Ionization Methods 
Many of the ionization methods used in SPMS are highly energetic. In some cases so 
much so that the vaporization / ionization technique can reduce the particle material to 
the elemental form. For particles that contain organic materials, detail of the structure 
can be lost if extensive fragmentation occurs40'43 Hence, some instruments have been 
fitted with ionization sources capable of softer ionization, in an attempt to detect 
intact organic species. 
For example an SPMS instrument was equipped with a modified atmospheric pressure 
chemical ionization (APCI) source. Particles were sampled through a ceramic tube 
into the centre of the APCI ion source. The aerosol together with a sheath flow of 
nitrogen was introduced into an interface vaporizer held at temperatures up to 450 °C. 
Airborne particles were then vaporized at atmospheric pressure without impacting on 
the vaporizer surface and the resulting gas phase molecules reacted with primary ions 
generated by a corona discharge in the ion source region19. 
Lithium ion attachment has been demonstrated during SPMS experiments on oleic 
acid. This type of experiment results in the formation of a Li adduct ion and in the 
case of oleic acid the ion at m/z 289 due to (M + Li) + dominates the mass spectrum 
23. 
Vacuum ultraviolet photoionization has also been recently introduced as an option for 
soft ionization of materials during a SPMS experiment. This was shown to give mass 
spectra with minimal fragmentation and hence an improved method for speciation of 
organic materials24.The use of tunable UV radiation from a synchrotron with SPMS 
instruments has also been demonstrated44' 45 In this case mass spectra were obtained 
that showed only the molecular ion (M+'); example applications include stearic acid 
and oleic acid. 
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2.3.4 Mass Analyzers 
Four types of mass analyzer have been prominent in the development of SPMS; these 
are the magnetic sector, the quadrupole, the ion -trap mass spectrometer and the time - 
of -flight (ToF) mass analyzer. As with other mass spectrometry experiments each has 
advantages depending on the information required from the experiment. The 
instruments used to produce the data described in this thesis were based on either 
quadrupole or ToF analyzers, and a detailed description is given for these, together 
with a brief discussion of the magnetic sector and ion trap analyzers. 
2.3.4.1 Magnetic Sector Mass Analyzers 
For the single focussing magnetic sector mass spectrometer a magnetic field is used as 
the mass analyzer. At the exit of the ionization source, small potentials are applied to 
a pair of electrodes used to focus the ion beam that enters the magnetic field through 
an ion slit which is used to control the width and shape of the ion beam. 
The magnet causes the ion beam to be deflected in a circular path37 as shown in 
Figure 2.2a. The magnitude of the deflection depends on the momentum of the ion. 
Ion focussing lenses 
Magnet 




Figure 2.2a. Diagram of magnetic sector mass spectrometer. Shows ion beam 
containing ions of different m/z values are separated by the influence of the magnetic 
field. Ions 1, 2 and 3 are deflected by different amounts depending on m/z value. In 
this case Ion 3 is the heaviest and is deflected the least. Ion 1 is the lightest and 
deflected the most 37,38 
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The m/z value of the ions which can pass though the exit slit depends on the radius of 
the ion path (r), the magnetic field, the field strength(B) and the ion accelerating 
potential (V, volts) as defined by : 
m/z = B2 r2 
2V 
This is derived on the basis that ions of charge e have all been given the same kinetic 
energy eV = '/1 mv2 (but different velocities v) in acceleration, and that the force 
excerted by the magnet (Bev) must be equal to the centrifugal force mv2 /r. Spectra are 
obtained on magnetic sector instruments of this type by holding the voltage V 
constant while varying the field on the magnet B37. 
Most of the mass spectrometers used for single particle mass spectrometry in the early 
1970s were based on magnetic sector analyzers. For example the instrument described 
by Davis6'7 was a conventional magnetic sector analyzer but with an inlet and 
ionization source modified to allow single particle analysis. The magnetic sector 
analyzers had the advantage of good resolution but were disadvantaged by a slow scan 
rate. These instruments were also heavy and so not portable6' 7' 9' " 
2.3.4.2 Quadrupole Mass Analyzers 
For the quadrupole mass analyzer electric fields are used to separate ions as they pass 
along a central axis of four rods. As shown in Figure 2.3, the rods are arranged so that 
a fixed direct current (dc) is applied to one pair of rods and a radio frequency (rf) ac 
potential on the other two. 
At the entrance to the quadrupole ions oscillate with a frequency depending on their 
mass to charge ratio (m /z). As an ion is accelerated through the quadrupole, if the 
frequency is compatible, the ion will travel all the way through to the detector. If the 
strength and frequency of the electric fields are varied then a range of m/z values can 
be filtered to produce a mass spectrum. The passage of an ion through the quadrupole 
is described by the Mathieu equation46 
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Source H dc and ac voltages 
applied to opposite rods 
Figure 2.3. Diagram of a quadrupole mass analyzer. Voltages are applied to the 
quadrupole rods so as to allow ions of specific m/z to travel though to the detector. 
Varying the voltage allows scanning of an m/z range46 
As the quadrupole is a scanning device and the scanning speed is relatively slow 
(compared with the data acquisition speed of a ToF), only one ion per particle could 
be measured when used in SPMS experiments. This meant that representative marker 
ions were used to confirm the presence of a given compound in each particle rather 
than the full scan spectra. 
Towards the end of the 1970s decade an SPMS instrument was built that used a 
quadrupole mass filter as the mass analyzer10. As this type of instrument was 
physically smaller and lighter than the magnetic sector instruments used previously, 
this meant that the instrument could be transported and used in the field. 
2.3.4.3 Ion Trap Mass Spectrometry 
The quadrupole ion trap is an ion storage and mass analysis device. The trap consists 
of a ring (doughnut shaped) electrode and two end caps as shown in Figure 2.2b and 
these form an electric field in which the ions are trapped. Hence instead of the ions 
passing through a central axis of rods as per the quadrupole (as discussed in Section 
2.3.4.2), the ions are trapped in a 3- dimensional volume and detected based on their 
mass to charge (m /z) ratio47'48. 
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Figure 2.2b. Schematic of ion trap mass analyzer47. 
Ions created in the ionization source (for example by electron ionization (EI), 
electrospray (ESI), or matrix -assisted laser desorption ionization (MALDI)) are 
focused into the ion trap using an electrostatic lens system. 
If too many ions are stored in the trap, a distortion of the electrical fields may occur 
leading to an overall reduction in performance and this is known as a space- charge 
effect. To reduce these effects the ions are allowed into the trap via an electrostatic 
gate which pulses open and closed to inject ions into the ion trap. The pulses can be 
adjusted to prevent overloading of the trap. The pulsing of the ion gate differentiates 
ion traps from "beam" instruments such as quadrupoles where ions continually enter 
the mass analyzer48. 
The ion trap is typically filled with helium to a pressure of about 1 mtorr (133 mPa). 
Collisions with helium dampen the kinetic energy of the ions and contracts 
trajectories toward the centre of the ion trap, enabling trapping of injected ions. 
Trapped ions are further focused toward the centre of the trap through the use of an 
oscillating potential, applied to the ring electrode. An ion will be stably trapped 
depending upon the values for the mass and charge of the ion, the size of the ion trap , 
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the oscillating frequency of the fundamental radio frequency voltage (rf), and the 
amplitude of the voltage on the ring electrode. 
An advantage of the ion trap is that is can be used for MS/MS analysis, which adds to 
the selectivity of the experiment and increases the amount of structural information 
available on the analyte of interest. 
An SPMS experiment reported in the late 1980s was based on an ion trap mass 
spectrometer. This type of instrument has the advantage of selectivity through its 
tandem mass spectrometry capability. Also it was able to scan fast enough to give a 
full mass spectrum of each particle19' 21 
2.3.4.4 Time -of- Flight Mass Analyzers 
Time -of -flight analyzers offer an advantage over scanning instruments (such as 
quadrupole mass analyzers) as data acquisition rates are much faster; thus in the 
SPMS experiment a full mass spectrum (or several full mass spectra) may be collected 
for each particle49' 5o 
The early ToF based SPMS instruments typically used a linear ToF but these 
instruments were capable of only low poor mass resolution14. The instruments 
designed and built in the late 1990s were based on reflectron ToF instruments and 
these were capable of giving mass spectra with improved mass resolution. The 
commercially available aerosol time -of -flight mass spectrometer described in Section 
2.4.2, is comprised of two reflectron ToF analyzers so that positive and negative ions 
from the same particle may be detected simultaneously16. A series of instruments 
currently commercially available from Aerodyne are based on a reflectron ToF22 
including an instrument that is capable of accurate mass measurement of ions 
observed in the mass spectra of single particles51. 
A separation of ions within a ToF analyzer is achieved because the velocity and hence 
flight time is dependent on mass, i.e. the heavier ions take a longer time to arrive at 
the detector than the lighter ions. 
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Ions created in the ion source are accelerated into the flight -tube by an electrical 
potential in the source region. As the ions of mass (m) enter the flight -tube they move 
at a velocity (v) acquired from their initial acceleration in the ionization source. As 
they leave the ionization source, all ions have the same kinetic energy (KE) as shown 
by Equation 2.3. 
KE = 1/2 m1v12 =' /2 m2v22 = %2 m3v32 etc. Equation 2.3 
So for a range of molecular weights (ml, m2 etc.) and in this case assuming that the 
ion is singly charged (i.e. z = 1), the velocity (v) of each ion is given by Equation 2.4 
in which the KE is constant. 
v = J 2xKE 
m 
Equation 2.4 
When the ions are produced in the source there is a small spread of kinetic energies 
which originates partly because ions are formed in different regions of the source; as a 
result they are accelerated to slightly different final kinetic energies49. In a linear ToF 
this small spread of kinetic energies can result in poor resolution. If a reflectron, as 
shown in Figure 2.4, is used to correct the energy spread an improved resolution is 
obtained. 
The reflectron consists of a number of parallel concentric electrodes to which a 
potential ramp is applied. As ions enter the reflectron they slow down, stop and are 
then accelerated in the opposite direction. Ions with a higher energy penetrate the 
reflectron deeper than ions with lower energy. Hence, faster ions travel deeper into the 
reflectron than slower ions of the same mass to charge ratio. This causes slower and 
faster ions to reach the detector at the same time hence a good resolution is 
achievable. 
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Figure 2.4. Diagram of a reflectron time -of- flight (ToF) mass analyzer. The ion beam 
path through the reflectron is such that the ion energies are focussed hence enhancing 
the resolution (compared with a linear ToF instrument)a9 
2.4 Instrumentation for the Study of Inhalation Products 
The instrumentation used for the work described in this thesis is discussed below. For 
the single particle mass spectrometry experiments on inhalation products, no sample 
preparation was required although the sample was conditioned prior to analysis via a 
sampling apparatus which is described in Section 2.4.1. 
The latter part of this chapter (Sections 2.4.2 & 2.4.3) describes the commercially 
available instruments that were evaluated during the course of this work. 
2.4.1 Sample Conditioning Apparatus 
For a SPMS experiment to monitor an environmental aerosol, the local atmosphere 
can be sampled and analyzed over a period of hours or days. For inhalation Product 
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analysis, the SPMS experiment needs some modification as material is released from 
the inhaler device during a short period (less than 1 second) after actuation. 
Hence, experiments on aerosols derived from inhalation products were performed by 
actuation of the device into a settling chamber. The SPMS instrument was used to 
sample and analyze the particles held in Brownian motion typically over a period of 
10 to 15 minutes. The technique described and used in this work was similar to a 
technique previously reported52 but with some modification53 as described below. 
Figure 2.5 shows the sample introduction apparatus used to condition materials from a 
dry powder inhaler (DPI). Also a photograph of this apparatus is shown in Figure 2.6. 
The DPI device was actuated, placed in an airtight plastic chamber and then a flow of 
air at approximately 60 L min 1 generated with a 3 litre syringe was used to carry the 
particles from the inhaler through a twin impinger54 to the 5 L glass settling chamber. 
The impinger stage was included so as to remove the larger particles (> 6 gm) present 
(many of which were captured in the water trap in the lower stage of the twin 
impinger); thus avoiding blockage of the MS inlet. Scanning electron microscope 
images of the larger particles are described in Section 4.2. 
The sample conditioning apparatus was cleaned between runs by either back flushing 
with air or by washing with solvent. 
3 litres @ 
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Figure 2.5. Diagram of sample introduction apparatus for DPIs in SPMS 
experiments. The DPI was actuated, placed in the airtight chamber and a flow of air 
carried the powder into the twin impinger. 
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Figure 2.6. Photograph of sample introduction apparatus for DPIs in single particle 
mass spectrometry experiments (photograph show the apparatus connected to the 
aerodynamic lens inlet of the AToFMS instrument). 
The contents of pressurized metered dose inhalers (pMDIs) were also sampled from 
the settling chamber using a similar apparatus to that described above, except that as 
the pMDI device contains a propellant, an additional flow of air was not required to 
transfer the particles into the settling chamber. Hence, the device was actuated 
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Figure 2.7. Diagram of sample introduction apparatus for pMDI in single particle 
mass spectrometry experiments. The pMDI was actuated directly into the twin 
impinger; Material flowed through the impinger then into the settling chamber. 
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Powders were also introduced into the settling chamber using the apparatus 
configured as shown in Figure 2.8. In this configuration a Penn- CenturyTM device55, 
(effectively a powder syringe) was used to inject the powder into a flow of air of 60 L 
min . 
Penn -Century 1m 
device 
Air filter 
3 litres - Settling 
c@äó4 L! minute IMO chamber 
Twin impinger 
apparatus 
Outlet to SPMS 
instrument 
Water in lower twin 
impinger 
Figure 2.8. Diagram of sample introduction apparatus for powders in single particle 
mass spectrometry experiments. The powder is loaded into the Penn- CenturyTM device 
(effectively a powder syringe) then injected into a flow of air which carries the sample 
particles through the twin impinger, then into the settling chamber. 
2.4.2 Characteristics of the Aerosol Time -of- Flight Mass 
Spectrometer 
An aerosol time -of -flight mass spectrometer (AToFMS) (TSI 3800, Shoreview, MN, 
USA) was used for the main part of the work described in this thesis and a photograph 
of this instrument is given in Figure 2.9. This instrument was developed at the 
University of California in the 1 990s56, and then later commercialized by TSI57. 
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Figure 2.9. Photograph showing some features of the TSI 3800 AToFMS instrument. 
The instrument is attached to a mobile metal frame and was powered by a 240 V 
mains supply or generator. The frame is approximately 170 (width) x 75 (depth) x 130 
(height) cm and the complete system weighs approximately 200 kg and it is thus 
easily transportable which is important for in -situ environmental monitoring. 
Figure 2.10 shows a cross section of the AToFMS instrument; the inlet, the particle 
size region and mass spectrometer are described below. The vacuum system allows 
the area between the nozzle and first skimmer to be maintained at a pressure of 2 Torr, 
the particle sizing region at approximately 5 x 10 -5 Torr and the mass spectrometer 
region at approximately 2.0 x 10 "7 Torr (1 Torr = 133 Pa). 
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Figure 2.10. A schematic of the TSI AToFMS instrument. The instrument shown was 
fitted with a nozzle -skimmer inlet which was later upgraded to an aerodynamic lens. 
Aerodynamic particle size is determined by measuring the particle transit time 
between two laser beams. The mass spectrometer region consists of a dual reflectron 
time -of- flight (ToF) analyzer 56' sa 
The measurement of aerodynamic particle size was developed based on the transit 
time of each particle between two laser beams. The transit times was calibrated using 
standards of known size (polymer beads) and then converted from transit times into 
particle diameters' i''2' 13 
Figure 2.11 shows a schematic of the particle sizing region of the instrument which 
consists of two laser beams which form a timing circuit. A particle passes through the 
first laser beam and the scattered light initiates the timer and when it passes through 
the second laser beam the scattered light stops the timer and the transit time for the 
particle is noted. This circuit is calibrated using particles of known size and hence the 
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Figure 2.11. The particle sizing region of the AToFMS instrument 58. The velocity of 
each particle can be calculated from the time taken for particles to travel the known 
distance (d). Particle velocities are converted to a measure of aerodynamic size by 
calibration using particles of known size (typically polymer beads). 
After sizing, the particles pass into the mass spectrometer where they are ablated and 
ionized using a Nd: YAG laser. For the Nd:YAG laser the fundamental wavelength is 
in the near infra -red (near -IR) at 1064 nm and for the AToFMS instrument the optical 
frequency is quadrupled to give a wavelength of 266 nm33. The Nd: YAG laser 
incorporated into the AToFMS instrument, has a 5 ns pulse width, generates pulses of 
up to 1.0 mJ and is synchronized with the particle sizing lasers. The laser ablation 
technique is discussed in Section 2.3.3.3. For the AToFMS instrument the laser 
energy is set to the required value and the actual value produced for each pulse is 
measured. 
The AToFMS instrument utilises two reflectron time -of -flight mass analyzers, of 
opposite polarity, which allows the simultaneous detection of both positive and 
negative ions from the same particle. The ability of the instrument to analyze both 
positive and negative ions simultaneously maximizes the amount of information 
obtained on a single particle. This is especially important for environmental samples 
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where the samples can only be analyzed once. For the analysis of inhalation products 
it is useful to acquire positive and negative ion spectra on the same particle especially 
in the case of drug compounds which are salts - for example, salmeterol xinofoate. 
2.4.3 Characteristics of the Aerodyne Aerosol Mass Spectrometer 
A series of aerosol mass spectrometry (AMS) instruments have been described in the 
literature and are commercially available from Aerodyne59. The Aerodyne AMS 
instruments (AAMS) used for the work described in this thesis were based on a 
quadrupole mass analyzer (Q- AAMS)20, or a reflectron ToF mass analyzer (TOF- 
AAMS)22 
A photograph of the ToF -AAMS is shown in Figure 2.12. As with the AToFMS 
instrument the AAMS instrument is powered by a mains power supply and is attached 
to a metal frame and is easily transportable. The frame size is approximately 104 









Figure 2.12. Photograph showing some key features of the Aerodyne Aerosol Mass 
Spectrometer. 
A diagram of a cross section of the ToF -AAMS instrument is shown in Figure 2.13. 
Similarly to the AToFMS instrument, the AAMS instrument is comprised of three 
regions i.e. a sample inlet, a particle sizing region and a mass spectrometer. Three 
turbo- molecular pumps are used to reduce the background pressure across these 
regions from 2 Torr at the inlet, to 10-3 Torr in the particle size region and then to 10 
"5 
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Ton in the mass spectrometer (1 Ton = 133 Pa),. A description of each region of the 

















Figure 2.13. Diagram of the ToF -AMS instrument (Aerodyne) to show sample inlet, 
particle sizing and mass spectrometer regions of the instrument58. 
The sample inlet for the AAMS instrument includes an aerodynamic lens and a 
general description of this type of device was given in Section 2.3.1. The Aerodyne 
aerodynamic lens is approximately 30 cm long and the discs are of 13 mm diameter3 °. 
Particles in Brownian motion in the sampled atmosphere enter the lens where the gas 
flow is approximately 8 m sec -'. The particles are accelerated through the lens by 
gas -particle collisions28 and when they exit, they typically have a velocity of between 
50 to 200 m sec -I. 
The focussed particle beam exits the aerodynamic lens and is directed into the particle 
sizing chamber where a measurement of the aerodynamic particle size is made. Time - 
resolved detection of the particles, coupled with the known flight distance, gives the 
velocity from which the particle aerodynamic diameter is obtained23. 
The start time for the particle sizing measurement is determined from the point at 
which the particle passes through a chopper wheel. The chopper wheel also modulates 
the particle beam so that the particle size region is not swamped and individual 
particles may be detected and analyzed. The chopper wheel is 5 cm in diameter with 
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two radial slits giving a sample duty cycle of typically 1.0 % when operated at 150 Hz 
20, 22 
Generally the AAMS instrument can be used in three modes23, the first is where the 
chopper is completely blocked and therefore no particles can pass through. This can 
be used for collecting a background signal in the mass spectrometer. The second 
mode (mass spectrum mode) is when the chopper is open and all particles pass 
through to give an ensemble mass spectrum. This is useful with the quadrupole -based 
AAMS instrument so that representative (or marker ions) ions can be chosen. 
The third chopper mode, particle time -of -flight (P -ToF), is a chopped mode in which 
the chopper spins and therefore modulates the beam transmission. This controls the 
particle density in the particle sizing region and prevents overloading so that 
individual particles may be detected and analyzed. The AAMS instrument is typically 
alternated between the mass spectrum mode and the P -ToF mode. 
For the AAMS instrument based on the quadrupole analyzer (Q- AAMS), in the 
particle time -of -flight (P -ToF) sizing mode, the average size distribution at pre- 
selected m/z values for the particle population (ensemble) is measured. The P -ToF 
mode generates mass spectra each measured at a specific particle flight time in a 
chopper cycle. This gives a two- dimensional matrix with a complete mass spectrum 
for each chopper cycle in columns and the P -ToF distributions for individual m/z 
values in rows2 °' 22. 
Particle arrival is indicated by the burst of ion signal at the selected m/z after a particle 
size dependent delay from the opening of the chopper. The particle velocities 
determined using P -ToF measurements can be converted into aerodynamic diameters 
by calibration using polymer beads of known size23. 
In the ionization source of the AAMS instruments a hotplate is used to vaporize the 
sample which is then ionized in the gas phase by electron ionization. Electron 
ionization is described in detail in Section 2.3.3.2. Under optimised conditions, the 
electron ionization (EI) spectra obtained using the AAMS instruments are comparable 
with those found in the National Institute of Standards (KIST) library23. 
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The speed of the mass spectral data acquisition is important in the AAMS experiment. 
The Q -AAMS instrument is limited to detecting one m/z value (one ion) per particle, 
because on the time scale of particle vaporization (approx 100 to 200 µsec) it can only 
scan a small mass range. This is compared with the data acquisition rate for the ToF- 
AAMS which is fast enough to give full mass spectra on each single particle and 
maximizes the amount of data available from each experiment22. 
For older versions of the AAMS instrument, mass spectra were continuously acquired 
and this gave large data files containing only a few meaningful mass spectra. On more 
recent AAMS instruments (including the ToF -AAMS used for the work presented in 
this thesis) the acquisition of mass spectra for each single particle, is triggered by the 
scattered light when the particle crosses a photodiode beam and in this case the data 
files are more compact and easier to process61' 62 
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The Application of Single Particle Mass 
Spectrometry to the Analysis of Inhalation 
Products 
3.1 Introduction 
In this chapter, the factors that can influence the appearance of a mass spectrum taken 
from a single particle mass spectrometry (SPMS) experiment are discussed. Later in this 
chapter, examples of SPMS mass spectra are presented; the interpretation of these data is 
important because the identification and classification of each particle in terms of 
composition is based on the presence of specific ions (or groups of ions), i.e. the 
fragmentation patterns give an insight into the origin of the ions on which the 
identification and classification of particles is based. 
3.2 Factors That Influence Aerosol Time -of- Flight Mass 
Spectrometry Data 
Individual particles can be identified and classified in terms of their chemical 
composition. The identification of each particle using SPMS spectra is typically based on 
the unique fingerprint given by each compound. The presence of a given compound in a 
particle may be determined from the mass spectrum based on the appearance of a few 
representative (marker) ions or by multivariate statistical analysis of the full mass 
spectrum. Data analysis methods based on this type of approach for AToFMS data are 
discussed in more detail in Chapter 4. 
The most significant variation for the mass spectra acquired from an AToFMS 
experiment originates from the laser ablation/ionization process. Other influences on this 
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type of data include the effects of particle size and shape as well as the ability of the 
analyte to absorb radiation at the ablation laser wavelength (266 nm). 
3.2.1 Ionization and Laser Wavelength 
le successful ionization of material ablated from particles depends on the extent to which 
nalyte absorbs the radiation from the AToFMS laser at 266 nm. Figure 3.1 shows the 
[ltra- violet (UV) spectra for FP and SX (taken from HPLC experiments the details for 
vhich are given in Appendix A3.2). These data can be used to predict the ease with which 
P and SX are likely to be ablated and ionized in the AToFMS instrument. 
n the UV spectra shown in Figure 3.1, much of the response at the lower wavelengths is 
ikely to be due to the solvent from the mobile phase used in the HPLC experiment. 
lowever, at a wavelength of 266 nm the molar absorptivity of SX was estimated to be 
pproximately double that of FP (calculation shown in Appendix A3). Hence, the AToFMS 
ristrument would be expected to be more sensitive to SX than to FP. 
'igurre 3.1. Ultra - Violet (UV) spectra of FP (JO mgL"I) (blue trace) and SX (JO mgL"') (red 
pace). (Experimental details are given in Appendix A3.2). 
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3.2.2 The Effect of Laser Energy 
Most of the particles that pass through the ionization source are not completely ablated 
(especially larger particles, > 4 gm) but it is assumed that a representative sample is 
produced during the ablation processi' 2. 
Shot -to -shot variations in the laser beam are most likely to be due to the Gaussian 
intensity distribution of the laser beam; i.e. some particles pass through the high 
intensity (peak) region while others pass through the lower intensity region (wings)3. 
It has been shown that if the profile of the laser beam is changed from a Gaussian 
profile to a flat top (top -hat) profile, this results in better shot -to -shot reproducibility; 
i.e. either the particle would (a) not interact with the beam or (b) it would be ionized 
with reproducible laser fluence4. 
The variation in response is exemplified, by the bar -graph of the peak area for the 
fluoride ion from FP for a group of particles of similar size shown in Figure 3.2. The 
laser energy was similar for each particle but a variation was found in the response, in 









2.12 2.14 2.17 2.30 2.34 2.37 2.61 
Particle size (pm) 
Figure 3.2. Bar -graph to show the variation in the AToFMS spectra (MS) peak area 
for the fluoride ion, for a number of particles of similar size. All data shown here 
were acquired at similar laser energies (0.88 to 0.90 mi). 
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Some examples of positive ion mass spectra taken from AToFMS experiments at high 
and low energies on single particles (- 2 µm) are shown in Figure 3.3. Neither a 
protonated molecule ((M +H)+ theoretically at m/z 501) nor an intact molecular ion 
(M + theoretically at m/z 500) was observed for FP, even at low laser energy. 
At high laser energy (> 0.8 mJ) many ions appear in the mass spectra (Figure 3.3 (a) 
and (c)) at lower m/z values. In this case, the ions with lower m/z values are difficult 
to interpret in terms of the FP structure, probably because they are due to secondary, 
tertiary or further fragmentation. At low laser energy (< 0.2 mJ; Figures 3.3 (b) and 
(d)) the mass spectra show relatively few ions, some of which can be interpreted in 
terms of the FP structure and this is discussed in Section 3.3. 
Table 3.1 lists some of the major ions observed in Figure 3.3 for FP and SX at high 
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High laser energy 
(Common ions below m/z 100) 
Low laser energy 
(Unique higher m/z ions) 
Figure 3.3 (a) Figure 3.3 (c) Figure 3.3 (b) Figure 3.3 (d) 
FP SX FP SX 
27 27 313 398 
38 38 294 380 
50 50 276 266 
62 62 179 114 
77 77 139 92 
91 91 121 55 
Table 3.1. The major ions observed in mass spectra acquired during AToFMS 
experiments on FP and SX, at high and low laser energy. The table shows the ions 
below m/z 100 that are common to the mass spectra of both FP and SX and the unique 
ions at m/z values above 100. Data taken from Figure 3.3. 
The effect of altering the laser energy was demonstrated using principal component 
analysis (PCA), a multivariate statistics based pattern recognition techniques. (The 
technique of principal component analysis is explained in Appendix 3.3. The 
application of principal component analysis is discussed further in Chapters 4 and 5). 
Figure 3.4 shows a number of PCA charts where data for pure FP and SX samples 
were overlaid on each chart. Each point in the cluster of data points shown in red for 
SX and blue for FP represents a mass spectrum of a single particle. Further detail of 
the application of principal component analysis to AToFMS data is given in Section 
4.4. 
Figure 3.4 (a) shows a set of data points for a range of laser energies between 0.2 and 
1.0 mJ i.e. it combines the data from charts (b) to (f). The remaining figures (Figures 
3.4 (b) to 3.4 (f)) show the PCA charts at a range of laser energies from the lowest (< 
0.2 mJ) to highest (1.0 mJ). 
At low laser energy (< 0.2 mJ) the PCA clusters for the two pure drug compounds are 
well resolved and this is because the mass spectrum for each component shows unique 
ions at higher m/z values. 
At higher laser energies (> 0.8 mJ) the mass spectra (Figure 3.3) show ions at low m/z 
(typically < 100) which are common to both drug compounds. This is reflected in the 
PCA charts by the convergence of the FP and SX clusters towards similar PCA co- 
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ordinates as the laser energy is increased. Hence the mass spectral patterns for FP and 
SX are more easily recognized with PCA at lower laser energies. Further explanation 
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Figure 3.4. PCA charts to show the effect of varying the laser energy (LE) on PCA 
clusters of FP and SX. Chart (a) combines the data from charts (b) to (fj. Charts (b)to 
a show that as the laser energy increases the clusters converge. This illustrates the 
points that (a) as the laser energy is increased, more fragments are formed that are 
common to both compounds and (b) the most unique spectral patterns are observed at 
low laser energy. 
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3.3 Interpretation of AToFMS Spectra 
The laser ablation/ionization process results in the formation of both positive and 
negative ions which are detected simultaneously by the dual (bipolar) mass analyzer. 
An interpretation of the positive and negative ion mass spectra for FP and SX is given 
below. 
3.3.1 Interpretation of the Aerosol Time -of- Flight (AToFMS) 
Spectra of Fluticasone Propionate 
A suggested fragmentation pattern for FP based on the positive ion mass spectra 
(Figure 3.3 (a) and (b)) is shown in Figure 3.5. This is typical of the fragmentation 
obtained for the pure drug acquired at high (> 0.8 mJ) and low (< 0.2 mJ) laser 
energy. 
At low laser energy the FP molecule fragments to give the ion at m/z 333 by the 
concerted loss of the 17 a and 170 side chains from the D ring of the steroid. The ions 
at m/z 58 and 43 probably also originate from the 1713 side chain. 
The ion at m/z 333 loses HF, F and then water to give the ions at m/z 313, 294 and 
276, respectively. It is likely that these losses involve trans -elimination of water or 
hydrogen fluoride from the 6 and 11 positions on the steroid ring, respectively (from 
the B and C rings of the steroid). 
At high laser energies organic molecules have been shown to fragment to give a series 
of elemental carbon ions C+ or a series of hydrocarbon ions with the formulae CH +, 
C H +n etc.6'7 and similar series of ions are observed for FP. 
Further evidence for the assignment of the ions in the mass spectra of the pure 
compounds was obtained with accurate mass measurements from electrospray LC/MS 
experiments, the details for which are given in Appendix A3. 
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F H2 \ 
S 
Low laser energy 
F 
[M +H]+ m/z 501 (not observed) 










m/z Suggested Ion 
27 C2 H3 + 
51 C4 H3 + 
77 C6 H5 + 
91 C2 H7 + 
115 C9 H+ 
127 C10 H 
137 C H5+ 
150 C12 H6 + 
163 C13 H + 
O 
F 
Figure 3.5. Suggested fragmentation pattern for FP based on the positive ion 
AToFMS spectra of single particles shown for example in Figure 3.3 (a) & (b). At low 
laser energy ions that can be interpreted in terms of the FP molecule are observed. At 
high laser energy the mass spectrum is dominated by hydrocarbon cations. 
61 
Chapter 3- The Application of Single Particle Mass Spectrometry to the Analysis of Inhalation Products 
3.3.2 Interpretation of the AToFMS Spectra of Salmeterol 
Xinofoate (SX) 
A suggested fragmentation pattern for SX based on the positive ion mass spectrum 
(Figure 3.3 (c) and (d)) is shown in Figure 3.6. 
At low laser energy, the SX molecule fragments at the ester oxygen to give the ion at 
m/z 266, and the alkyl chain breaks to give the tropylium like ions at m/z 91. Ions are 
observed at m/z 398 and at m/z 380 for the ions produced by the loss of one and two 
water molecules respectively. This is comparable with the electrospray LC/MS 
spectrum for SX shown in Appendix A3. 
The mass spectrum acquired with higher laser energy shows many ions at the lower 
m/z values (below m/z 100). At higher laser energy, fragment ions at m/z 171 and 114 




Low laser energy 
(M +H)+ at m/z 416 (not observed)--...... 
nz 262 
rrz 380 
High laser energy 
m/z Suggested ion 
29 G2 H5+ 
39 C3 H3+ 
55 G2 H7+ 
61 CSH+ 




Figure 3.6. Suggested fragmentation pattern of salmeterol based on the AToFMS 
spectra shown in Figure 3.3 (c) &(d) taken from single particles. At low laser energy 
ions that can be interpreted in terms of the salmeterol molecule are observed. At high 
laser energy the hydrocarbon cation series is more prominent. 
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3.3.3 Interpretation of Negative Ion AToFMS Spectra 
The negative ion spectrum for SX is dominated by an ion at m/z 188 due to the 
xinofoate ion at both high and low laser energy. This ion was found to be a good 
marker ion for SX and is discussed further in Chapter 4. 
The negative ion mass spectra for FP were found to vary with laser energy. The 
average negative mass spectra for groups of FP particles (rather than for single 
particles) acquired at various laser energies are shown in Figure 3.7 and these data are 
summarized in Table 3.2. 
The negative ion mass spectra for FP show a series of carbon ions. For example m/z 
24, 36, 48, 60, 72 and 96 are consistent with the ions for C2 C3 -, C4 C5-, C6-, and C8 , 
respectively. There are also series of ions for CnH- where n = 2, 4, 6 and 8 at m/z 25, 
49, 73 and 97 respectively; for CnH2 where n = 4, 6 and 8 at m/z 50, 74 and 98 
respectively; for where n = 3, 5 and 7 at m/z 41, 65 and 89, respectively, and for 
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Laser energy (mJ) 
m/Z Assignment 0.1 0.45 0.75 0.85 
19 E 0 105 146 186 
24 C " 0 
r 
0 34 91 
25 C2H- 0 25 109 144 
32 C2H$ 0 0 32 37 
33 CH2F" 0 40 100 113 
34 H2S? 0 15 10 9 
36 C3 0 0 35 92 
37 C3H" 0 0 17 21 
38 C3H- O 0 12 12 
39 C3H3- 0 52 77 70 
40 C3H4 12 32 31 13 
41 'C3H5- 0 8 33 32 
42 C3H6." 0 0 12 7 
43 C3 H " 0 0 13 7 
44 C3He " 0 0 5 0 
48 C4" 0 0 27 60 
49 atH" 0 17 73 121 
50 C:.H;" 0 0 33 44 
57 CH3CH2C0" 0 0 19 38 
60 CE, O O 13 40 
61 C=H" 0 0 15 55 
62 C5H2" 0 O 11 33 
65 C=H, 18 61 69 81 
66 C_H," 152 110 61 36 
67 C=H-" 27 13 7 3 
72 C= 0 0 7 9 
73 C.:H 17 69 97 120 
74 C.H2- 131 138 106 84 
75 C6H3 40 16 0 3 
89 C7H3- 0 19 18 23 
90 C7H8" 85 18 4 5 
91 C71-17- 17 14 0 9 
96 C- O 0 O 5 
97 
. 
C:H" _ 27 32 39 
98 C,H2" 30 60 35 35 
99 C,H-,' 0 15 0 5 
Table 3.2. Summary and assignment of the negative ions observed using the AToFAS 
instrument for FP, showing the average intensities of ions at different laser energies: 
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Figure 3.8 shows that ions in the series Cn- (where n= 2 to 6), are not present in 
spectra acquired at low laser energies, but become abundant as the laser energy is 
increased. Moreover, it can be seen from Table 3.2 that the signal intensity for many 
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Figure 3.8. The variation in relative abundance of C, ions as a function of laser 
energy in the average negative ion AToFMS spectra from FP. The traces shown are 
m/z 24, 36, 48, 60, and 72 which are consistent with the ions for C2-, C3-, Ci C5-, C6 
respectively. 
Alternative assignments for some of the ions shown in Table 3.2 are possible. For 
example, the ion at m/z 33 assigned as CH2 F could also be due to SH -. The ion at m/z 
65 given as SCH2F -, derived from the terminal of the 17- thiomethyl fluoride side 
chain, could also be due to C5H6 -. Also the ion at m/z 73 is attributed to the 
CO2CH2CH3- ion derived from the 17- ethylcarboxy side chain but could also be due to 
C6H. 
Figure 3.9 shows a comparison of the abundance of C5- ions with that of C5H6 ions at 
varying laser energy, in the average negative ion AToFMS spectra of FP. At low laser 
energy (0.1 mJ) C5- ions are not detected. As the laser energy is increased 
(approaching 1.0 mJ) the C5- ions become more abundant, while the abundance of 
C5H6 ions decreases. 
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Figure 3.9. The variation in the relative abundance for m/z 60 due to C5 and m/z 66 
due to C5H6 ions as a function of laser energy in the average negative ion AToFMS 
spectra of FP. 
Figure 3.10 shows the relative abundance of C3H- ions as a function of varying laser 
energies in the average negative ion AToFMS spectra of FP. At low laser energy (0.1 
mJ) the ions for C3H5" and C3H4- are prominent; whilst at higher laser energies 
(approaching 1.0 mJ) the ions with lower number of hydrogen atoms (for example 
C3H3- and C3H2) are evident. At the maximum laser energy (0.85 mJ), the C3- ion (i.e. 
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Figure 3.10. The relative abundance of (C3H) - ions as a function of laser energy in 
the average negative ion AToFMS spectra of FP. The traces shown are m/z 36, 37, 
38, 39, 40 and 41 which are consistent with the ions for C3 , C3H-, C3H2 , C3H3 , 
C3H4 , C3H5 and C3H6 respectively. 
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In the negative ion mass spectrum of FP at higher laser energy, the ion observed at 
m/z -19 is attributed to the fluoride ion (F). The relative abundance of fluoride ions 
with varying laser energies is shown in Figure 3.11. This demonstrates that fluoride 
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Figure 3.11. Graph to show the variation in the abundance of the fluoride (F) ion 
over a laser energy range of 0.1 to 1.0 mJ in the average negative ion AToFMS 
spectra of FP. 
3.3.4 The Formation of Negative Ions 
The processes by which negative ion formation may occur can be categorised as (a) 
electron capture, (b) dissociative attachment or (c) ion pair formation. As the energy 
of the electrons increases, or if the ionization source pressure is relatively high, then it 
becomes increasingly likely that negative ion formation will involve more than one of 
these processes°. 
If the negative ion is to be stabilized, following electron capture, then the kinetic 
energy that the electron possesses prior to capture and at least some of the binding 
energy, needs to be dissipated. This can occur either by (a) radiation, for which the 
probability is small, or by (b) transferring the energy to a third body (typically' an 
atom or a molecule) via a collision. 
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The simplest way in which a negative ion can be formed is by the direct capture of a 
free electron by a neutral atom or molecule. This electron capture process occurs at 
low electron energies (less than 1 eV) and is summarized by Equation 3.1, where M is 
a third body. 
XY + é H (XY-)*+ M XY- + M + Equation 3.1 
If the electron energy is greater than that required to break a bond and form a negative 
ion, then direct dissociation, (dissociative attachment) as summarized in Equation 3.2, 
may occur. 
XY + e <--* (XY-)* -> X +Y- Equation 3.2 
At higher electron energies ( -10 eV), the molecule can be excited to an unstable state 
from which it dissociates into a positive and a negative ion, as summarized in 
Equation 3.3. This differs from the process summarized by Equation 3.2 as the 
electron is not captured, but provides the source of energy to produce the electronic 
transition in the molecule. 
XY + é X+ + Y- + é Equation 3.3 
3.3.5 The Influence of Particle Size on Negative Ion Formation 
Differences in positive and negative signal intensities and their dependence on particle 
size suggest that the formation of negative ions may involve more than one 
mechanism. Laser ablation using UV radiation is known to produce free electrons and 
the interaction of these electrons with molecules can result in the formation of 
negative ions typically by dissociative attachment" 12. Furthermore, it has been 
shown that smaller particles tend to give much higher negative ion yields relative to 
the total mass of the particle12. 
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3.4 Factors that Influence Aerodyne Aerosol Mass 
Spectrometry (AAMS) Data 
Although the Aerodyne Aerosol Mass Spectrometer (AAMS) is of different design to 
the AToFMS instrument (see Sections 2.4.2 and 2.4.3), many of the factors that 
influence the data are common to both instruments. For example, particle shape has a 
major influence on the particle sizing data'3' 14 and as with the AToFMS instrument, 
vaporization and ionization efficiency are key factors that determine the appearance of 
the AAMS data15 
For the AAMS instrument, only ions of one polarity can be analyzed at one time. 
Although it is possible to detect negative ions with the AAMS, all spectra shown in 
this section were acquired using positive ion detection as better sensitivity was 
obtained using this mode. 
3.4.1 Operational Modes of the Aerodyne Aerosol Mass 
Spectrometer (AAMS) 
Figure 3.12 compares particle sizing data acquired on the AAMS -ToF instrument in 
the chopper open mode with the chopper spinning mode. In the chopper open mode 
average mass spectra for groups of particles can be acquired and in the chopper 
spinning mode mass spectra can be acquired for single particles as described in 
Section 2.4.3. From Figure 3.12 it can be seen that the particle size distribution for the 
chopper spinning mode only involves the smaller particles. Also very few particles 
were detected in this mode, compared with the many particles observed in the chopper 
open mode, due to the reduced duty cycle. 
For the chopper open mode, the sloping tail for the particles between 103 and 104 nm 
is probably due to slow vaporization of large particles16. Also, if the particles are of an 
irregular shape, there may be some divergence of the particle beam so that not all of 
the particles detected by light scattering hit the hot plate'. 
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Figure 3.12. A comparison of particle sizing data in chopper open (green trace) and 
chopper spinning (black trace) modes, (data shown for sample MDI 4, FP /SX 50/25). 
3.4.2 Vaporization Efficiency 
in this thesis, the hotplate temperature was set 
at 500 °C and it was assumed that most organic material would flash vaporize at this 
temperature. Figure 3.13 shows a graph of mass spectral signal versus particle size for 
particles taken from a pMDI. Larger particles theoretically should give a larger signal; 
assuming the particles are spherical, the signal size should increase as the cube of the 
particle radius (as the volume of a sphere is 4 /3itr3 ). 
The data points shown in blue, in Figure 3.13, are within 20% of the third order 
polynomial line and are nominally assumed to be fully vaporized. The points shown 
in red are outside this limit and are assumed to be incompletely vaporized. The data 
acquired for pMDIs using the AAMS instrument, showed that the vaporization 
efficiency varied between 40 and 70 %. 
The incomplete particle vaporization originates predominantly from particle bounce; 
thus rather than being fully vaporized the particle bounces from the hotplate and 
remains intact rather than being fully vaporized'. 
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Figure 3.13. Demonstration of partial vaporization in an AAMS experiment. Blue 
points - taken as fully vaporized; red points - vaporization is incomplete. Sample 
MDI 9 FP/SX 250/25. 
3.4.3 The Influence of Particle Size 
In some samples, particle composition may vary with particle size. A comparison of 
the average mass spectra over the particle size range from 200 to 270 nm and from 
500 to 1300 nm, from a pMDI sample, is shown in Figure 3.14. These mass spectra 
are clearly different i.e. 3.14 (b) shows ions at m/z 91, 114, 121 and 170 which are 
indicative of SX. For this sample, the smaller particles consist predominantly of FP 
and the larger particles are a mixture of FP and SX. Further discussion of this data is 
given in Chapter 6. 
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Figure 3.14. Comparison of mass spectra, for different particle size ranges, from a 
sample MDI 4 FP /SX 50/25, (a) average mass spectrum for particles in the 200 to 
270 nm size range and (b) average mass spectrum for particles in the 500 to 1350 nm 
size range. 
3.5 Interpretation of Aerodyne Aerosol Mass Spectrometry 
(AAMS) Data 
By analysing the mass spectra from particles of pure compounds, indicative ions for 
each component were determined (see Chapter 6). The data sets for samples, 
containing blends of components, taken from dry powder inhalers (DPIs) and 
pressurized metered dose inhalers (pMDIs), were analyzed and classified using the 
indicative ions from the pure compounds. 
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The data shown in the following sections are average spectra that were acquired for 
the individual components and also for some blends of formulated DPI product using 
the Q -AAMS instrument. The data from the pure drugs (FP and SX) are shown first, 
followed by the results for lactose (acquired using a ToF -AAMS instrument) a 
common excipient. Excipients18 are materials added to the formulation that have no 
therapeutic activity; for example lactose is used as a carrier for the active drug in DPI 
formulations. Finally the Q -AAMS spectra obtained for a blend of active drug 
compounds and excipients in an inhalation product are presented and discussed. 
All of the data shown in Sections 3.5.1 and 3.5.2 were obtained using the quadrupole 
based AAMS instrument (Q -AAMS) apart from the mass spectrum for lactose which 
was acquired using the ToF based instrument (ToF -AAMS). Additionally, a similar 
set of experiments performed using the ToF -AAMS instrument on single particles are 
discussed in Section 3.5.4. 
3.5.1 Q -AAMS Spectra of Drug Compounds 
Figure 3.15 shows the Q -AAMS spectrum for FP: it shows that ions with relatively 
low m/z values (below m/z 200) were observed and some of these were found to be 
unique to the structure of FP. For example the ion at m/z 57 is assigned to the 
H3CCH2COs fragment and the ion at m/z 139 is due to cleavage across steroid ring B 
as shown in Figure 3.16. This spectrum is comparable with the electrospray LC/MS 
spectrum for FP shown in Appendix A3. 
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Figure 3.15. The average mass spectrum of FP acquired using the Q -AAMS 
instrument, showing marker ions for FP. 
F H2C 
[08 H7 O F ( +HTT+ 
m/z 139 
Figure 3.16. Suggested fragmentation pattern showing origin of the representative 
marker ions for fluticasone propionate (FP), based on the EI mass spectrum shown in 
Figure 3.15, acquired using the Q -AAMS instrument. 
03 H5 O 
in/z 57 
The average Q -ARMS EI mass spectrum for salmeterol xinofoate is shown in Figure 
3.17. A highly abundant ion appears in the spectrum of SX at m/z 91 due to the 
tropylium ion and at m/z 170 due to the loss of water from the xinofoate salt and a 
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suggested fragmentation pathway for the major products is shown in Figure 3.18. This 
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Figure 3.17. Average mass spectrum of SX, acquired using the Q -AAMS instrument 
showing marker ions for SX. 
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Figure 3.18. Suggested fragmentation pattern showing origin of the representative 
marker ions for salmeterol (shown at the top of this figure) and the xinofoate ion, 
(shown at the bottom of this figure) based on the EI mass spectrum shown in Figure 
3.17, acquired using the Q -AAMS instrument. 
3.5.2 AAMS Spectra for Excipients 
An advantage of the AAMS (compared with the AToFMS) is that mass spectra of 
excipients may be acquired. For example the average ToF -AAMS EI mass spectrum 
for lactose is shown in Figure 3.19 (examples some other mass spectra of excipients 
acquired using AAMS are given in Appendix A3). Although no intact molecular ion 
is observed, possibly because of thermal decomposition, a number of unique ions are 
observed. These are shown in the fragmentation pathway suggested in Figure 3.20. 
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Figure 3.19. Average ToF -AAMS spectrum of lactose, showing potential marker ions. 
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Figure 3.20. Suggested fragmentation to give representative ions for lactose based on 
the ToF -AAMS EI mass spectrum shown in Figure 3.19. 
3.5.3 An Example Q -AAMS Spectrum for an Inhalation Product 
Figure 3.21 shows the mass spectrum for the FP /SX 50/50 blend with lactose and 
cellobiose octaacetate (COA) as excipients. 
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Figure 3.21. Average Q -AAMS spectrum of 50/50 blend DPI with COA and lactose. 
The unique fragment ions for the individual compounds are shown in Table 3.3. All of 
these fragments are present in the blend indicating that the blend matrix has minimal 
effect on the mass spectra of the individual components. 
Compound m/z 
29 43 57 73 81 91 109 139 169 170 
FP X X 
SX X X 
Lactose* X X X X 
COAt X X X X 
Blend X X X X X X X X X X 
Table 3.3. Summary of Q -AAMS spectral data (* Ions for lactose data based on ToF- 
AAMS spectrum, f Mass spectrum for COA shown in Appendix A3.). An X indicates 
the ion is present in the given mass spectrum; the data shows that all marker ions are 
present in the spectrum of the blend 
3.5.4 ToF -AAMS Spectra for Single Particles 
Figure 3.22(a) shows the ToF -AAMS spectrum taken from a single representative FP 
particle. The ions at m/z 57 and m/z 139 that were previously shown to be 
representative of FP from the average Q -AAMS spectrum are clearly visible. 
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Similarly Figure 3.22 (b) shows the ToF -AAMS spectrum of a SX particle. The ions 
at m/z 91 and 170 that were previously shown to be representative of SX from the 
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Figure 3.22. ToF -AAMS spectrum of (a) single particle of FP and (b) single particle 
of SX. The spectra are labelled with representative ions for each compound. 
Figure 3.23 shows the ToF -AAMS spectrum of a mixed particle. The ions at m/z 91 
and 170 from SX and m/z 57 and 139 from FP are all clearly visible. 
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Figure 3.23. ToF -AAMS spectrum of a single particle containing a mixture of FP and 
SX. The presence of FP is indicated by ions at m/z 57 and 139 and the presence of SX 
indicated by the ions at m/z 91, 170 and 262. 
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Chapter 4 
Data Analysis Methods for Aerosol Time -of- 
Flight Mass Spectrometry (AToFMS) 
4.1 Introduction 
This chapter describes how the data processing methods were developed for the 
analysis of Aerosol Time -of- Flight Mass Spectrometry (AToFMS) data. These 
methods were then applied to the data taken from AToFMS experiments designed to 
investigate the degree of co- association in a wide range of samples of inhalation 
product material; the results from which are presented in Chapter 5. 
The AToFMS, datasets are divided into data relating to particle size and mass spectra 
which are collated and linked through the tables of a Microsoft AccessTM database'. 
The MS- AnalyzeTM software2 (supplied with the AToFMS instrument) uniquely 
labels data for each particle with an identifier as it is acquired by the data system. This 
identifier is used to reference and link data on particle size to the corresponding mass 
spectra. Data arranged in this way is easily retrieved and interrogated either directly 
through the database, via MS- AnalyzeTM, or via third party software such as 
MatlabTM3 
The identification of particles by the appearance of the mass spectrum was achieved 
based on (i) the identification of representative marker ions and (ii) on mass spectral 
fragmentation pattern recognition. Marker ions are fragmentation ions that are 
representative of a given drug compound. The formulated inhalation product is a well 
defined blend of two or three compounds (i.e. drugs and excipients) hence, it was 
possible to ensure that the marker ions chosen were representative and unique to each 
compound. The marker ion analysis shown in this and the next chapter are based on 
one marker ion per compound. Data analysis methods based multiple marker ions 
were explored but found to be unreliable hence this approach was not pursued. For 
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example the use of four marker ions resulted in large numbers of particles (up to 40 
%) remaining unclassified. The identification and classification of particles based on 
composition determined by marker ions is discussed in Section 4.3. 
Additionally, the identification of particles based on their mass spectral pattern was 
performed by using a multivariate statistical analysis based on principal components. 
In this approach, rather than selecting individual pieces of data it is the variation in the 
whole of the dataset that is considered. This gives a more complete analysis of the 
dataset4 and is generally a more sophisticated approach compared with the use of 
marker ions. The identification and classification of particles based on composition 
determined by principal component analysis (PCA) is discussed in Section 4.3. A 
general description of (PCA) is given in Appendix (A3.3). 
The details of the samples of inhalation products used for the data analysis 
development described in this Chapter are given in Appendix A4.1. A complete list of 
samples is given in Appendix A5.1. 
For the AToFMS experiments described in this and the next chapter, initial data were 
acquired using the nozzle- skimmer as the sample inlet and a range of laser energy 
from 0.1 to 1.0 mi. Further experiments to investigate co- association were performed 
using low laser energy (0.2 m.) on the upgraded instrument incorporating an 
aerodynamic lens inlet. Examples of the data acquired using the nozzle -skimmer and 
aerodynamic lens inlets (which are described in Section 2.3) are given later in this 
chapter. 
4.2 Particle Size Analysis 
Some discussion of the particle sizing data is given in this section although the 
emphasis of this work was to determine the degree of co- association present. Figure 
4.1(a) shows the particle size distribution for particles of pure FP in terms of the 
number of particles that were detected by light scattering in the particle sizing region 
of the AToFMS instrument (in this case 5794), compared with the number of particles 
that were ablated in the mass spectrometer ionization source. In this example 3.5% of 
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the particles detected in the light scattering region were ablated. The particle size 
range shown is from 0.3 to 10 gm. Note that particles which are detected by both 
timing lasers are said to have been `sized' and those which are desorbed and ionized 
by the third laser to produce mass spectra are said to be `hit' (See Section 2.3.3.3). 
An enlarged view of the particle size distribution for the FP particles that were ablated 
is shown in Figure 4.1(b). Most of the particles were found to be in the size range of 
between 0.75 and 3.5 gm and the average particle size was found to be approximately 
2 gm which was expected as the pure FP was micronized5 before use to an average 
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Figure 4.1. Particle size distribution for pure FP particles introduced via a nozzle - 
skimmer inlet. (a) shows particles detected by light scattering (Total) and ablated 
particles (Hits) using the mass spectrometer, (b) shows an expanded normalised view 
of the ablated particles (Hits). These data were collected at laser energies from 0.1 to 
1.0 mJ. 
The nozzle -skimmer inlet does not transmit particles of all sizes equally and the 
particle size distribution can be corrected6 (See Section 2.3.1) However, as the 
primary objective of this thesis was to study co- association a correction for the 
particle size transmission efficiency was not applied. 
Further work was performed using the aerodynamic lens for the experiments 
described in Chapter 5 to estimate the amount of co- association and to estimate the 
reproducibility of the measurement. 
An example of the particle size distribution for pure FP particles determined under 
these conditions is given in Figure 4.2(a). This shows a much narrower particle size 
distribution compared with the nozzle -skimmer inlet (Figure 4.1) and indicates that 
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the largest particles detected have an aerodynamic diameter of approximately 3 gm. 
Figure 4.2(b) shows that the ablated particles were smaller than those detected in the 
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Figure 4.2. Particle size distribution for pure FP particles introduced via a 
aerodynamic lens inlet. (a) shows particles as detected by light scattering (Total) and 
as ablated particles (Hits) using the mass spectrometer (b) shows a normalised view 
of the ablated particles (Hits). These data were collected at a laser energy of 0.2 mJ. 
Only a few of the particles that are detected in the particle sizing region are ablated 
and ionized. The hit efficiency for the AToFMS (EAToFMS) is given by Equation 4.1. 
Where: 
EAToFMS = P P Total X 100% Equation 4.1 
P MS = Number of particles hit by the ablation laser 
P Total = Total number of particles detected by light scattering 
Table 4.1 summarises the hit efficiency for the data acquired using the AToFMS 
instrument and shows the average particle size for each dataset. The hit efficiency for 
particles of SX was shown to be over twice the value for FP due to the fact that SX 
absorbs energy from the ablation laser (at 266 nm) more efficiently (as shown in 
Section 3.2). The average size for the particles that were hit (shown in Table 4.1) was 
0.4 gm for SX and 0.8 µm for FP. 
Table 4.1 also shows the average particle size for each sample; in this case the particle 
size shown is for the particles that were hit by the ablation laser (as opposed to the 
total particle population that was detected using light scattering). 
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Sample File Total Particles Particles hit Hit efficiency Av PS* 







SX powder SX4 4129 160 3.9 0.4 
FP powder FP2 5051 74 1.5 0.8 
Serevent® SERE 6311 121 1.9 1.2 
Flovent® FLO_1 8336 101 1.2 1.3 
c. 
FP/SX, 250/25 MDI_1 4081 101 2.5 0.9 
FP/SX, 250/25 MDI_2 5006 104 2.1 1.0 
FP/SX, 250/25 MDI3 3590 102 2.8 0.9 
FP/SX, 250/25 MDI__4 4768 102 2.1 1.0 
FP/SX, 250/25 MDI_5 3836 101 2.6 0.9 
Q. 
FP/SX, 125/25 MDI_6 5474 104 1.9 0.9 
FP/SX, 125/25 MDI_7 2899 100 3.4 1.0 
FP/SX, 125/25 MDI_8 3793 101 2.7 0.9 
FP/SX, 125/25 MDI_9 4183 102 2.4 0.9 
FP/SX, 125/25 MDI_10 3960 101 2.6 0.9 
c. 
FP/SX, 50/25 MDI_11 3786 101 2.7 0.8 
FP/SX, 50/25 MDI_12 3406 109 3.2 0.9 
FP/SX, 50/25 MDI_13 3724 101 2.7 0.7 
FP/SX, 50/25 MDI_14 3337 106 3.2 0.8 
FP/SX, 50/25 MDI_15 3813 103 2.7 0.8 
o 
FP/SX, 250/50 DPI_1 5078 68 1.3 1.2 
FP/SX, 250/50 DPI_2 6218 57 0.9 1.3 
FP/SX, 250/50 DPI3 6621 68 1.0 1.3 
FP/SX, 250/50 DPI__4 7379 79 1.1 1.3 
FP/SX, 250/50 DPI_5 8985 130 1.4 1.3 
Y. o 
FP/SX, 500/50 DPI_7 13484 102 0.8 1.2 
FP/SX, 500/50 DPI_8 11998 109 0.9 1.3 
FP/SX, 500/50 DPI_9 13376 100 0.7 1.2 
FP/SX, 500/50 DPI_10 11428 103 0.9 1.3 
FP/SX, 500/50 DPI_11 12202 102 0.8 1.2 
Table 4.1. AToFMS hit efficiency and particle size data for (z) pure FP and SX (ii) 
DPIs containing a blend of one active drug and lactose ( Flovent© and Serevent®) and 
(iii) combination pMDI and DPI devices containing both FP and SX. *Av PS = 
average particle size. An explanation of each sample is given in Appendix A5.1. 
The aerodynamic size of the particle reflects the shape of the particle as well as the 
size. Hence particles of the same diameter but different shape, will give different 
transit times that translate into different particle sizes. 
To investigate the shape of particles found in the materials used, scanning electron 
microscope (SEM) images were acquired. These images were taken using a Hitachi S- 
4700, field emission SEM (Hitachi High Technologies America, Pleasanton, CA, 
87 
Chapter 4 -Data Analysis Methods for Aerosol Time -of- Flight Mass Spectrometry (AToFMS) 
USA). The images of the particles found in the pure powders8 and in a pMDI are 
shown in Figure 4.3. 
The SEM images give an impression of the two dimensional shape of the particles, 
and it can be seen that they appear irregularly shaped; for example the FP particles in 
Figure 4.3 (a) are approximately disc shaped. The images also show some particles 
that are much larger than those detected using the AToFMS (or the AAMS) 
instrument. For these experiments, the larger particles were not detected mainly 
because they were prevented from entering the instrument by the sample conditioning 
apparatus (See Section 2.4.1). 
The shape of the particles taken from the inhaler appears to be different from that of 
the two active drug compounds. It is speculated that the shape was affected by the co- 
association between the drug materials, i.e. if the greasy FP material were spread onto 
the surface of the irregular SX particles it may have resulted in the formation of 
particles with a much smoother surface. However further investigation would be 
required to prove this to be the case unequivocally. 
Figure 4.3. Scanning electron microscope images of particles from (a) FP powder (b) 
SX powder (c) pMDI inhaler. 
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Figure 4.4 compares the SEM images taken from lactose and from material used in a 
DPI device. Figure 4.4 (a) shows the much larger lactose particles typical of the 
material used in DPI devices as an excipient. The image shown in Figure 4.4(b) was 
taken from DPI inhaler particles and shows the larger lactose particles and smaller 
particles from the drug materials present. Lactose cannot be detected using the 
AToFMS instrument as it does not absorb light at 266 nm. However, it was found that 
lactose can be detected using the AAMS instrument, as described in Section 3.5.2. 
There may be some advantage in the AAMS in this respect as it is able to detect 
excipients in single particles comprised of mixtures of components. For example the 
difference between a particle containing FP and a mixture of FP and lactose would be 
apparent using the AAMS but not with the AToFMS. It may be useful to be able to 
detect excipients such as lactose in the SPMS experiment however further work 
would be required to explore the application of this observation. 
Figure 4.4. Scanning electron microscope images of particles from (a) lactose 
powder (b) DPI inhaler. 
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4.3 The Identification and Classification of Particles Based 
on Composition Determined by Marker ions 
4.3.1 Identification of Marker Ions for Pure Drug Compounds 
The aim of data analysis based on marker ions, is to be able to identify and classify 
the particles from inhalation products in terms of their composition. In this section 
the choice of characteristic, marker, fragment ions used to identify particle 
composition is discussed. An example of the identification of particles from inhalation 
products is presented later in this chapter (see Section 4.3.2) and the use of 
classification of particles from AToFMS data sets to determine co- association is 
described in detail in Chapter 5. 
The choice of marker ions from the mass spectra of particles of pure drug material 
was based on the fragment ions observed in the average AToFMS spectra. The MS- 
AnalyzeTM software enables the number of particles that give a mass spectrum 
showing a particular ion to be counted. Note that the AToFMS is able to detect both 
positive and negative ions simultaneously (see Section 2.4.2) However the data 
analysis performed using the MS- AnalyzeTM software separates the positive and 
negative ion spectra and labels the ions as such. For example in the data analysis 
shown in this thesis, a positive ion would be shown as m/z 100 and a negative ion 
would be shown as m/z -100. For the negative ions m/z -100 does not infer a negative 
value for the m /z, (clearly impossible!!) but that the ion originated from a negative ion 
spectrum. 
For example Figure 4.5 shows the analysis of a dataset of FP particles in terms of the 
ions found in the average AToFMS spectrum of FP (see Appendix A4.2). In this 
figure the x -axis gives the m/z value for each fragment ion and the y -axis shows the 
number of particles that yield mass spectra that contain the given ion. The most 
prominent fragment ions for FP shown in Figure 4.5 are at m/z -39, -66, -74, 97 and 
58 which means that the majority of the single particles from pure FP gave mass 
spectra that showed these ions. 
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Figure 4.5. Analysis of the AToFMS dataset of pure FP particles showing potential 
marker ions for FP. Negative m/z values indicate negative ions, positive m/z values 
indicate positive ions. 
Analysis of a SX data set is shown in Figure 4.6. The ions from the xinofoate counter - 
ion at m/z -188, -152 and -144 dominate the negative ion AToFMS mass spectrum 
and are present in the mass spectra of the majority of the particles. The most 
prominent positive ions are shown at m/z 115 and 92 however these are present in 
fewer of the particles analyzed, hence are less indicative of SX compared with than 
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Figure 4.6. Analysis the AToFMS dataset for pure SX particles showing potential 
marker ions for SX. Negative m/z values indicate negative ions, positive m/z values 
indicate positive ions. 
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The most prominent ions in Figures 4.5 and 4.6 (i.e. m/z -188 for SX and m/z -74 for 
FP where the negative m/z values indicate negative ions) were used as marker ions for 
the data analysis described in Chapter 5. These ions are abundant in the average mass 
spectra of each of the pure drug compounds, appear in the mass spectra for the 
majority of the particles of each pure drug compound and are unique to the mass 
spectrum of each pure drug compound. The use of the marker ions m/z -188 for SX 
and m/z -74 for FP was tested on the datasets of the pure drug compounds. Figure 4.7 
is an example dataset from pure SX particles and based on the marker ions mentioned 
above and shows that 96.3 % of the particles from the pure SX material were 
identified as SX. Similarly, Figure 4.8 shows a dataset from pure FP particles and 
shows that 94.6 % of the particles from the pure FP material were identified as FP. 
The Boolean OR operation was used to give the FPORSX category and is discussed in 
the next section. In this case it is used to show the total number of particles containing 
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Compound 
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Figure 4.7. Classification of the AToFMS dataset for pure SX particles in terms of 
one marker ion for FP (m /z -74) and one marker ion for SX (m /z -188); see text above 
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Figure 4.8. Classification of the AToFMS dataset for pure FP particles in terms of 
one marker ion for FP (m /z -74) and one marker ion for SX (m /z -188); see text above 
for further details. Negative m/z values indicate negative ions 
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4.3.2 Classification of Particles from Inhalation Products 
The data analysis method based on marker ions was developed further using the MS- 
AnalyzeTM software, with the application of `AND' and `OR' Boolean operations 
which were used in the identification of co- associated particles. The formulated 
product of the pressurized metered dose inhalers (pMDIs) only contains the active 
drugs FP and SX. This gives the possibility of identifying three types of particle i.e. 
(a) containing FP, (b) containing SX or (c) containing a mixture of both FP and SX 
(i.e. co- associated). The required result from this data analysis is the number of co- 
associated particles given by `FPANDSX' which gives a measure of the amount of 
co- association present. The total number of particles, i.e. those identified as 
containing FP or containing SX is given by `FPORSX'. 
It is noted that in using this method, the category for FP recognizes the presence of FP 
but does not exclude the presence of SX. Hence when samples containing co- 
associated particles were analyzed, the FP category showed particles that contained 
FP i.e. from either pure or co- associated particles and similarly the SX category 
showed particles that contained SX, i.e. from either pure or co- associated particles 
The number of pure FP particles can be calculated by subtracting the number 
categorised as FP from the number of particles shown as `FPORSX', however for this 
work it is the particles composed of a mixture of FP and SX that are of most interest 
as these are used to measure the degree of co- association present. An example of the 























FP AND SX 
Figure 4.9. An example of the classification of particles from a pMDI based marker 
ions (m /z -188 for FP and m/z - 74 for SX). The example shown is from MDI_1 
(FP /SX 250/25). Negative m/z values indicate negative ions 
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The formulation for the dry powder inhaler (DPI) samples contained the excipient 
lactose as well as the active drugs FP and SX. This gives the possibility of forming 
seven categories of particle i.e. pure FP, pure SX, a mixture of FP and SX as well as 
FP + lactose, SX + lactose and FP + SX + lactose. However, lactose was not detected 
by the AToFMS instrument which meant that the particle would be identified and 
classified based only on the drug content; i.e. particles containing a mixture of FP + 
SX + lactose would be classified as FP + SX, particles containing a mixture of FP + 
lactose would be classified as FP and particles containing a mixture of SX + lactose 
would be classified as SX. 
An example dataset for the particles taken from a DPI (formulation FP /SX 250/50) is 
shown in Figure 4.10. Further discussion of the data analysis for pMDIs and DPIs 
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Figure 4.10. An example of the classification of particles from a DPI based marker 
ions (m /z -188 for FP and m/z - 74 for SX). The example shown is from DPI_3 
(FP /SX 250/50). Negative m/z values indicate negative ions 
4.3.3 Summary of the use of Marker Ions for Identifying and Classifying 
Particles 
To use an ion as a marker for a given compound, the ion must be abundant in the 
average mass spectrum for the given compound, be unique to the mass spectrum of 
the given compound and appear in the mass spectrum of the majority of the particles 
of in the dataset for the given compound. 
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The identification and classification of particles based on marker ions described in the 
previous sections is summarized in Figure 4.11 and this includes example data 
analysis for pMDI, a DPI and the pure drug materials (FP and SX). For the pure drug 
materials, over 90 % of the particles were identified as FP OR SX with only a small 
number of particles (typically fewer than 3 %) remaining unclassified. This figure also 
shows that more than 80% of the particles from DPI are co- associated and also that 
over 40 % of the pMDI particles are co- associated. This result is explored in more 
detail in Chapter 5. 





FP AND SX 
Unclassified 
Figure 4.11. An example results set from the classification of particles in samples of 
DPI, pMDI, and pure FP and SX based on marker ions. These were m/z -74 for FP 
and m/z -188, for SX. Formulation of samples : DPI 5; FP /SX 250/50 and MDI_1; 
FP /SX 250/25. Negative m/z values indicate negative ions. 
4.4 The Identification and Classification of Particles Based on 
Composition Determined by Multivariate Statistical Analysis 
A pattern recognition technique based on multivariate statistical analysis4' 9 was 
applied to the AToFMS data to identify and classify the particles from inhalation 
products in terms of their composition. 
There are major differences in a multivariate analysis approach compared with the use 
of the marker ion technique described earlier, notably as much of the data acquired is 
discarded in the marker ion analysis. Also, multivariate analysis offers a much more 
sophisticated, rigorous and complete analysis of the whole dataset. Moreover, where 
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the choice of marker ion was based on the average mass spectrum from a group of 
particles, multivariate analysis is used to investigate variation across the data set in 
terms of each individual data point (i.e. all of the ions from the positive and negative 
ion mass spectra of each individual particle were included in the multivariate 
analysis). 
A general explanation of how principal component analysis charts are drawn is given 
in Appendix A3.3. Section 4.4.1 describes the application of the principal component 
analysis technique to the data initially acquired using an AToFMS instrument 
equipped with a nozzle - skimmer inlet and by using a range of laser energies. Section 
4.4.2 describes how the method was developed further for application to experiments 
designed to give a more detailed study of co- association in inhalation products 
including an assessment of the reproducibility of this measurement. 
4.4.1 Principal Component Analysis (PCA) 
Principal component analysis (PCA) is a multivariate analysis method that can be 
used to detect trends in large complex datasets, by mathematically generating a series 
of new variables called principal components. The principal components can be 
considered as information -rich super variables because they represent the principal 
source of variability in the dataset. This is a method of identifying patterns in data and 
highlighting similarities and differences between datasets. Once the patterns have 
been found, the datasets can be compressed to the principal components with minimal 
loss of information. 
The data matrix from the AToFMS experiment that was analyzed with the PCA 
software package corresponds to the normalized mass spectra of FP and SX stacked in 
rows. From PCA, two sets of vectors were extracted, (the scores and the loadings), 
and these were then projected into charts that show the major trends responsible for 
most of the variation in the data matrix. 
A typical PCA scores plot is given in Figure 4.12 and this shows the clusters of data 
points taken from separate samples of pure FP and SX that were then overlaid onto 
the same PCA chart. In this case, the scores within the same cluster indicate the 
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groups of particles which have similar mass spectra. These data were acquired using 
the AToFMS equipped with the nozzle- skimmer inlet and using a range of laser 
energies. The PCA chart shows that there is good resolution between the clusters of 
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Figure 4.12. PCA scores plot for separate samples of pure FP and pure SX particles, 
overlaid on the same PCA chart. Data taken over a range of laser energies from 0.1 
to 1.0 mJ, samples (pure FP and SX) were introduced using a nozzle -skimmer inlet. 
An example of a loadings plot for the AToFMS spectra taken from pure FP and pure 
SX particles is shown in Figure 4.13. The loadings represent the weights ascribed to 
the original variables (m /z values) in projecting the mass spectra in the scores plot. 
The most influential ions appear in the cluster furthest away from the origin of the 
loadings plot. Additionally, potential ion markers for a specific group emerging in the 
scores plot are shown as clusters in analogous regions in the loadings plot. 
The loadings plot shown in Figure 4.13 gives an indication of the strongest marker 
ions which in this example are m/z values 139, 57, 121 and 23 for FP; and m/z values 
91, 55, 44 and 92 for SX . The upper region identifies particularly intense m/z values 
that may occur in both compounds, i.e. m/z values 39, 63, 51, and 27. It is noted that 
the data analysis is based on different marker ions compared with the marker ion 
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technique described earlier in this chapter. This is mainly because PCA is based on 
the variation in the dataset compared with the marker ion technique where the markers 
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Figure 4.13. Loadings plot indicating marker ions for each group from the same data 
as shown in Figure 4.12. 
4.4.2 Assessment of Co- association in Inhalation Products using 
Principal Component Analysis (PCA) 
Initially two types of inhaler device were used to demonstrate the application of PCA 
to the measurement of co- association, these were: (a) The Seretide® Diskus® inhaler 
in which the inhalation product consists of a blend of FP, SX and lactose, held in a 
number of blisters on a tape strip. In this case, the blister is ruptured on use of the 
inhaler by the patient and the active drugs are administered as a blend (b) The 
Gemini® Diskus® inhaler, in which the two drugs FP and SX are held in separate 
blisters which are also ruptured on use by the patient but where the active drugs are 
administered concurrently as separate powders. 
The PCA charts shown in Figure 4.14 indicate that that the degree of co- association is 
dependent on the method and point at which the particle are mixed. Figure 4.14 shows 
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co- ordinates from (a) the Seretide® and (b) the Gemini® inhalers overlaid on the co- 
ordinates from samples of pure FP and SX. The PCA chart in Figure 4.14 (a) shows 
that the data points from particles from the Seretide® Diskus® formulation sample 
overlap only minimally with those from the particles of pure FP and SX. This is 
consistent with the Seretide® Diskus® formulation which is an intimate blend of FP 
and SX, homogeneously mixed, so there is a high likelihood of co- association. The 
points on the PCA chart for the Seretide® Diskus® formulation show that the particles 
are different from the samples of pure FP and SX. Hence, the Seretide® Diskus® 
formulation was shown to contain particles composed of a mixture of FP and SX, 
derived from co- association of these compounds. 
For the Gemini® Diskus® formulation, the PCA chart shown in Figure 4.14 (b) gives 
the opposite result to that for the Seretide® Diskus®, in that there is a high degree of 
overlay with the co- ordinates derived from pure FP and SX; In this case there are only 
a few co- ordinates in the gap between the FP and SX clusters. This shows that the 
particles in this inhaler are similar to the individual particles of pure FP and SX. As 
the materials are mixed together only when the device is actuated by the patient, there 
is little scope for interaction between FP and SX and hence co- association is unlikely. 
Hence the PCA chart reflects the fact that the particles found in this type of 
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Figure 4.14. PCA analyses of AToFMS data from inhalers (a) Seretide® Diskus® DPI 
FP /SX 100 /50, (b) Gemini° Diskus° FP /SX 100 /50. Both charts were produced by 
superimposing data from samples onto that from the pure drug compounds. Sample 
introduction for these data was by nozzle -skimmer inlet. A range of laser energy 
between 0.6 and 1.0 mJ was used for the acquisition of these data. 
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The PCA charts shown in Figure 4.14 were a significant finding during the 
development of SPMS techniques for the investigation and detection of co- association 
This results goes some way to validating the approach of the application of PCA to 
AToFMS data in terms of the identification and classification of the different types of 
particle present. There may be some advantage in terms of improved efficacy if the 
particles in an inhaled product are composed of a mixture of the active drugs (FP and 
SX) due to the synergistic effect discussed in Chapter 1 (see Section 1.5). 
4.4.3 Identification and Classification of Particles from Inhalation 
Products using Principal Component Analysis. 
In this section the development of the principal component analysis (PCA) technique 
for the data analysis from experiments performed to estimate the amount of co- 
association present in inhaler samples is discussed. A low laser energy was used in 
this case to maximize the distinction between the spectra for FP and SX particles and 
the particles were introduced into the instrument via the aerodynamic lens. The effect 
of laser energy on AToFMS data as depicted by the principal component analysis 
charts and the dependence of the appearance of the mass spectrum on laser energy is 
discussed in is Section 3.2. The results of the PCA to investigate co- association are 
presented in Chapter 5. 
Figure 4.15 shows the PCA clusters from separate AToFMS runs of pure FP and SX 
particles overlaid onto the PCA chart. From this chart it is clear that the co- ordinates 
for FP and SX are distributed into separate clusters, hence gives a good method for 
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Figure 4.15. PCA chart showing clusters of data, for pure samples of FP and SX. 
The sample was introduced via an aerodynamic lens and collected at low laser energy 
(0.2 mJ). 
Figure 4.16 shows the co- ordinates from a DPI superimposed on the co- ordinates for 
pure FP and SX particles (as used in Figure 4.15). Many of the co- ordinates appear 
outside of the clusters for the pure drug materials. For these co- ordinates the DPI 
particles give a different mass spectral pattern compared with that obtained from pure 
FP and SX and must be due to particles composed of a mixture of both FP and SX. 
It is possible to classify the particles by manually dividing the chart into sections as 
shown in Figure 4.16. Although AToFMS is not generally considered to be a 
quantitative technique, an estimate of the number of particles in each category, 
including a measure of the number of or co- associated particles, can be obtained by 
counting the number of points in each zone. 
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Figure 4.16. PCA Chart for DPI_1 divided into zones for FP, SX and co- associated 
particles. The sample (DPI 1; FP /SX 250/50) was introduced via the aerodynamic 
lens. These data were collected at low laser energy (0.2 mJ). 
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Defining ellipses around the clusters of points from samples of pure FP and SX, as 
shown in Figure 4.17, gave an improved method of identifying and classifying 
particles. These ellipses define an equal distance from the class centre using 
Mahalanobis10 metrics, which take into account how particles distribute within the 
plot. For example, because FP particles distribute mainly along the vertical axis, this 
is assumed to be characteristic of this group and therefore the distance along this 
direction is underweighted, resulting in an equidistance ellipse that is tilted vertically. 
The standard confidence ellipses have been overlaid onto the PCA plot for a DPI 
sample in Figure 4.18. In this chart the majority of the data points for the DPI sample 
appear towards the centre of the axis and are not overlaid by the standard ellipses. 
This shows that there is a difference in the mass spectral patterns for these particles 
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Figure 4.17. Definition of ellipses using PCA for pure FP and SX. These data were 
collected at low laser energy (0.2 mJ). 
The ellipses defined in this way were overlaid onto the PCA chart of the co- ordinates 
taken from a DPI as shown in Figure 4.18. The co- ordinates were then classified 
according to the area in which they appeared on the chart and these were then counted 
to determine the number in each category. The results for this type of data analysis as 
applied to the investigation of co- association in particles from inhalation products are 
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Figure 4.18. Shows the ellipses defined (for samples of pure drug material) in Figure 
4.17 overlaid onto data from DPI_1 (FP /SX 250/50). The sample was introduced via 
the aerodynamic lens and data were collected at low laser energy (0.2 mi). 






Blue points = FP particles 
Red points = SX particles 
Black points - mixed particles 
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4.5 Summary 
Methods for analyzing AToFMS data were developed based on marker ion analysis 
and on multivariate statistical analysis. 
The choice of marker ions from particles of pure drug material was based on the 
fragment ions observed in the average AToFMS spectra and these were previously 
interpreted in terms of the structure of the given molecule. The marker ions used were 
abundant in the average mass spectrum of each of the pure drug compounds, unique to 
the mass spectrum of the pure drug compounds and appeared in the mass spectra of 
the majority of the particles of each pure drug compound. 
There are some risks associated with marker ion analysis especially when based on 
only one ion per compound, not least the fact that much of the data that is available is 
actually discarded. However, in this case samples were well defined blends of two or 
three compounds hence it was easy to attribute marker ions that were unique and 
representative of the individual drug compounds present. Thus the marker ion 
technique was found to be a useful screen of the data and gave a reasonable way of 
identifying and classifying particles. 
It was found that the analysis of the AToFMS data using multivariate analysis based 
on principal component analysis (PCA) is a viable and efficient approach. Compared 
with marker ion analysis multivariate analysis is a much more sophisticated, rigorous 
and complete analysis technique that was applied to the whole of the dataset (rather 
than selected ions). Moreover, whereas the choice of marker ion was based on the 
average mass spectrum from a group of particles, a multivariate analysis approach 
was used to investigate variation in the dataset from the mass spectrum of each 
individual particle. 
The methods developed in this chapter and the application of marker ion analysis and 
PCA are discussed in more detail in the next chapter and the methodology is extended 
to examine a range of inhalation products. 
104 
Chapter 4 -Data Analysis Methods for Aerosol Time -of- Flight Mass Spectrometry (AToFMS) 
4.6 References 
(1) Microsoft AccessTM software, (Microsoft Corporation, Seattle WA, USA) 
http:// www .microsoft.com/en/us /default.aspx (Accessed 31 May 2008). 
(2) MS- AnalyzeTM TSI Shoreview, MN, USA. (http: / /www.tsi.com/). (Accessed 
31 May 2008). 
(3) MatlabTM software, (The Mathworks, Natick, MA, USA). 
http: / /www.mathworks.com/ (Accessed 31 May 2008). 
(4) Chemometrics: Data analysis for the laboratory and chemical plant. R. 
Brereton. First edition (2003), Wiley- Blackwell. ISBN 0- 471 -489 786. 
(5) Micronization of pharmaceutical powders for use in inhalation. J -M. Larran. 
Pharmaceutical Manufacturing and Packing Source. p1 -4, Spring 2005. 
(6) Single particle detection efficiencies of aerosol time -of -flight mass 
spectrometry during the North Atlantic Marine Boundary layer experiment. M. 
Dall'Osto, R. Harrison, D. Bedows, E. Freney, M. Heal, and R. Donovan. 
Environ. Sci. Technol. 40 5029 -5035, (2006). 
(7) Particle morphology and density characterization by combined mobility and 
aerodynamic measurements. Part 1: Theory. P. DeCarlo, J. Slowick, D.R. 
Worsnop, P. Davidovits and J -L. Jimenez. Aerosol Sci. and Tech. 38 1185- 
1205, (2004). 
(8) Private Communication from N. Mistry and J. Warrack (GSK Stevenage). 
(9) Principal component analysis. S. Wold, K. Esbensen and P. Geladi, 
Chemometrics and Intelligent Laboratory Systems. 2 37 -57 (1987). 
(10) The Mahalanobis Distance. R. De- Maesschalck, D. Jouan- Rimbaud and D. 
Massart. Chemometrics and Intelligent Laboratory Systems. 50 1 -18, (2000). 
105 
Chapter 5 
The Determination of Co- association Using 
Aerosol Time -of- Flight Mass Spectrometry 
(AToFMS) 
5.1 Introduction 
A major aim of the work presented in this thesis was to assess the amount of co- 
association in particles taken from a wide range of inhalation products. As discussed 
in Chapter 1 (see Section 1.5) there may be some advantage in terms of improved 
efficacy if the particles in an inhaled product are composed of a mixture of the active 
drugs (FP and SX). Hence, the data analysis was performed with an emphasis on this 
aspect based on either marker ion analysis or on multivariate analysis (i.e. principal 
component analysis). 
In this chapter, the results from processing AToFMS data analysis using the 
techniques described in Chapter 4 are presented and discussed; the data obtained 
using the Aerodyne AMS instrument are described in Chapters 6 and 7. A comparison 
of AToFMS and AAMS data is given in Chapter 8. 
AToFMS experiments were performed on a range of inhalation products using an 
aerodynamic lens (see Chapter 2) and low laser energy (0.2 mJ), (the effect of 
variation in the Iaser energy on the AToFMS spectrum is discussed in Chapter 3). 
5.2 Assessment of Co- association using Marker Ion Analysis 
In Chapter 4, the selection and use of marker ions to determine co- association was 
discussed. In the first part of this section, the AToFMS results for pMDIs and DPIs 
based on data analysis using marker ions are presented. The reproducibility of this 
type of data analysis is explored in later in Section 5.2.3. 
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5.2.1 Pressurized Metered Dose Inhalers (pMDIs) 
A summary of data analysis for the pMDIs based on marker ions is shown in Figure 
5.1. Particles were classified as (i) containing FP, (ii) containing SX (iii) mixed (co- 
associated) particles of FP and SX using the marker ion techniques described in 
Chapter 4. 
The number of mixed particles was used to give an estimate of the degree of co- 
association in each sample. Figure 5.1 shows that for the FP /SX 250/25 formulation, 
-45 to 55 % of the particles were classified as mixed; for the FP /SX 125/25 
formulation -40 to 50 % were classified as mixed; and for the FP /SX 50/25 
formulation -35 to 45 % % were classified as mixed. Typically less than 3.0 % of the 
particles remained unclassified (i.e. in this case the particles could not be identified or 
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Figure 5.1. Data 
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analysis for pMDI aerosols using one marker ion for each 
component. Category FP - particles that contain FP; Category SX - particles that 
contain SX; Category - FPAND SX particles that contain FP and SX (i.e. mixed due to 
co- association). Samples are described in detail in Appendix A5.1 The data used to 
plot these bar -charts is shown in Appendix A5.3. 
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Thus it was shown that the degree of co- association was found to be between 35 to 55 
% for the three formulations of pMDIs. The reproducibility of this measurement is 
discussed in Section 5.2.3. 
5.2.2 Dry Powder Inhalers (DPIs) 
The classification of particles taken from DPIs based on marker ion analysis is shown 
in Figure 5.2. The formulation for DPIs contained lactose which was not detected 
using the AToFMS (See Chapter 3). Hence, particles were classified similarly to the 
pMDIs as (i) containing FP, (ii) containing SX (iii) mixed particles of FP and SX 
using the marker ion techniques described in Chapter 4. 
Similarly to the pMDI, the number of mixed particles was used to measure the degree 
of co- association in each sample. Based on the intra -batch measurements, in the 
FP /SX 250/50 formulation, -79 to 92 % of the particles were found to be co- 
associated; for the FP /SX 500/50 formulation -85 to 87 % of the particles were found 
to be co- associated. Typically less than 1.5 % of the particles remained unclassified 
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Figure 5.2. Data analysis for DPIs using one marker ion for each component. 
Category FP - particles that contain FP; Category SX - particles that contain SX; 
Category- FP AND SX particles that contain FP and SX i.e. mixed due to co- 
association. Samples are described in detail in Appendix A5.1 The data used to plot 
this bar -chart is shown in Appendix A5.3. 
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Thus it was shown that the degree of co- association was found to be between 79 to 92 
% for the DPIs with a similar range of measurements observed for the two 
formulations. The reproducibility of this measurement is discussed in Section 5.2.3. 
5.2.3 Reproducibility of the Determination of Co- association using 
Marker Ion Analysis 
To estimate the reproducibility of the experiment, the relative standard deviation 
(RSD) of the number of mixed particles in three runs of the same batch of each 
formulation was calculated (intra- batch). Also the RSD of runs of three different 
batches (of the same formulation) were used to estimate the inter -batch variation. The 
results for marker ion analysis are shown in Table 5.1. 
Table 5.1 shows that the average number of co- associated particles found in the pMDI 
intra -batch measurements was found to be 42.2 to 50.2 %. Also the error shown by 
the relative standard deviation (RSD) for the pMDI intra -batch experiments varied 
from 5.4 % for samples of FP /SX 50/25 to 10.8 % for samples of FP /SX 250/25. The 
average number of co- associated particles found in the DPI intra -batch measurements 
was found to be similar ( -85 %) in both formulations. Also the error shown by the 
relative standard deviation (RSD) for the DPI intra -batch experiments varied from 1.1 
% for samples of FP /SX 500/50 to 7.1 % for samples of FP /SX 250/50. 
The average number of mixed particles found in the pMDI inter -batch measurements 
was found to be between 37.6 to 49.5 %. Also the error shown by the RSD for the 
pMDI intra -batch experiments varied from 10.0 % for samples of FP /SX 125/25 to 
16.4 % for samples of FP /SX 50/25. The average number of mixed particles found in 
the DPI inter -batch measurements was found to be between 81.7 to 85.4 % indicating 
a similar amount of co- association in the two formulations. Also the error shown by 
the relative standard deviation (RSD) for the DPI intra -batch experiments varied from 
7.8 % for samples of FP /SX 250/50 to 7.9 % for samples of FP /SX 500/50. 
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FP /SX 250/25 Inter 49.5 5.8 11.7 




FP /SX 125/25 Inter 45.2 4.5 10.0 




FP /SX 50/25 Inter 37.6 6.2 16.4 
FP /SX 50/25 Intra 47.2 2.3 5.4 
a 
FP /SX 250/50 Inter 85.4 6.7 7.8 




FP /SX 500/50 Inter 81.7 6.4 7.9 
FP /SX 500/50 Intra 85.9 1.0 1.1 
Table 5.1. Determination of co- association (mixed particles) in pMDI and DPI 
aerosols based on marker ions. The table shows the average % number of particles 
found in inter- or intra- batch experiments. In each case and estimate of the error is 
given by the relative standard deviation % (RSD %) (i.e. the Standard Deviation/ 
Average (x 100 %)). 
5.3 Assessment of Co- association Based on Principal 
Component Analysis 
The results for the application of principal component analysis (PCA) to the AToFMS 
data to determine the degree of co- association are described in Section 5.3.1. The 
reproducibility of this measurement is discussed in Section 5.3.2. 
The particles were classified using ellipses defined by the standards of FP and SX as 
described in Section 4.4.3. Using PCA, particles were classified as (i) FP, (ii) SX (iii) 
mixed particles of FP and SX. An example of a PCA chart used to classify the 
particles from a pMDI is shown in Figure 5.3 and from a DPI in Figure 5.4. 
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Figure 5.3. Example of a PCA chart for a pMDI (FP /SX 250/25 (file MDI_1)). This 
chart shows data only from the pMDI but with the ellipses defined pure FP and SX 
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Figure 5.4. Example PCA chart for DPI formulation FP /SX 250/50 (DPI_1). This 
chart shows data only from the DPI but with the ellipses defined by pure FP and SX 
overlaid on the chart used to classify the particles present. 
0.4 0.5 0.6 
5.3.1 Particle Classification for Inhalation Products 
A summary of data analysis for the pMDIs based on principal component analysis 
(PCA) is shown in Figure 5.5. As with the marker ion analysis, the number of mixed 
particles was used to give an estimate of the degree of co- association in each sample. 
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Based on the intra -batch measurements the results show that for the FP /SX 250/25 
formulation 55.9 to 63.7 % of the particles were classified as mixed; for the FP /SX 
125/25 formulation 62.4 to 68.6 % were classified as mixed; and for the FP /SX 50/25 
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Figure 5.5. Data analysis for samples from pMDIs using PCA ellipses. Samples are 
described in detail in Appendix A5. The data used to plot this bar -graph is also shown 
in Appendix A5. 
Figure 5.6 shows the data analysis for the set of samples from DPIs investigated and 
the particles were classified using ellipses defined by the standards of FP and SX. 
Approximately 83.1 to 92.6 % of the particles were classified as mixed particles for 
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Figure 5.6. Data analysis for samples from DPIs using PCA ellipses. Samples are 
described in detail in Appendix A5.1. The data used to plot this bar -graph is also 
shown in Appendix A5.3. 
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5.3.2 Reproducibility of the Determination of Co- association 
Based on Principal Component Analysis. 
Similarly to the marker ion analysis, the reproducibility of the experiment was 
estimated using the relative standard deviation (RSD) of the number of mixed 
particles determined using PCA from three runs of the same batch of each formulation 
(intra- batch). Also the RSD of runs of three different batches (but of the same 
formulation) were used to estimate the inter -batch variation. The results for the PCA 
are shown in Table 5.2. 
Table 5.2 shows that the average number of mixed particles found in the pMDI intra- 
batch measurements was found to be 61.1 to 63.7 %. The error shown by the relative 
standard deviation (RSD) for the pMDI intra -batch experiments varied from 4.7 % for 
samples of FP /SX 125/25 to 10.3 % for samples of FP /SX 50/25. The average number 
of mixed particles found in the DPI intra -batch measurements was found to be 
between 86.4 and 88.9 % indicating a similar amount of co- association in both 
formulations. The error shown by the relative standard deviation (RSD) for the DPI 
intra -batch experiments varied from 4.4 % for samples of FP /SX 500/50 to 6.2 % for 
samples of FP /SX 250/50. 
The average number of mixed (co- associated) particles found in the pMDI inter -batch 
measurements was found to be between 59.6 and 68.1 %. The RSD for the intra -batch 
experiment gave an estimate of the error in the measurement of co- association and 
for the pMDI intra -batch experiments varied from 3.1 % for samples of FP /SX 125/25 
to 6.7 % for samples of FP /SX 50/25. 
The average number of mixed (co- associated) particles found in the DPI inter -batch 
measurements was found to be 86.6 to 86.7 % indicating a similar amount of co- 
association in the two formulations. The RSD for the intra -batch experiment varied 
from 5.5 % for samples of FP /SX 250/50 to 6.0 % for samples of FP /SX 500/50. 
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250/25 Inter 59.6 4.2 7.0 
FP /SX 
250/25 Intra 61.1 4.5 7.4 
g a 
FP /SX 
125/25 Inter 64.7 5.6 8.6 
FP /SX 
125/25 Intra 65.4 3.1 4.7 
m 
Q. 
FP /SX 50/25 Inter 68.1 2.0 3.0 
FP /SX 50/25 Intra 65.4 6.7 10.3 
ó 
FP /SX 
250/50 Inter 86.7 6.0 6.9 
F P /SX 
250/50 Intra 86.4 5.4 6.2 
o 
FP /SX 
500/50 Inter 86.6 5.5 6.4 
FP /SX 
500/50 Intra 88.9 3.9 4.4 
Table 5.2. Determination of co- association (mixed particles) in pMDI aerosols based 
on PCA. The table shows the average % number of particles found in inter- or infra- 
batch experiments. In each case and estimate of the error is given by the relative 
standard deviation (RSD) (i.e. the Standard Deviation/ Average (x 100 %)). 
5.4 AToFMS Data Analysis Summary 
The relavenace of the presence of co- association is discussed in Chapter 1. The 
synergistic effect of treatment for lung disease using the two active drugs 
simultaneously may be explained by the two drugs acting on the lung tissue 
simultaneously. Intuitively it might be that the easiest way for this to happen would be 
via particles that consist of a mixture of the two active materials. The data shown in 
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this chapter provides evidence of high levels of co- associated particles in the inhaler 
devices investigated. 
It has been reported previously that quantitation using the AToFMS is difficult 
because of the shot -to -shot variation in the laser (See section 3.2). The data presented 
in this chapter, to investigate the composition of each particle is probably semi - 
quantitative at best. However the variation measured expressed as an RSD % (1 to 16 
% for marker ions and 3 to 10 % for PCA) was good when the small amounts of 
sample per particle around the femtogram level or less (see Section 9.2.3) are 
considered. 
In Figure 5.7, the average number of mixed (co- associated) particles found for DPIs is 
shown to be between 85 to 89 %. The spread of results was broader for the pMDI as 
the average number of mixed particles was between 42 and 50 % as given by the 
intra -batch data. The reproducibility of the measurement for both marker ions and 
PCA expressed as the RSD % was typically found to be between 1.1 and 10.8 % . 
The results shown in this chapter are quoted to one decimal place, however the data is 
semi -quantitative at best. Further work would be required to (a) improve on the 
reproducibility of the experiment for example by improving the shot -to -shot 
reproducibility of the laser (see Section 3.2) and (b) increase the numbers of samples 
analyzed and particles measured to improve on the statistical significance of this data. 
It might have been expected that PCA would provide a more reliable way to show the 
presence of co- association in these samples as it is a more sophisticated data analysis 
technique. However broad agreement between the marker ion analysis and the PCA 
was found as summarized in Figure 5.7. Also the errors estimated from the RSD were 
similar using both techniques. 
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Figure 5.7. Summary of data to measure co- association in DPI and pMDI aerosols 
based on marker ions and PCA. Data shown is based on three replicates of each 
batch for each formulation. 
The good agreement between the data analysis techniques may be because the 
samples analyzed consisted of well defined, simple mixtures of only two or three 
components. Even though the use of marker ions is a fairly crude technique, a good 
estimate of the degree of co- association was possible mainly because it was possible 
to choose marker ions that were unique and representative of the drug compounds. 
PCA is an established technique that provides a rigorous approach to data analysis 
and uses all of the dataset so may avoid missing information (as for example in the 
marker ion technique where much of the data is discarded). If the inhalation products, 
were comprised of more complex mixtures then PCA analysis might give further 
advantage as it would become increasingly more difficult to choose marker ions that 
were unique and representative as the formulation became more complex. 
For the data presented in this chapter however, it was possible to use either data 
technique to obtain a similar estimate of the degree of co- association. 
The difference in co- association levels between DPIs and pMDIs is likely to result 
from the very different nature of the formulations and the mechanisms by which co- 
association may occur. The difference in co- associated for these devices and the level 
of co- association estimated using the AToFMS and the AAMS instruments are 
discussed further in Chapter 8. 
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Data Analysis Methods for Aerodyne Aerosol 
Mass Spectrometry (AAMS) 
6.1 Introduction 
The potential of an Aerodyne Aerosol Mass Spectrometry (AAMS) for the analysis of 
inhalation products was explored. Initially a number of trial experiments were 
designed and performed using an AAMS instrument (described in Chapter 2). These 
were designed to show that the materials used in inhalation products would give data 
that could be used to determine the composition of the particles originating from the 
inhalation products. A second set of experiments were designed to further evaluate 
the instrumentation for the analysis of inhalation products and to assess the potential 
of the technology for the measurement of co- association. This chapter describes how 
the data processing methods were developed and the initial results produced are 
presented in Chapter 7. Note that this work was performed in the manufacturers' 
laboratories (Aerodyne, Boston, MA, USA) which meant that instrument time and 
access was limited. 
The AAMS instruments have previously been used to produce quantitative data on the 
composition of environmental aerosol particles'' 2 hence an estimation of the 
composition of individual particles for inhalation products is given along with an 
estimate of the errors encountered when making this type of measurement. The results 
for the efficiency of production of mass spectra and on the measurement of particle 
size are presented however the emphasis of this work was on the assessment of the 
degree of co- association. 
During the AAMS experiment, the data for each particle size measurement is linked 
to the mass spectrum via a Microsoft Exce1TM spreadsheet3. A spreadsheet was also 
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used to process the data using marker ions; the AAMS spectra of pure drug 
compounds showed some representative fragment ions which were used as markers to 
identify the particles in an analogous way to that described for the AToFMS data in 
Chapter 4. The data was also analyzed with multivariate statistical analysis software; 
this technique has previously been shown to give both a quantitative and qualitative 
assessment of particle composition4. 
6.2 Particle Size Analysis 
Not all of the particles that are detected by light scattering in the particle sizing region 
of the instrument give a mass spectrum. The efficiency of mass spectrum production 
for the AAMS (E AAMs) is given by Equation 6.1. 
Where: 
E AAMS = P MS ' P Total x 100% Equation 6.1 
P Ms = Number of particles that give a mass spectrum 
P Total = Total number of particles detected by light scattering 
The efficiency of mass spectrum production for the AAMS (E AAMs) for material 
taken from pMDIs and DPIs is shown in Table 6.1. For pMDIs the efficiency was 
found to be between 23.7 to 38.5 % which is much higher than the efficiency of the 
AToFMS (see Section 4.2). For the DPIs the mass spectrum efficiency was 
determined on the samples shown as between 13.9 and 33.2 %. 
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Sample Batch Formulation Number 
of 
particles 









MDI 1 * 002/78 FP /SX 50/25 96 n/a n/a 
MDI 2 002/78 FP /SX 50/25 445 122 27.4 
MDI 3 05/97F FP /SX 50/25 422 102 24.2 
MDI 4 AX7099/23 FP /SX 50/25 405 120 29.6 
MDI _5 
i6 
AX7099/23 FP /SX 50/25 378 103 27.2 
MDI AX7099/23 FP /SX 50/25 597 172 28.8 
MDI 7 1/22 FP /SX 250/25 431 102 23.7 
MDI 8 1/22 FP /SX 250/25 445 169 38.0 
MDI 9 AX7102/82 FP /SX 250/25 435 121 27.8 
MDI 10 D040861 FP /SX 250/25 304 103 33.9 
MDI 11 D040861 FP /SX 250/25 403 155 38.5 
DPI 11- R15404 -20 FP 100 183 50 27.3 
DPI 2 R25237 250/50 FP /SX 346 48 13.9 
DPI_3 R25240 500/50 FP /SX 385 128 33.2 
Table 6.1 The mass spectrum efficiency for pMDIs and DPIs. All samples were run 
under the same conditions except for MDI 11 where the spacer was removed from the 
sampling orifice. *No data are shown for file MDI _I as this was a trial run. f DPI_1 
was a Flovent® inhaler containing a blend of FP and lactose. DPI_2 &3 were 
Seretide® containing a blend of FP, SX and lactose. 
As in the case of the AToFMS instrument, the shape of the particle has an influence 
on the particle size measurement determined with the AAMS instrument5'6. The 
influence of the particle shape on the measurement of aerodynamic size is discussed 
in Chapter 4 (Section 4.2). 
The particle distribution for a series of pMDIs (FP /SX 50/25) is shown in Figure 6.1. 
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Figure 6.1. Particle size distribution for a series of pMDIs (FP /SX 50/25). MDI 2 to 
4 were repeats of the same batch; Samples MDI 4 to 6 were three runs, of different 
batches of the same formulation. 
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Similarly an example particle distribution from a second series of pMDIs, (FP /SX 
250/25) is shown in Figure 6.2 and in this case the particles are slightly larger as 
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Figure 6.2. Particle size distribution ranges for a series of pMDIs (FP /SX 250/25). 
Samples MDI_7 to 9 were repeats of the same batch; MDI_ 9 to 11 three runs, of 
different batches of the same formulation. 
The conclusion of the particle sizing experiments using the AAMS are that firstly the 
FP /SX 50/25 sample contained a high number of small particles; these were found 
later to be due from FP fines probably originating from the micronization process. 
The particle size distribution for the 5 runs appeared to be consistent both for inter - 
batch and intra -batch analysis. The particle size distribution for the FP /SX 250/25 
samples appeared to show more variation for example the % number of particles in 
the 500 to 1000 gm category varied from 25 % to 60 % within the samples 
investigated. These samples were found to contain more SX either as pure particles or 
as a co- associated mixture (with FP).The increased variation in this data may have 
been due to the shape of the particles. Particle shape is discussed in Chapter 4. 
6.3 Identification of Particles Based on Marker Ions 
6.3.1 The Analysis of Marker Ions for Pure Drug 
Compounds 
The aim of data analysis based on marker ions, was to be able to identify the particles 
from inhalation products in terms of composition and ultimately use this information 
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to make an assessment of the degree of co- association present. In this section the 
identification of marker ions based on the AAMS spectra of pure drug compounds is 
discussed. 
The identification of particles from pure drug material using marker ions was based 
on the fragment ions observed in the average ToF -AAMS spectra for the pure drug 
compounds. To use an ion as a marker for a given compound, the ion must be 
abundant in the average mass spectrum of each of the compounds, be representative 
of the individual compound and appear in the mass spectra for the majority of the 
particles of each pure compound (i.e. similar criteria for AToFMS marker ion 
analysis). 
The average ToF -AAMS mass spectrum take from 78 particles of pure FP is shown in 
Figure 6.3. This mass spectrum is similar to that acquired using the Q -AAMS 
instrument as described in Chapter 3 (Section 3.5.1). 
An AAMS dataset was also acquired on pure particles of SX. The average mass 
spectrum taken from 92 particles of pure SX is shown in Figure 6.4. The SX mass 
spectrum is similar to that acquired using the Q -AAMS instrument as described in 
Chapter 3 (Section 3.5.1). 
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Figure 6.3. Average mass spectrum of FP taken from 78 particles of pure drug. The 
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Figure 6.4. Average spectrum taken from 92 particles of pure SX drug material. The 
particle size range was from 207 to 1037 nm. 
The major ions from the average mass spectrum of FP are compared with those from 
the average AAMS spectrum of SX in Figure 6.5. This bar -graph was used to 
determine the most relevant marker ions and to estimate the amount of overlap for the 
marker ions in the mass spectra of the two compounds. 
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Hence, the ion at m/z 57 was used as a marker ion for FP and m/z 91 used for SX 
based on the data shown in Figure 6.5. An interpretation of the fragmentation patterns 
is given in Chapter 3 (Section 3.5). 
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Figure 6.5. Bar -graph to compare the major (the most abundant) ions in the mass 
spectra of FP and SX. This shows that m/z 57 is representative of FP and m/z 91 is 
representative of SX. 
Note that m/z 57 and m/z 91 could originate from other sources for example as generic 
hydrocarbon ions. The use of these ions as markers might be a problem if the samples 
under investigated were unknowns, for example from environmental samples. 
However, the data reported in this thesis was acquired on clinical grade material 
originating from inhalation products. This meant that the samples were already well 
defined. To give extra confidence that the ions chosen as markers were valid, data 
were acquired and analyzed for samples of pure FP and pure SX and this data was 
used as a reference for this work. The data acquired on the pure samples showed that 
although there was some commonality of the ions chosen as markers (for example 
there was an ion of low abundance for m/z 57 in the SX spectrum) it was shown that 
there was a high confidence (more than 70 %) of correctly identifying the particle 
using this method (see Section 6.3.2). 
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6.3.2 Determination of the Fractional Composition of Individual Particles 
Based on Marker Ion Analysis 
The FP fraction based on marker ions was calculated using Equation 6.2. 
FPfr = [ FP / (FP + SX)] x 100% Equation 6.2 
FPfr = Fraction of FP based on one marker ion for each compound 
FP = Mass spectral signal for m/z 57 
SX = Mass spectral signal for m/z 91 
Similarly the SX fraction based on marker ions was calculated using Equation 6.3. 
SXfr = [ SX / (FP +SX)] x 100% Equation 6.3 
SXfr = Fraction of SX based on one marker ion for each compound 
FP = Mass spectral signal for m/z 57 
SX = Mass spectral signal for m/z 91 
Equation 6.2 was used to calculate the fraction of FP for each particle in a sample of 
the pure FP drug compound; this fraction is plotted against particle size to give the 
fractional composition chart shown in Figure 6.6. In this most (92 %) of the particles 
identified using the mass spectral signal for m/z 57 have an FPfr fraction higher than 
70 %. 
If the marker ions used were completely unique then the fraction of SX in FP would 
be expected to be zero as in this case, the ion at m/z 91 would not appear in the FP 
spectrum. Hence, to investigate how representative the marker ions used were, the 
SXfr was calculated for the pure FP drug compound. It can be seen from Figure 6.6 
that this was low (below 20 %) but not zero. However Figure 6.5 shows that this ion 
is much more abundant in the SX spectrum compared with FP hence it was used as a 
marker ion for SX. 
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Figure 6.6. Fractional composition chart for particles in pure FP, determined by 
marker ion analysis (using m/z 57 for FP and m/z 91 for SX). 
Figure 6.7 shows the fractional composition chart for pure SX drug compound, 
calculated using equation 6.3. In this case the majority of the particles (91 %) have an 
SXfr fraction above 70 % and this is a good indication that the marker ion for SX (m /z 
91) is representative of SX. The data points for the fraction of FP calculated using 
Equation 6.2 are also shown on this chart and give a fraction of below 30 %. 
There are a number of data points (6 % of the population shown in Figure 6.7) in the 
SXfr range between 30 and 70 %. This area of the chart would be expected to 
represent co- associated particles in samples where both FP and SX are present. As the 
SX was known to be pure the data points in this region in Figure 6.6 were used as a 
baseline for the noise associated with the AAMS experiment. 
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Figure 6.7. Fractional composition chart for particles in pure SX, determined by 
marker ion analysis (using m/z 57 for FP and m/z 91 for SX). 
The particles were classified by using marker ion analysis in terms of a range for the 
fraction of each material, so as to account for the experimental error. Some variation 
in the vaporization efficiency of the particles taken from inhalation products was 
found and this is discussed in more detail in Section 6.5. Hence for identification and 
classification of particles based on fractional composition a threshold was used; i.e. if 
the SXfr was above 70% the particle was identified as SX, (for consistency the same 
threshold was adopted for FP). The remaining particles (with a FP or SX fraction 
between 30 to 70 %) were identified as a co- associated mixture of both FP and SX. 
Some example data for typical spectra taken from the various types of particles are 
discussed; for pMDIs three categories of particle are possible i.e. (i) pure FP, (ii) pure 
SX and (iii) mixed composition. Figure 6.8 shows example mass spectra of particles 
taken from a pMDI (Sample MDI_4; FP /SX 50/25). 
The mass spectrum given in Figure 6.8 (a), acquired on a particle of diameter 314 nm, 
shows a number of fragment ions that are consistent with FP (for example, m/z 57, 
121 and 139). The fraction of FP calculated for this particle using Equation 6.2 was 
91.8 %, which showed that the particle composition was predominately FP. The mass 
spectrum given in Figure 6.8 (b), acquired on a particle of diameter 332 nm, shows a 
number of fragment ions that are consistent with SX (for example, m/z 91, 114, 170 
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and 262). The SX fraction (SXfr) calculated for this particle using Equation 6.3 was 
99.9 %, which showed that the particle composition was predominately SX. 
The mass spectrum given in Figure 6.8 (c) was acquired on a particle of diameter 697 
nm. This mass spectrum shows a number of fragment ions that are consistent with 
both FP (m /z 57, 121 and 139), and SX (m /z 91, 114, 170 and 262). The FP fraction 
(FPO) calculated for this particle using Equation 6.2 was 47.7 % and the SX fraction 
(SXfr) calculated for this particle using Equation 6.3 was 52.3 % which showed that 
that the particle was composed of a mixture of FP and of SX. The application of the 
data analysis techniques based on marker ions to assess the degree of co- association 
in inhalation products is explored in further detail in Chapter 7. 
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Figure 6.8. Single particle AAMS spectra (a) FP particle (314 nm) (b) SX particle 
(333 nm) (c) mixed (co- associated) particle (697 nm) taken from a pMDI (Sample 
MDI 4; FP /SX 50/25). 
As for the AToFMS data there are some risks associated with marker ion analysis for 
AAMS data especially when it is based on only one ion per compound (all of the 
examples shown were based on one marker ion per compound), not least the fact that 
much of the data that is available is actually discarded. However, in this case samples 
were well defined blends of two or three compounds hence it was easy to attribute 
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marker ions that were unique and representative of the individual drug compounds 
present. Thus the marker ion technique was found to be a useful screen of the data and 
gave a reasonable way of identifying and classifying particles. Marker ion analysis 
was performed using multiple ions per compound, however this method was found to 
give no real advantage over the use of single marker ions and was not pursued. 
6.4 Data Analysis for Dry Powder Inhalers (DPIs) 
A practical difficulty was encountered during the experiments to acquire AAMS data 
on DPIs. The orifice at the inlet of the AAMS instrument was found to be susceptible 
to blockage with DPI particles so a study of quantitative data for this type of 
inhalation product was not possible and only qualitative data is presented. However, 
the results described below show that the data analysis methods could be applied if in 
the future the experiment were modified to make DPIs particles accessible to the 
experiment. 
Figure 6.9 shows AAMS size distributions for the experiment on a DPI (Sample 
DPI_3; FP /SX 500/50). This shows that over 80 % of the particles in the population 
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Figure 6.9. Particle size distribution for 128 particles that gave mass spectra taken 
from a DPI (Sample DPI 3; FP /SX 500/50). 
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Figure 6.10 shows the average mass spectrum taken from 51 particles of Flovent® (a 
blend of FP in excess lactose). The ions previously assigned to FP at m/z 29, 57, 121 
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Figure 6.10. Average ToF -AAMS spectrum taken from 50 particles (average particle 
size 942 nm) from a DPI (Sample DPI 1; Flovent a blend of FP and lactose). 
Figure 6.11 shows a mass spectrum taken from a single particle of Flovent® (particle 
size of 894 nm). The mass spectrum consists of fragment ions from both FP and 
lactose (as discussed above for Figure 6.10) which indicates that the particle 
composition is a mixture of these two compounds. 
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Figure 6.11. ToF -AAMS spectrum of a single particle (894 nm) showing a mixture of 
FP and lactose (Sample DPI 1; Flovent a blend of FP and lactose). 
130 
Chapter 6 -Data Analysis Methods for Aerodyne Aerosol Mass Spectrometry (AAMS) 
The average ToF -AAMS spectrum for a DPI containing both FP and SX (Sample 
DPI_3; FP /SX 500/50) is shown in Figure 6.12. Major fragment ions can be observed 
for FP at m/z 57, 121 and 139, for SX at m/z 91, 114, 170 and 262 and for lactose at 
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Figure 6.12. Average ToF -AAMS spectrum from 126 particles taken from a DPI 
(Sample DPI 3; FP /SX 500/50). 
The ToF -AAMS spectrum acquired on a single particle taken from a DPI (Sample 
DPI_3; FP /SX 500/50) is shown in Figure 6.13. In this mass spectrum there are ions 
that are indicative of both FP and SX showing that this particle is of mixed 
composition and gives qualitative evidence for the presence of co- association. Also, 
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Figure 6.13. ToF -AAMS spectrum taken from a single particle (of 1327 nm size) that 
consisted of a mixture of FP, SX and lactose (Sample DPI 3; FP /SX 500/50). 
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6.5 Data Analysis Based on Multivariate Statistical Analysis 
The mass spectra obtained from the AAMS experiment are typically complex and 
multivariate analysis has previously been used to process this type of data. Many of 
the multivariate methods applied to AAMS data are based on factor analysis for 
which the overall aim is to determine the dimensionality of the data and the 
relationships between the variables. 
The most common form of factor analysis is principal component analysis (PCA) 
which was discussed in Chapter 4. More recently, multivariate statistical analysis has 
been developed to include methods such as positive matrix factorization (PMF) has 
been used successfully to de- convolute mass spectra acquired using the AAMS8. 
For all multivariate analysis the data is conditioned before it is analyzed to ensure that 
the data is in a suitable form for analysis. For example the data analysis for a variable 
that has a large numerical range, may be weighted towards the variance for the data at 
the higher end of the scale i.e. in this case the data analysis may be biased towards the 
larger values. Therefore in order to give all variables equal weight in the data analysis 
they are standardized and this is known as scaling9. 
The improvements in the scaling of the data using PMF (compared with PCA) mean 
that a more detailed analysis of the data can be made. For example in PCA analysis 
the data is scaled by columns or by rows, but in the PMF analysis there is the facility 
to scale each data point individually and this gives the opportunity for better 
modelling of the data. However although the end result may be better it is more 
complex to use PMF as a routine tool compared with PCA. 
In the case of the application of PMF to the mass spectra of particles, so long as the 
spectral pattern of each component can be recognized, then the contributions of each 
component can be measured. For the work presented in this section the mass spectra 
of the pure drug compounds were compared with the components determined by de- 
convolution of the spectrum using PMF. However, it has been previously reported 
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that PMF can be applied to data taken from individual particles without prior 
knowledge of the compound identity or of the numbers of compounds present10. 
Although the inhalation products studied were well defined mixtures of two or three 
components the mass spectra still appeared as complex fingerprints of the material(s) 
present in each particle, hence PMF analysis was applied to the datasets on a particle - 
to- particle basis4. The aim of this was to detect the mass spectral pattern for each 
component and to identify and classify each particle in terms of composition. 
Figure 6.14 shows the mass spectrum taken from a particle of mixed composition 
from a pMDI inhaler (Sample MDI_9; FP /SX 250/25) de- convoluted into the PMF 
components. In this case the PMF components, shown in Figures 6.14 (h) and (c), 
were comparable with mass spectra acquired on pure FP and pure SX respectively. In 
this case the fact that the mass spectrum from a particle was de- convoluted to give 
PMF components that appeared similar to the mass spectra of the pure drug materials, 
provided good evidence that the particle was composed of a co- associated mixture of 






























Figure 6.14. De- convolution of a mass spectrum to the PMF components. (a) Shows 
the mass spectrum taken from a particle composed of a mixture of FP and SX; (b) and 
(c) show the PMF components of FP and SX derived from the mixture. These mass 
spectra are comparable with the mass spectra of the pure compounds. (Example 
shown: Sample MDI 9, FP /SX 250/50). 
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Figure 6.15 shows the PMF de- convolution of a mass spectrum acquired on a particle 
of mixed composition taken from a DPI (Sample DPI_3; FP /SX 500/50). In this case 
the formulation consisted of three components i.e. FP, SX and lactose and the PMF 
components in the figure reflect this. The PMF components were found to be 
comparable with the mass spectra acquired on particles of pure FP, pure SX and pure 
lactose. An interpretation of the AAMS spectra of pure FP, pure SX and pure lactose 
is given in Chapter 3 (Section 3.5). 
AMS spectrum from a single particle 
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Figure 6.15. PMF de- convolution of the mass spectrum of a three component particle 
from a DPI (Figure (a)) to show the PMF components for (b) FP (c) SX and (d) 
lactose (L). (Example data shown: Sample DPI 3; FP /SX 500/50). 
If the particle were only partially vaporized then quantitative measurements would be 
compromised because of non -representative sampling of the particle, e.g. in the case 
of different vaporization efficiencies of the material present. 
If particle size is plotted against mass spectral signal for a pMDI (MDI_9 FP /SX 
250/25) the graph shown in Figure 6.16 is obtained. As described previously (see 
Chapter 3) the points within 20% of the line represent fully vaporized particles 
(shown in blue), the remaining particles (shown in red) are only partially vaporized. 
Clearly many of the larger particles were not fully vaporized and hence were not used 
in the PMF analysis which limited the size of the data set used. For this sample 435 
particles were detected by light scattering of which 169 gave a mass spectrum and 36 
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were found to be fully vaporized (see Table 6.1). In the future further work needs to 
be performed to improve the consistency of vaporization for this type of particle. 
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Figure 6.16. Demonstration of partial vaporization in an AAMS experiment. Blue 
points - taken as fully vaporized; red points - vaporization is incomplete. Sample 
MDI 9 FP /SX 250/25. (Same as Figure 3.13 in Chapter 3). 
6.6 Summary of Data Analysis Methods for Aerodyne Aerosol 
Mass Spectrometry (AAMS) 
Methods for analyzing AAMS data were developed based on marker ions and on 
multivariate statistical analysis. 
As for the AToFMS data, the choice of marker ions from particles of pure drug 
material was based on the fragment ions observed in the average AAMS spectra 
(these were previously interpreted in terms of the structure of the given molecule). By 
choosing ions that were representative, the data sets for the inhalation products were 
then interrogated and a method for the assessment of the degree of co- association 
based on the number of mixed particles present was successfully developed. 
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A method for the analysis of the AAMS data using multivariate analysis, based on 
positive matrix factorization (PMF), was also developed. This type of multivariate 
analysis requires no prior knowledge of the compounds present as the mass spectra 
can be de- convoluted to give the PMF components which appear very similar to the 
mass spectra of the individual drug compounds. 
Application of these data analysis methods to give an estimate of the degree of the 
level of co- association using the AAMS instrument is explored in Chapter 7. 
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The Determination of Co- association using 
Aerodyne Aerosol Mass Spectrometry (AAMS) 
7.1 Introduction 
A major aim of the work presented in this thesis was to assess the amount of co- 
association in particles taken from a range of inhalation products. The data analysis 
was performed with emphasis on this aspect for both the AToFMS instrument (see 
Chapters 4 and 5) and the AAMS instrument. In this chapter, the results from a series 
of initial experiments designed to evaluate the potential of AAMS for assessing co- 
association in a range of inhalation products are presented and discussed. Note that 
these experiments were performed in the manufacturers' laboratories (Aerodyne, 
Boston, Ma, USA) which meant that instrument time and access was limited. 
The data analysis was performed based on marker ion analysis or on multivariate 
analysis (i.e. positive matrix factorization (PMF)) as described in Chapter 6. Using 
these techniques, each particle was identified in terms composition as either 
fluticasone propionate (FP), salmeterol xinofoate (SX) or a co- associated mixture of 
both FP and SX. The reproducibility of the experiment and the major source of 
variation in the experiment are also discussed. 
7.2 Assessment of Co- association Using Data from AAMS 
experiments 
7.2.1 Assessment of Co- association Using Marker Ion Analysis 
Figure 7.1 shows a fractional composition chart (see Chapter 6) determined from the 
marker ion analysis of each particle in a pMDI (MDI_2; FP/ SX 50/25). From this 
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chart it can be seen that the particles sizes were predominantly between 200 and 600 
mn and that the majority of the particles measured were pure FP. 
The results from for a number of repeat runs for the pMDI formulation FP /SX 50/25 
is summarized in Table 7.1 and this indicates that between 10.8 and 14.0 % of the 
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Figure 7.1. Fractional composition chart for particles in a pMDI, determined by 
marker ion analysis (Sample MDI 2 ; FP /SX 50/25). 
File Formulation Batch/id % FP % SX % Mixed 
MDI_1 FP/SX 50/25. 002/78. n/a n/a n/a 
MDI_2 FP/SX 50/25. 002/78. 82.0 5.7 12.3 
MDI_3 FP/SX 50/25. 05/97F 76.3 10.3 13.4 
MDI_4 FP/SX 50/25. AX7099/23 83.3 3.3 13.3 
MDI 5 FP/SX 50/25. AX7099/23 86.3 2.9 10.8 
MDI_6 FP/SX 50/25. AX7099/23 80.8 5.2 14.0 
Table 7.1. To show the % number of pure FP, pure SX and mixed (co- associated) 
particles as defined by the fractional composition determined from the marker ion 
analysis of pMDIs (Samples MDI 2 to MDI 6; FP /SX 50/25). *No data is shown for 
MDI 1 as this was used as a trial run. 
Figure 7.2 shows an example fractional composition chart (see Chapter 6) determined 
from marker ion analysis for each particle in a second pMDI (sample MDI_9; FP/ SX 
250/25). From this chart it can be seen that the particles size is between 200 and 1500 
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observed as depicted by the data points with a fractional composition of between 30 to 
70% of either FP or SX. The results for a number of repeat runs for the pMDI 
formulation FP /SX 250/25 is summarized in Table 7.2 and this indicates that between 
10.3 and 21.3 % of the particles were of mixed composition. The error in this 
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Figure 7.2. Fractional composition chart for particles in a pMDI, determined by 
marker ion analysis. (Sample MDI 9; FP /SX 250/25). 
File Formulation Batch /id FP SX Mixed 
M D I_7 F P /SX 250/25. 1/22. 71.6 7.1 21.3 
M D I_8 F P /SX 250/25. 1/22. 74.5 4.9 20.6 
MDI 9 FP /SX 250/25. 1/22. 84.9 4.8 10.3 
MDI_10 FP /SX 250/25. AX7102/82. 77.7 4.9 17.5 
MDI_11 FP /SX 250/25. DO40861. 76.1 5.2 18.7 
Table 7.2. To show the % number of pure FP, pure SX and mixed (co- associated) 
particles as defined by the fractional composition determined from the marker ion 
analysis of pMDIs (Samples MDI 7 to MDI 12; FP /SX 250/25). 
7.2.2 Reproducibility of the Measurement for Assessment of Co- 
association Using Marker Ion Analysis 
The relative standard deviation (RSD) of the number of mixed particles in three runs 
of the same batch of each formulation was calculated to give an estimate of the 
variation in the intra -batch measurement. The RSD % was also calculated for runs of 
three different batches of the same formulation to estimate variation in the inter -batch 
measurement. The variation in the results for marker ion analysis determined in this 
way is shown in Table 7.3. 
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The average number of mixed particles found in the pMDI inter -batch measurements 
FP /SX 250/25 was found to be 15.5 %. Also the error shown by the RSD for the 
pMDI inter -batch experiments was found to be 29.2 %. The average number of mixed 
particles found in the pMDI intra -batch measurements FP /SX 250/25 was found to be 
17.4 %. Also the error shown by the RSD for the pMDI inter -batch experiments was 
found to be 35.3 %. The average number of mixed particles found in the pMDI inter - 
batch measurements FP /SX 50/25 was found to be 13.0 %. Also the error shown by 
the RSD for the pMDI inter -batch experiments was found to be 4.8 %. The average 
number of mixed particles found in the pMDI intra -batch measurements FP /SX 50/25 
was found to be 12.7 %. Also the error shown by the RSD % for the pMDI inter -batch 
experiments was found to be 13.2 %. 
The RSD % shown in Table 7.3 is much higher for the FP /SX 250/25 formulation 
compared with the FP /SX 50/25 formulation. This is because, for the FP /SX 50/25 
formulation, the majority of the particles were shown to be mainly small particles of 
FP (i.e. FP fines) (see Section 6.2). Previously, small FP particles from a sample of 
pure FP were easily identified; however there was an amount of noise associated with 
larger particles especially those from a sample of pure SX (see Section 6.3.2). This 
was probably due to a difference in the vaporization efficiency of each compound. 
Hence, the larger error for the FP /SX 250/25 formulation was attributed to the 
presence of larger SX containing particles in the formulation which were difficult to 
vaporize efficient y. 
Type Formulation Batch type Average RSD % 
a 
2 a 
FP /SX 250/25 Inter -batch 15.5 29.2 
FP /SX 250/25 Intra -batch 17.4 35.3 
rzl 
2 a 
FP /SX 50/25 Inter -batch 13.0 4.8 
FP /SX 50/25 Intra -batch 12.7 13.2 
Table 7 3. Determination of co- association (mixed particles) in pMDI aerosols based 
on marker ion analysis. The table shows the average % number of particles found in 
inter- or intra- batch experiments. In each case an estimate of the error is given by the 
relative standard deviation % (RSD %) (i.e. the Standard Deviation/ Average (x 100 
%)). 
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7.2.3 Assessment of Co- association in Inhalation Products Based on 
Multivariate Statistical Analysis 
The data analysis using PMF was based on fully vaporized particles determined as 
described in Chapter 6. The results obtained from the PMF analysis of the pMDI data 
set of AAMS data are give in Table 7.4 and this shows the fraction of FP, SX or 
mixed particles in each sample. A comparison of the data from each formulation was 
performed and the results shown are broadly comparable with the marker ion analysis. 
However, the PMF data analysis was found to be extremely sensitive to background 
noise probably originating from inconsistent vaporization of larger particles 
containing SX. This was especially so for MDI_7, MDI_10 and MDI_11 (samples of 
the FP /SX 250/25 formulation which comprised of relatively large particles 
containing significant amounts of SX according to the marker ion analysis discussed 
earlier in this chapter). These datasets were found to be too noisy to provide any 
meaningful results and were excluded from Table 7.4. 
Sample Formulation FP SX Mix 
MDI_1 * FP/SX 50/25. n/a n/a n/a 
MDI_2 FP/SX 50/25. 89.8 4.1 6.5 
MDI_3 FP/SX 50/25. 26.0 15.9 59.6 
MDI_4 FP/SX 50/25. 79.3 4.1 16.4 
MDI_5 FP/SX 50/25. 87.9 3.9 8.7 
MDI_6 FP/SX 50/25. 86.2 2.9 10.5 
MDI_7 FP/SX 250/25. n/a n/a n/a 
MDI_8 FP/SX 250/25. 64.3 9.6 26.1 
MDI_9 FP/SX 250/25. 85.8 2.3 11.6 
MDI 10 FP/SX 250/25. nia nia nia 
MDI^11 FP/SX 250/25. n/a n/a n/a 
Table 7.4. PMF results for AAMS data. *MDI I was a trial run. n/a = data not 
available due to high level of background noise. 
Comparison of the PMF results for the two formulations is shown in Figure 7.3 for 
FP /SX 50/25 and Figure 7.4 for FP /SX 250/25. The PMF analysis determined that 
most of the particles in these samples contained a high amount of FP which is 
consistent with the results from the marker ion analysis. The figures also show that the 
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mixed (co- associated) particles ( -19% compared with -11% for the FP /SX 50/25 
formulation), although the bulk of the particles were found to consist mainly of FP. 
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Figure 7.3. Comparison of FP fractions from PMF analysis of pMDIs (MDI_2 and 
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Figure 7.4. Comparison of FP fractions from PMF analysis of pMDIs (MDI_8 and 
MDI 9; FP /SX 250/25). 
7.3 Summary of Data Analysis for AAMS 
The results for the measurement of co- association were described for a number of 
pMDIs. The results showed that the presence of co- association can be determined 
using this instrument although further work would be required to improve the 
143 
Chapter 7 - The Determination of Co- association using Aerodyne Aerosol mass spectrometry (AAMS) 
consistency of the data produced especially in terms of quantification. (This was not 
possible in the current work as access to the instrument was limited). 
The AAMS data acquired on the pMDIs was analyzed using both marker ions and 
positive matrix factorization (PMF) and it was shown that the particles present could 
be identified using either method. It would be expected that PMF analysis would give 
a more consistent result (compared with marker ion analysis) as it is based on the 
analysis of the complete data set rather than a single ion to represent each component 
However the PMF analysis was hampered by the noise in the data, probably 
originating from inconsistent vaporization of the sample particles. 
The results from the intra -batch analyses (repeat analysis of the same material) were 
averaged and are summarised in Table 7.5 which shows that co- associated particles 
were observed in both formulations. Lower levels of co- association were found in the 
FP /SX 50/25 formulation because this material was dominated by smaller particles 
(fines) of FP. 
Sample Technique Average % number of 
coassociated particle 
present 
FP /SX 50/25 Marker ion analysis 12.7 
FP /SX 50/25 PMF 7.1 
FP /SX 250/25 Marker ion analysis 17.4 
FP /SX 250/25 PMF 10.9 
Table 7.5. Comparison of assessment of co- association using marker ion analysis 
(from the intra -batch data) and multivariate analysis based on positive matrix 
factorization (PMF). 
A comparison of the AAMS results with the AToFMS results is given in Chapter 8 
and this shows that there is broad agreement between data acquired using the two 
techniques in the determination of the level of co- association found. 
There is potential for the AAMS experiment to be the preferred instrument for this 
type of analysis as it can detect both pure FP and pure SX particles, co-associated 
particles and the excipient (in this case lactose) and has previously been shown to 
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produce quantitative data. However, the initial results presented in this chapter 
highlighted some limitations of the AAMS experiment in the current configuration 
(i.e. primarily noise associated with the vaporization of larger SX containing particles) 





Two commercial single particle mass spectrometers were used in this work and 
although the general layout of these instruments was similar, there were some 
differences in their design. For example, the ionization source of the Aerosol Time -of- 
Flight Mass Spectrometer used a single step process involving laser ablation and 
ionization while the Aerodyne Aerosol Mass Spectrometer used a two step process 
involving thermal desorption from a hot plate followed by electron ionization. These 
instruments were compared and evaluated in terms of their design and the 
characteristics of the data acquired on aerosols of pharmaceutical materials. 
Data analysis methods for single particle mass spectrometry were developed based on 
the mass spectrometric fragmentation patterns indicative of either pure or co- 
associated particles. Data analysis was performed by either using representative ions 
from the mass spectrum taken from each particle or by using multivariate statistical 
analysis as a pattern recognition tool applied to the complete mass spectrum for each 
particle. 
High levels (above 50 %) of co- association were found in the emitted doses from both 
pMDI and DPI products. Although the design of each instrument was different, 
reasonable agreement in the levels of co- association was found as long as the size of 
particle that was analyzed by the mass spectrometer in each case was taken into 
account. 
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8.2 Measurement of Co- associated Particles 
For both the AToFMS and AAMS instruments, the mass spectra that were acquired 
from particles of pure drugs showed unique fragment ions that could be reasonably 
interpreted in terms of the structures of the drug compounds (see Chapter 3). 
The measurement of co- association was based on the appearance of the mass spectra 
for each of the single particles analyzed. This enabled the identification and 
classification of the individual particles as a pure material or as a co- associated 
mixture of drug compounds. 
The inhalation products analyzed were well defined samples containing the two active 
drugs present (FP and SX) and this was reflected in the mass spectra. For example 
Figure 8.1 shows the mass spectra taken from two single particles of similar size, 
from a pMDI (Sample FP /SX 250/25) using the AToFMS instrument (Figure 8.1a) 
and the AAMS instrument (8.1b). The ions present in the two spectra are different 
because of (i) the different ionization techniques used (see Chapter 3) and (ii) the 
different detector polarity used (negative ions for AToFMS and positive ions for 
AAMS). However, both mass spectra show a combination of ions originating from FP 
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Figure 8.1. Mass spectra of particles of similar size taken from a pMDI aerosol 
(Sample FP /SX 250/25) using (a) the AToFMS instrument (negative ion mass 
spectrum) for a particle of size = 1.2 pm and (b) the AAMS instrument (positive ion 
spectrum) for a particle of size = 1.0 pm. Both spectra show a number of ions 
previously found to be unique to FP and SX, indicating that each of these particles is 
of mixed composition. 
For the DPIs, co- association was observed and measured using the AToFMS 
instrument, however, the AToFMS experiment is limited in that lactose is not detected 
(See Chapter 3); i.e. a particle containing only FP could not be distinguished from a 
particle containing a mixture of FP and lactose. A mass spectrum of pure lactose was 
acquired using the AAMS instrument and lactose ions were also identified in particles 
comprised of a mixture of FP, SX and lactose which indicated a potential advantage 
of the AAMS instrument. However some experimental difficulties were encountered 
with the analysis of DPI particles using the AAMS and further work would be 
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required to develop the accessibility of the experiment to this type of particle. This 
work was not performed at the time because of the limited access to the instrument. 
8.3 Estimation of the Level of Co- association 
The synergistic effect of treatment for lung disease using the two active drugs 
simultaneously may be explained by the two drugs (FP and SX) acting on the lung 
tissue simultaneously. Probably the easiest and most consistent way for this to happen 
would be via particles that consist of a mixture of the two active materials. The data 
presented in this thesis provides strong evidence of high levels of co- associated 
particles in the inhaler devices investigated and goes some way to explaining the 
synergistic effect discussed in Chapter 1 (Section 1.5). 
Further work in this area could show an advantage of GSK inhalation products in 
which co- associated particles exist compared with competitor products that contain a 
mixture of pure particles. A further series of experiments would need to be designed 
and executed to confirm this. 
It has been reported previously that quantitation using the AToFMS is difficult or not 
possible because of the shot -to -shot variation in the laser (See Section 3.2). The data 
presented in this thesis for the AToFMS, to investigate the composition of each 
particle is probably semi -quantitative at best. However the variation measured 
expressed as an RSD % (1 to 16 % for marker ions and 3 to 10 % for PCA) was good 
when the small amounts of sample per particle (- femtograms or less) (see Section 
9.2.3) are considered. This level of variation is broadly comparable with the level of 
error expected when mass spectrometery is applied quantitatively to measure at the 
femtogram level in other application such as drug metabolism or environmental 
analysis2. 
The use of multivaraiate analysis was a good method for handling large amounts of 
data. For some samples over 100 particle were analyzed and each was associated with 
a mass spectrum typically containing many ions. PCA charts were used identify and 
classify groups of particles based on the mass spectral pattern. Further analysis of the 
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PCA charts was performed by defining each particle category mathematically with an 
ellipse for each particle type. This worked well and the ellipses were able to take into 
account some of the variation in the AToFMS experiment. Although this was still a 
semi -quantitative measurement of the composition of each particle it is probably the 
best estimate of the composition of this type of particle to date. 
Groups of particles with similar mass spectra could be used to identify and classify 
individual single particles. This is an advantage compared with techniques previously 
associated with inhalation product analysis that provide an an average analysis of a 
group of particles such as the Anderssen Cascade Impactor (see Section 1.6). The 
single particle mass spectrometry technique also provides an advantage compared 
with techniques previously used to analyze single particles such as Raman 
spectroscopy which is slower and relies on analyzing samples of the material off -line 
(i.e. particles from an inhaler are deposited on a plate and each particle is imaged). 
The SPMS technique provides some advantage in being able to analyze the particles 
from ana inhaler aerosol in near real -time and avoid possible artefacts that may be 
associated with off -line analysis. 
Although the experimental difficulties associated with the experiments on the AAMS 
instrument meant a limited data set, some good qualitative evidence for the presence 
of co- association was obtained from the positive matrix factorization analysis (PMF). 
It was shown that mass spectra from single particle of mixed composition could be 
deconvoluted to give spectra very similar to those obtained from pure samples of FP 
and SX. It is envisaged that this might be developed into a more reproducible and 
quantitative technique as applied to pharmaceutical aerosols in the future as it is 
currently regularly used quantitatively in other fields (see Section 6.5). 
The AAMS instrument also shows some advantage in that is able to detect excipients 
that may be in the formulation. Compounds such as magnesium stearate, cellulose 
octaacetate and lactose are all potentially useful excipients for drug formulations and 
these can all be detected by the AAMS but not the AToFMS. This is because the 
electron ionization source of the AAMS is able to ionize these materials, whereas they 
do not absorb laser energy at the given wavelength of the AToFMS laser (see Section 
3.2.1). 
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In general the larger particles in the formulation of inhalation products would be more 
likely to be of mixed composition as a result of co- association between smaller 
particles. As the upper limit of the particle size range of the AToFMS instrument is 
larger than that of the AAMS instrument (see Chapters 5 and 7), then it would be 
expected that more co- associated particles would be detected using the AToFMS 
instrument and this was found to be the case. 
Figure 8.2 shows a comparison of typical particle sizing data for a pMDI (FP /SX, 
50/25) using the AAMS and the AToFMS instruments. Both instruments measured 
particles at the lower end of the respirable range (which is 0.6 to 6.0 gm) and this 
figure shows that more of the larger particles (> 1000 gm) were detected using the 
AToFMS instrument compared with the AAMS instrument. The particle size range 
measured for the pMDI using the AToFMS instrument was typically 0.5 to 1.5 gm 
with an average particle size of 0.9 gm. Alternatively, using the AAMS instrument the 
typical particle size range found was 0.2 to 1.0 pm with an average of 0.3 pm. The 
difference in particle size range detected was attributed to the different designs of the 
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Figure 8.2. Comparison of particle sizing distributions (PSD) as measured using the 
AAMS and AToFMS instruments for sample FP /SX 50/25. 
Table 8.1 shows a comparison of the average level of co- association found in pMDI 
samples using the results from the marker ion analysis. The AToFMS gives a 
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measurement of co- association higher than that given by the AAMS which is 

















FP /SX 250/25 1.0 50.2 ( ±10.8 %) 0.4 17.4 (±- 35.3 %) 
FP /SX 50/25 0.8 45.4 (±4.3 %) 0.4 13.7 (± 13.2 %) 
Table 8.1. The level of co- association in a series of pMDI determined using (a) the 
AToFMS instrument and (b) the AAMS instrument. In this case the data taken from 
the AToFMS experiment was processed using marker ions and is from three repeat 
runs of the same sample in each case (see Chapter 5). The data for the AAMS 
experiment was based on marker ions from three repeat runs of the same sample (see 
Chapter 7). 
8.4 Differences in Co- association in DPIs and MDI's 
There were high levels of co- association in both DPIs and pMDIs (see Chapters 5 and 
7) and it was noted that higher levels were found in DPIs compared with the pMDIs. 
The difference in the degree of co- association in the different devices is likely to 
result from the very different nature of the formulations and the mechanisms by which 
co- association may occur. In the pMDI, co- association is believed to occur between 
the two types of solid particles (pure FP and SX particles) while still in the suspension 
within the inhaler3. Furthermore, on actuation, it is likely that the droplets emitted 
from the device contain multiple particles of FP and of SX. When a droplet collapses 
through propellant evaporation these particles can remain associated. Alternatively, 
coalescence of droplets within the plume could also lead to co- association. 
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In DPIs co- association would arise from drug -drug interactions as a result of high 
shear forces during the blending process. However, lactose added to the blend as an 
excipient will both reduce the level of co- association by acting as a diluent and 
potentially increase the level of co- association by acting as a `carrier' of both drug 
types. The dominant mechanisms contributing to the levels of co- association observed 
in such combination products require further study. 
8.5 Summary 
The SPMS experiments presented in this thesis were successful in that particles 
composed of the individual drug compounds could be recognised and distinguished 
from particles that were composed of a co- associated mixture of the drug materials. 
Furthermore, an estimate of the degree of co- association was made for a range of 
inhalation products there was broad agreement between the results obtained from two 
commercially available SPMS instruments. 
Single particle mass spectrometry (SPMS) techniques were applied to the analysis of 
the aerosols originating from inhalation products. This was specifically to investigate 
the levels of co- association between FP and SX in individual particles. High levels of 
co- association were observed for both pMDIs and DPIs. The results presented, gave a 
unique particle analysis in terms of measurement of size and composition for 
inhalation products which previously proved difficult using other techniques. 
The instruments used for this work were originally designed for environmental studies 
and would benefit from some further development to modify the experiment for 
pharmaceutical analysis. For example to allow accessibility to the larger particles in 
the respirable range and more consistent mass spectra for the larger, more fragile 
organic molecules found in inhalation products. 
Application of this technique in the future may give some benefit to the patient from a 
better understanding of the manufacturing process and as a tool to monitor the 
optimization of the amount of co- association in terms of clinical efficacy. 
153 
Chapter 8 - Conclusions 
8.6 References 
(1) Microdosing assessment to evaluate pharmacokinetics and drug metabolism in 
rats using liquid chromatography -tandem mass spectrometry. J. Ni, H. Ouyang, 
M. Aiello, C. Seto, L. Borbridge, T. Sakuma, R. Ellis, D. Welty and 
A. Acheampong. Pharma. Research. 25 1572 -1582, (7), (2008). 
(2) Femtogram detection and quantitation of residues using laser ionization 
orthogonal time -of -flight mass spectrometry. Q. Yut, Z. Caot, L. Lit, B. Yant, 
W. Hang, J. He and B. Huang, Anal. Chem. 81, (20), 8623 -8626, (2009). 
(3) Characterisation of the aggregation behaviour in a salmeterol and fluticasone 
propionate inhalation aerosol system. Y. Micheal, M. Snowden, B.Z. Chowdhry, 
I.C. Ashurst, C. Davies -Cutting and T. Riley. Int. J. Pharmaceutics. 221, 165- 
174 (2001). 
(4) Development of a systematic theory of suspension inhalation aerosols. I. A 
framework to study the effects of aggregation on the aerodynamic behaviour of 
drug particles. I. Gonda. Int. J. Pharmaceutics. 27 99 -116 (1985). 
154 
Chapter 9 
Suggested Further Work 
9.1 Scope for Future Developments 
The blending process used in the manufacture of inhalation products is currently not 
well understood; for example a link between the blending process and the degree of 
co- association present has not been established. This is mainly because in the past it 
has not been easy to detect or quantify co- association in individual particles using 
existing analytical techniques. In the current manufacturing process for inhalation 
products the materials are blended for a given amount of time (typically a few 
minutes) and give an unknown and uncontrolled amount of co- association. However, 
from the work presented in this thesis it appears likely that a better understanding of 
the blending and co- association processes can be obtained from SPMS. 
The current US Food and Drug Administration (FDA) process analytical technologies 
(PAT) initiative1 has an objective of giving a benefit to the patient through a better 
understanding of the manufacturing process. There would be some benefit in applying 
single particle mass spectrometry (SPMS) techniques to investigate the relationship 
between the blending process to co- association and hence to the efficacy of the 
inhalation product. 
In the future inhalation products in development could be clinically tested to relate the 
amount of co- association (measured with SPMS) to the clinical efficacy. While this 
might appear to be an expensive exercise in the short term, there could be longer term 
benefits to the manufacturer (in this case GSK) in terms of a possible extension of the 
product lifetime (via a new patent) and to the patient in terms of improved 
characterization of the inhalation product. 
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9.2 Future Developments in Instrument Design 
9.2.1 Particle Sizing 
The experiments described in this thesis show the detection and estimation of the level 
of co- association in a range of inhalation products. As mentioned in Chapter 8, it is 
likely that there would be more co- association in the larger particles. However, the 
sizes of the particles detected with both the AAMS (- 0.2 to 1.0 gm) and the 
AToFMS instruments (- 0.5 to 1.5 gm) were at the lower end of the respirable range 
(0.6 to 6 gm). This was at least partially due to the poor transmission of the larger 
particles through the aerodynamic lens. Hence, for further study of co- association, the 
particle sizing range would need to be extended so that the experiment is accessible to 
larger particles. The most likely way to do this would be through further development 
of the aerodynamic lens to enable transmission of the larger particles, a possible 
starting point for this would be with the use of modelling programs such as 
FLUENT'`. 
The measure of aerodynamic diameter is very dependent on the shape of the particle 
as well as its size. Currently the calibration of the particle size measurement is 
typically performed using spherical latex beads. However, it is known that the particle 
shape is irregular for FP, SX and lactose from scanning electron microscope images 
shown in Section 4.2. It is likely that the calibration would be improved using 
materials that are closer in character and morphology to the drug compounds used in 
the inhalation products (for example via a series of FP particles micronized to a range 
of different sizes which had previously been checked with scanning electron 
microscopy). 
The future of calibration for the SPMS experiment may follow the example of a 
recently reported method of calibration where the particle sizing and mass 
spectrometer were calibrated simultaneously using the same sample3. This was 
performed by producing polyethylene glycol (PEG) containing micro -particles, that 
gave a reproducible sample set used for calibration of particle size and an easily 
recognized mass spectrum that was used in calibration of the m/z axis. 
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9.2.2 Vaporization /Ionization 
For both of the commercial instruments, the consistency of vaporization of particles 
was found to be limited. For the AAMS instrument this originated from particle 
bounce and for the AToFMS instrument from shot -to -shot variability of the laser 
beam. 
For the AAMS instrument the ionization source design is such that the particle should 
vaporize as it hits the hotplate. However, it has been shown that a source of poor 
vaporization is particle bounce, i.e. rather than being vaporized, the particle instead 
bounces on the hotplate (even at high temperature >500 °C) in which case it may 
remain non -vaporized or only partially vaporized. Further development of the 
hotplate in terms of the shape and texture may improve the consistency of 
vaporization especially of the larger particles4. 
For the AToFMS instrument a major source of inconsistent particle 
ablation/ionization is in the shot -to -shot variation in the laser beam. The Gaussian 
profile of the laser beam means that there is scope for each particle that crosses the 
laser beam to be exposed to a different amount of energy if it crosses the profile at a 
different point. To ensure that all particles are subjected to the same amount of laser 
energy, the laser energy profile can be flat topped5'6. This makes it more likely that 
each particle would be exposed to the same amount of laser energy hence the mass 
spectra would be more representative of the sample. 
An additional problem of using laser desorption ionization is that if the analyte 
molecule does not absorb radiation at the laser wavelength then ionization will not 
occur. There are two possible solutions to this : (a) Treat the particles so that they can 
absorb radiation at the given wavelength of the laser or (b) Separate the ablation and 
ionization into two steps 
It was shown previously that it is possible to coat the analyte particles with a material 
that is more able to absorb at the given wavelength. For example this technique was 
employed to enhance the detection of small (10 to 20 nm) ammonium sulfate particles 
(which are difficult to ionize due to poor UV absorption at 266 nm) with laser ablation 
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aerosol mass spectrometry by coating them with naphthyl acetate which absorbs the 
energy from the laser and facilitates ionization. This would however be a complex 
solution and the consistency in application to inhalation products would need to be 
investigated. 
Perhaps a more practical solution is to separate the ablation and ionization. This has 
been demonstrated successfully for AToFMS type instruments using a low power 
(typically infra -red) laser pulse for evaporation followed by a more intense pulse for 
ionization that use laser desorption as the ionization techniques although such 
instruments are not currently commercially available. The ablation and ionization 
techniques are separated in the AAMS instruments and these typically use a hotplate 
for vaporization and electron ionization, although once the particle is vaporized the 
use of a range of ionization techniques is possibles, 9 
For successful application of single particle mass spectrometry (SPMS) to inhalation 
products the instrument should be capable of detecting the range of compound classes 
used as drugs and excipients. An important aspect of this is the method of ionization, 
which would ideally be compatible a wide a range of compounds. For example the 
active drugs in pMDI formulations are two structurally and chemically very different 
classes of compound i.e. FP and SX are a steroid and a beta -agonist respectively. The 
DPI formulations also contain lactose; a third structurally different compound. 
There are a number of alternative ionization techniques, most of which are not 
currently commercially available; these include soft ionization techniques such as 
lithium attachments°, chemical ionization11 or synchrotron radiation12' 13. The mass 
spectra obtained using these techniques are typically dominated by the protonated 
(M +H) + or the lithiated molecule (M + Li) + and show little fragmentation. This 
would be an advantage in compound identification so long as all the compounds of 
interest had different molecular weights. 
9.2.3 Mass Spectrometer 
Although the amount of material in each particle is very small, the sensitivity of the 
mass spectrometers used were compatible with the detection and quantitation at this 
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level. For example, a homogeneous, spherical, 1 gm diameter particle of FP would 
have a mass of approximately 0.7 fg (approximately one million molecules) and both 
instruments were able to detect particles of 1 gm aerodynamic size that consisted of 
either pure FP, pure SX or a co- associated mixture of both. 
In the future drug compounds will probably become more potent and lower levels of 
drug may thus be incorporated in the formulated product, hence improved sensitivity 
would be required. Also the formulated products of the future may be comprised of 
more complex mixtures, of three, four, or more, active drugs. Thus the mass 
spectrometer should still retain sensitivity to the drug compounds even if they are 
diluted in this type of complex mixture. 
If the softer ionization techniques mentioned above were used, then it is likely that the 
mass spectra would show few fragments. In this case mass spectrometry techniques 
such as accurate mass measurement and tandem mass spectrometry (MS/MS) would 
be useful in maximising the amount of information available from the SPMS 
experiment. Currently accurate mass measurement are available using the Aerodyne 
AAMS instruments14, however the signal -to -noise ratio in the mass spectrum is only 
good enough to give an average mass spectrum taken from several particles. Hence 
there is scope to develop this to be compatible with single particles with the aim of 
increasing the confidence of assignment of ions in the mass spectra obtained. 
9.2.4 Quantitative Analysis 
AToFMS is not generally considered a quantitative technique mainly because of the 
shot -to -shot variation in the laser as discussed in Chapter 3. However by identifying 
and counting the number of mixed particles identified a semi -quantitative estimate of 
the composition of single particles was made. An improvement in the quantitation 
would originate from better consistency in the ablation/ionization step. 
The AAMS has been reported as a quantitative technique9 "° and this is possible 
because the vaporization and ionization steps are separated. In this case the 
identification and classification of particles present are based on the fractional 
composition of each particle. For the work on inhalation products, an improvement in 
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the quantitation would originate from better consistency in the vaporization step and 
further development of positive matrix factorization (PMF) as a data analysis 
technique. 
The quantitative measurement of the composition of each particle gives an additional 
piece of information when measuring co- association. Further development of the 
AAMS technique to be able to produce quantitative results with improved 
consistency, would give a real advantage over the AToFMS instrument for this 
application. 
9.2.5 Automation 
The automation of an analytical technique (and sample preparation) can give 
advantages in terms of the speed of the analysis and also in terms of consistency of 
the data produced. It is envisaged that ultimately SPMS would be used as a technique 
where high numbers of samples would need to be analyzed (for example in for quality 
control analysis in a pharmaceutical manufacturing environment), hence automation 
of the SPMS technique would be advantageous. 
Many of the individual operations involved in inhalation product analysis have 
already been automated; for example it has been shown previously that automated 
actuation of inhaler devices can be performed15. Also, sampling of particles from the 
settling chamber for a given time is relatively easy to do. Hence most of the effort in 
automating the SPMS experiment for inhalation products would be centred on the 
sample conditioning apparatus and the automation of the flow of air to sweep particles 
from the inhalation product into the settling chamber. 
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Appendices are linked to individual Chapters e.g. Appendix A3 refers to Chapter 3 
etc. 
Section 1- Supplementary Data 
A3 Appendices to Chapter 3 
A3.1 LC /MS of FP and SX Including Accurate Mass Measurement 
The electrospray ionization (ESI)' mass spectra of FP and SX were acquired to aid 
interpretation of the SPMS data. These data were acquired using a time -of -flight 
(T0F) instrument (Agilent, San Jose, CA, US). Many of the ions found in the mass 
spectra for FP and SX were found to be common to their ESI, EI and laser desorption 
mass spectra. The advantage of acquiring mass spectra using the Agilent time -of- 
flight instrument was that accurate mass measurements could be made and used as an 
aid to structural elucidation. The LC/MS conditions given in Tables All and A3.2 
were used for acquiring ESI spectra and UV spectra of FP and SX. 
Parameter Value 
Flow rate 1.4 mL min' 
Column Zorbax C18, 2.1 x 30 mm (3 p.m particle size) 
Injection volume 10 µL 
Oven temperature 50 °C 
Mobile Phase A Water/ 0.1% v/v formic acid 
Mobile phase B Methanol/ 0.1 % v/v formic acid 
Gradient 40 to 95% B in 2 minutes, hold at 95% for 2 min then re- 
equilibrate at 40% B for 1 minute. 
Detector wavelength 190 to 400 nm (UV spectra collected via Diode array 
detector on HPLC) 
Table A3.1. HPLC conditions for LC /MS experiment to analyze FP and SX. 
Parameter Value 
Ion s e Ian Positive 
Ca1ill.1 vol . _e 4000 v 
F. 2 1 1 entor vol ._e 300 v 
I in _ _ . flow 7 L miñ 
I in _ -t.: tem 300 °C 
I+l uh-f- - -i.: il 15 lisi_ 
m/z ran r e 100 to 1000 
Table A3.2 Electrospray mass spectrometry conditions for LC /MS experiment to 
analyze FP and SX. 
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A3.1.1 LC /MS analysis of fluticasone propionate (FP) 
The ESI mass spectrum of FP is shown in Figure A3.1. The instrument was calibrated 
for accurate mass measurements which are shown on the mass spectrum. A list of 
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Figure A3.1. The ES1 mass spectrum of FP acquired using LC /MS using a ToF mass 
spectrometer. The ions are annotated with the accurate mass measurements which are 
summarized in Table A3.3 together with an explanation based on the suggested 












523.17432 523.17373 0.08 C25 H31 F3 05 S Na (M +Na)+ 
501.19238 501.19190 0.2 C25 H32 F3 05 S (M +H)+ 
481.18615 481.18587 0.4 C25 H31 F2 05 S Ion (a) 
333.16671 333.16610 0.04 C20 H23 F2 02 Ion (b) 
313.16048 313.16040 0.6 C20 H22 F 02 Ion (c) 
295.14991 295.15156 2.3 C20 H2O F O Ion (d) 
293.15425 293.15460 0.9 C20 H21 02 Ion (e) 
265.15934 265.15946 0.8 C19 H21 O Ion (f) 
275.14368 275.14379 0.7 C20 H19 O Ion (g) 
179.08841 179.08767 0.1 Cg H13 F2 02 Ion (h) 
121.06652 121.06626 0.3 C5 H10 F 02 Ion (i) 
Table A3.3 ESI accurate mass data for FP (taken from mass spectrum shown in 
Figure A3.1). Structures for the ions (a) to (i) are shown in Figure A3.2. 
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The suggested fragmentation pattern based on accurate mass determinations for the 
ions shown in the ESI mass spectrum of FP is shown in Figure A3.2. This shows that 
the protonated molecule at m/z 501 loses of HF probably by trans- elimination of the 
fluoride (F) at position 6 on the steroid B ring. The remainder of the ESI mass 





[M+H]+ m/z 501 
CH3 




(g) m/z 275 
F 
Loss of C3 H3 F 
and rearrangement 
(h) m/z 179 
o 
HOH 
(i) m/z 121 
Figure A3.2. Suggested fragmentation pattern for FP based on accurate mass 
measurements based on electrospray ionization. This is based on accurate mass 
measurements for ions (a) to (i) listed in Table A3.3. 
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A3.1.2 LC /MS mass spectrometry analysis of salmeterol xinofoate (SX) 
The ESI mass spectrum of SX is shown in Figure A3.3. Prior to the acquisition of this 
data, the instrument (Agilent ToF) was calibrated for accurate mass measurements 


























400 450 500 
Figure A3.3. The ESI mass spectrum of SX acquired using LC /MS with a ToF -mass 
spectrometer. The ions are annotated with the accurate mass measurements which are 
summarized in Table 3.7 (below). Note that fragmentation was induced by in- source 
collision induced dissociation. 
The suggested fragmentation pattern based on accurate mass determinations for the 
ions observed in the ESI mass spectrum of SX is given in Figure A3.4. This shows a 
protonated molecule at m/z 416 and two sequential losses of water to give ions at m/z 
398 and 380 respectively. Additionally the molecule appears to fragment along the 
aliphatic chain to produce ions from the opposite ends of the molecule. The ions at 
m/z 232 and 230 are formed via rearrangements and m/z 248 via cleavage across the 
chain next to the ester oxygen atom. The ion at m/z 91 is a tropylium ion which is 
characteristic of benzyl compounds. 
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(Shown in Fig. A3.4) 
438.26219 438.26270 0.5 C25 H37 N 04 Na (M +Na)+ 
416.28025 416.28048 0.2 C25 H38 N 04 (a) 
398.26968 398.26975 0.07 C25 H36 N 03 (d) 
380.25911 380.25938 0.3 C25 H34 N 02 (e) 
248.16515 248.16588 0.7 C15 H22 N 02 (f) 
232.17024 232.17218 1.9 C15 H22 N O (b) 
230.15458 230.15365 0.9 C15 H20 O (c) 
91.05481 91.05586 1.0 C7 H7 (g) 
Table A3.4. ESI accurate mass data for SX. Structures for the ions (a) to (g) are 
shown in Figure A3.4. 
OH 
+N 
(a) m/z 416 
(b) m/z 232 
(c) m/z 230 
-H20 
HO 
(d) m/z 398 
-H2O 




(f) m/z 248 
Figure A3.4. Suggested fragmentation pattern for salmeterol xinofoate based on 
accurate mass measurements taken from the electrospray ionization mass spectrum 
shown in Figure A3.3. 
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Appendix A3.2 Molar Absorption of FP and SX 
The molar absorptions2 of the solutions of FP and SX were calculated from an HPLC 
experiment (Conditions given in Appendix A3.1) using Equation A3.1. The UV 
spectra were acquired for FP and SX solutions (10 mg L-'). The absorbance for each 
compound was compared at 266 nm (the wavelength of the ablation laser in the 
AToFMS instrument). The path length of the UV cell in the Agilent 1100 UV diode 
array detector was 0.1 cm. 
A = scl (Equation A3.1) 
A= absorbance (arbitrary units) taken at 266 nm. 
s = molar absorption coefficient (L moll m') 
c = solution concentration (mol L-') 
1= path length (m) 
Therefore; The molar absorption coefficient s = A/cl 
So for solutions of: 
(a) FP (molecular weight 500) at 10 mg L-' (0.002 mol L-') that has an absorbance of 
50 at 266 nm measured in a flow cell of path length 0.01 m, the molar absorption 
coefficient c = 2.5 x 10 6 L mol "' m'. 
(b) SX molecular weight 415 at 10 mg L-' (0.003 mol L -') that has an absorbance of 
160 at 266 nm measured in a flow cell of path length 0.01 m, the molar absorption 
coefficient c = 5.3 x 10 6 L mol -' m-'. 
Therefore at 266 mn the absorptivity of SX is approximately double that of FP. 
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Appendix A3.3 Principal component analysis 
Principal component analysis is a way of identifying patterns in such a way to 
highlight similarities and differences between data sets3. The principle of using 
principal component analysis is illustrated with an arbitrary dataset of weight against 







1 1.3 49 
2 1.25 46 
3 1.6 53 
4 1.7 52 
5 1.8 54 
6 1.26 47 
7 1.4 50 
8 1.5 51 
9 1.3 48 
10 1.1 45 
11 1.1 46 
12 1.7 52 
13 1.8 54 
14 1.4 49 
15 1.5 51 
16 1.6 51 
17 1.7 55 
18 1.8 54 
19 1.4 50 
20 1.3 48 
Table.3.5. An arbitrary data set (weight y height) used to illustrate principal 
component analysis. 
The data set is plotted in a graph of weight against height as shown in Figure A3.6. 
Before principal component analysis is performed the data is conditioned so that it 
becomes more meaningful. For example variables may have substantially different 
numerical ranges. In the graph shown in Figure A3.6 all of the components appear in 
one corner of the graph and it is apparent that the scale in which the data is viewed 
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15 20 
Figure A3.6. Graph using arbitrary dataset of weight and height (See Table 3.5). 
In order to give both variables equal rating in the data analysis they are standardized 
or `scaled' and this means that the length of each co- ordinate axis in the variable 
space is regulated according to pre - determined criteria.. Figure A3.7 shows the same 
graph after scaling both the x and y axis. This is much easier to read visually and if 
there were an untypical observation it would be much easier to see. 
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Height (m) 
1.8 2 
Figure A3.7. Graph using arbitrary dataset of weight and height (See Table 3.5)) 
with adjusted scale. 
Further conditioning or pre -processing of the data is performed by mean centring. 
This is done by subtracting the mean value from each of the data points to give a data 












Figure A3.8. Mean centred data (See Table 3.5). 
4 
After the data has been scaled and mean centred, the first principal component is 
calculated. This component is the line that best approximates the data by a least 
squares fit. This line goes through the average point (0) as shown in Figure A3.9 and 
shows the maximum variance in the data set (PC 1). Each observation is now 
projected on this line in order to get a coordinate value. which. This new co- ordinate 
is known as a score. 
One principal component is not normally sufficient to model the variation of a data 
set. So the second principal component PC2 is calculated and this is shown in Figure 
A3.9 by a line orthogonal to PC 1 through the average point. 
PC 2 
G 
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Figure A3.9. The first two principal components (See Table 3.5). 
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The first two principal components define a plane from which the data set can be 
visualized as shown in Figure A3.10. The co- ordinate values of the observations on 












IS. e .1 0.2 0.3 0 
G 
Figure A3.10. First two principal components define a plane from which the data set 
(See Table 3.5) can be visualized. 
Geometrically the principle component loadings express the orientation of the model 
plane. The direction of PC 1 in relation to the original variables is given by the cosine 
of the angles a 1, a 2 and a 3. These values indicate how the original variables x1, x2 
and x3 load (i.e contribute) to PC 1 - hence they are called the loadings. A second set 
of loading coefficients expresses the direction of PC2. 
PC 2 PC 
Q5 -0 4 -0 -0.2 0.2 0-3 0 4 
Figure A3.11. Loadings plot - indicates how the original variables X1, X2 X3 etc 
contribute (or load) into PC1. 
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Appendix A3.4 Q -AAMS Spectra for Excipients 
The average Q -AAMS EI mass spectrum for COA is shown in Figure A3.12. Unique 
ions for COA are shown at m/z 169 and at m/z 109; The ion at m/z 169 corresponds to 
the loss of seven moieties of acetic acid. The final loss of acetic acid is shown in 
Figure A3.13. The major fragmentation products are summarized in Figure A3.13. 
Although a major ion is observed in the mass spectrum of COA at m/z 43, this is not 
unique as it is also observed in the mass spectra of both SX and lactose. For COA and 
lactose m/z 43 is likely to be due to acetate, for SX it may be due to an alternative ion 
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Figure A3.12. Average Q -AAMS spectrum of cellobiose octaacetate (COA), showing 
potential marker ions. 
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Figure A3.13. Suggested fragmentation to give representative ions for COA based on 
the Q -AAMS EI mass spectrum shown in Figure A3.12. 
The average Q -AAMS EI mass spectrum for magnesium stearate is shown in Figure 
A3.7. No intact molecular ion is observed, but the unique fragmentation pattern for 
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this molecule is clearly visible and the major ions are shown in Figure A3.8. Also 
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Figure A3.15. Suggested fragmentation for the representative ions of magnesium 
stearate based on Q -AAMS EI mass spectrum shown in Figure A3.14. Magnesium 
stearate has the formula [CH3 [CH2116 COOJz Mg 2+ and most of the fragmentation 
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Appendices 
A4.1 Samples Used as Examples in Chapter 4 
FP Pure drug material 
SX Pure drug material 
MDI1 pMDI formulation: FP /SX 250/25 
DPI 3 DPI formulation: FP /SX 250/50 
A full list of samples is given in Appendix A5.1. 
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Figure A4.1. Average positive ion mass spectrum for pure FP particles at fixed laser 
energy (0.2 mJ). Particles were introduced via an aerodynamic lens for the 
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Figure A4.2. Average negative ion mass spectrum for pure FP particles at fixed laser 
energy (0.2 mJ). Particles were introduced via an aerodynamic lens for the 
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Figure A4.3. Average positive ion mass spectrum for pure SX particles at fixed laser 
energy (0.2 mi). Particles were introduced via an aerodynamic lens for the 
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Figure A4.4. Average negative ion mass spectrum for pure SX particles at fixed laser 
energy (0.2 mi). Particles were introduced via an aerodynamic lens for the 
acquisition of this data. 
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A5 Appendices to Chapter 5 
A5.1 List of Samples for AToFMS Experiments 
MDI DPI 
AToFMS AToFMS 
Identifier FP /SX formulation Batch /id Identifier FP /SX formulation Batch /id 
MDI_1 250/25 Lot031012991 DPI_1 250/50. R252654 
MDI 2 250/25 SE004/97F DPI_2 250/50. R252237 
MDI 3 250/25 AX7102/82. DPI 3 250/50. R252265. 
MDI 4 250/25. AX7102/82. DPI 4 250/50. R252265. 
MDI_5 250/25. AX7102/82. DPI 5 250/50. R252265. 
MDI6 125/25. 002/78 DPI_6 500/50. R252400 
MD117 125/25 AX7100/60 DPI 7 500/50. R252323 
MDI 8 125/25. 1/18, 04/97F. DPI 8 500/50. R252238 
MDI 9 125/25. 1/18, 04/97F. DPI 9 500/50 R252238 
MDI 10 125/25. 1/18, 04/97F. DPI 10 500/50 R252238 
DPI 11 500/50 R252400 
MDI 11 50/25 002/78 
MDI 12 50/25 AX7099/32 SERE 1 LOT R262956 
MDI 13 50/25 05/97F Flovent 1 F100 
MDI 14 50/25. 05/97F FP 2 FP 
MDI 15 50/25. 05/97F SX _4 SX 
Table A5.1. Samples used in AToFMS experiments, showing formulation and batch 
identifier. 
3 were three runs of one batch of the same formulation of 
pMDI (FP /SX 250 /25) and runs MDI_3 to MDI_5 were of three different batches of 
the same formulation of pMDI (FP /SX 250/25). Runs MDI_6 to MDI_8 were three 
runs of one batch of the same formulation of pMDI (FP /SX 125 /25) and runs MDI _8 
to MDI 10 were of three different batches of the same formulation of pMDI (FP /SX 
125/25). Runs MDI 11 to MDI 13 were three runs of one batch of the same 
formulation of pMDI (FP /SX 50/25) and runs MDI_13 to MDI_15 were of three 
different batches of the same formulation of pMDI (FP /SX 50/25). 
Runs DPI 1 to DPI 3 were three runs of one batch of the same formulation of DPI 
(FP /SX 250 /50) and runs DPI_3 to DPI_5 were of three different batches of the same 
formulation of DPI (FP /SX 250/50). Runs DPI_6 to DPI 9 were three runs of one 
batch of the same formulation of DPI (FP /SX 500/50) and runs DPI_9 to DPI_11) 
were of three different batches of the same formulation of DPI (FP /SX 500/50). 
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A5.2 The Classification of Particles by Size 
The particles were classified by particle size range; the ranges used for this were (a) > 
1600 nm, (b) 1200 to 1600 nm (c) 1200 to 800 nm (d) 400 to 800 nm and (e) < 400 
nm. The numbers of particles in each category were counted and the results for the 
pMDIs are shown in Table A5.2 and for the DPIs in Table A5.3. 
Type Formulation File Particle size range 
> 1600 nm 1200 to 1600 nm 800 to 1200 nm 400 to 800 nm < 400 nm 
a 
FP/SX, 250/25 MDI_1 2.0 6.9 44.6 36.6 9.9 
FP/SX, 250/25 MDI_2 1.0 21.2 36.5 31.7 9.6 
FP/SX, 250/25 MDI3 5.0 15.0 43.0 33.0 4.0 
FP/SX, 250/25 MDI__4 1.0 13.7 49.0 25.5 10.8 
FP/SX, 250/25 MDI_5 2.0 13.9 47.5 28.7 7.9 
a 
FP/SX, 125/25 MDI_6 2.9 15.4 41.3 29.8 10.6 
FP/SX, 125/25 MDI_7 3.0 6.0 47.0 32.0 12.0 
FP/SX, 125/25 MDI_8 3.0 9.0 40.0 36.0 12.0 
FP/SX, 125/25 MDI_9 2.0 12.7 37.3 26.5 21.6 
FP/SX, 125/25 MDI_10 2.0 5.9 39.6 38.6 13.9 ' 
a 
FP/SX, 50/25 MDI_11 0.0 7.9 30.7 52.5 8.9 
FP/SX, 50/25 MDI_12 1.8 16.5 33.0 37.6 11.0 
FP/SX, 50/25 MDI_13 2.0 7.0 26.0 52.0 13.0 
FP/SX, 50/25 MDI_14 1.9 7.5 28.3 46.2 16.0 
FP/SX, 50/25 MDI_15 2.9 4.9 27.2 45.6 19.4 
Table A5.2. Particle size distribution for pMDIs. The % number of particles in each 
size range is shown. 
Type Formulation File Particle size range 
> 1600 nm 1200 to 1600 nm 800 to 1200 nm 400 to 800 nm < 400 nm 
a 
FP /SX 250/50 DPI_1 16.2 32.4 47.1 4.4 0.0 
FP /SX 250/50 DPI_2 14.0 42.1 31.6 10.5 1.8 
FP /SX 250/50 DPI_3 13.4 43.4 37.3 3.0 3.0 
FP /SX 250/50 DPI_4 20.3 31.6 34.2 10.1 3.8 
FP /SX 250/50 DPI 5 19.2 27.7 43.8 9.2 0.0 
E. 
FP /SX 500/50 DPI_7 9.8 30.4 47.1 10.8 2.0 
FP /SX 500/50 DPI_8 12.8 35.8 38.5 11.0 1.8 
FP /SX 500/50 DPI_9 16.0 32.0 39.0 10.0 3.0 
FP /SX 500/50 DPI_10 15.5 31.1 39.8 11.7 1.9 
FP /SX 500/50 DPI 11 15.7 28.4 43.1 10.8 2.0 
Table A5.3. Particle size distribution for DPIs. The % number of particles in each 
size range is shown. 
The average particle size distributions are shown in Figure A5.1 for the pMDIs and in 
Figure A5.2 for the DPIs. Figure A5.1 shows that most of the particles 
(approximately 80 %) from the pMDI samples were in the 400 to 1200 nm range. 
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Figure A5.2 shows that most of the particles (approximately 80 %) for the DPI 
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Figure A5.1. Particle size distributions for pMDI aerosols. Example data shown for 
samples of FP /SX 250/25 (file MDI I), FP /SX 125/25 (file MDI 6) and FP /SX 50/25 
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Particle size (nm) 
-.0-250/50 
-0-500/50 
Figure A5.2. Size distributions for DPI particles. Example data shown for FP /SX 
250/50 (file DPI 1), and FP /SX 500/50 (file DPI 7) . 
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A5.3 Particle Size Distribution Graphs for Individual Samples 
< 400 400 to 800 800 to 1200 1200 to 1600 >1600 






Figure A5.3. Particle size distribution for pMDIs (formulation FP /SX 250/25). 
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Figure A5.5. Particle size distribution for pMDIs (formulation FP /SX 50/25). 
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Figure A5.6. Particle size distribution for DPIs (formulation FP /SX 250/50). 
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Figure A5.7. Particle size distribution for DPIs (formulation FP /SX 500/25). 
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A5.4 Data Tables 







M D I_1 250/25. Lot031012991 101 85 61 45 101 0 
MDI2 250/25. SE004/97F 104 79 75 50 104 0 
MD113 250/25. AX7102/82. 102 79 80 57 102 0 
MDI_4 250/25. AX7102/82. 102 73 74 46 101 1 
MDI 5 250/25. AX7102/82. 101 74 74 50 98 3 
MDI_6 125/25. 002/78 104 71 80 50 101 3 
MDI7 125/25. AX7100/60 100 50 86 40 96 4 
MD118 125/25. 1/18, 04/97F. 101 69 80 48 101 0 
MDI9 125/25. 1/18, 04/97F. 102 61 87 46 102 0 
MDI__10 125/25. 1/18, 04/97F. 101 68 75 44 99 2 
MDI11 50/25. 002/78 101 52 79 31 100 1 
MDI__12 50/25. AX7099/32 109 51 101 43 109 0 
MDI_13 50/25. 05/97F 101 54 90 43 101 0 
MDI_14 50/25. 05/97F 106 53 100 47 106 0 
MDI_15 50/25. 05/97F 103 51 93 41 103 0 
Table A5.4. pMDI Data analysis based on marker ion analysis. (For FP, m /z -74 and 
for SX -188). Category FP - particles that contain FP, Category SX - particles that 
contain SX, Category FPANDSX- particles that contain FP and SX i.e. mixed due to 
co- association. Table shows number of particles in each category. 







MDI1 250/25. Lot031012991 84.2 60.4 44.6 100.0 0.0 
MD112 250/25. SE004/97F 76.0 72.1 48.1 100.0 0.0 
MDI 3 250/25. AX7102/82. 77.5 78.4 55.9 100.0 0.0 
MDI_4 250/25. AX7102/82. 71.6 72.5 45.1 99.0 1.0 
MDI 5 250/25. AX7102/82. 73.3 73.3 49.5 97.0 3.0 
MDI6 125/25. 002/78 68.3 76.9 48.1 97.1 2.9 
MDI 7 125/25. AX7100/60 50.0 86.0 40.0 96.0 4.0 
MDI_8 125/25. 1/18, 04/97F. 68.3 79.2 47.5 100.0 0.0 
MDI_9 125/25. 1/18, 04/97F. 59.8 85.3 45.1 100.0 0.0 
MDI_10 125/25. 1/18, 04/97F. 67.3 74.3 43.6 98.0 2.0 
MDI_11 50/25. 002/78 51.5 78.2 30.7 99.0 1.0 
MDI_12 50/25. AX7099/32 46.8 92.7 39.4 100.0 0.0 
MDI_13 50/25. 05/97F 53.5 89.1 42.6 100.0 0.0 
MDI 14 50/25. 05/97F 50.0 94.3 44.3 100.0 0.0 
MDI_15 50/25. 05/97F 49.5 90.3 39.8 100.0 0.0 
Table A5.5. pMDI Data analysis based on marker ion analysis. (For FP, m /z -74 and 
for SX -188). Category FP - particles that contain FP, Category SX - particles that 
contain SX, Category FPANDSX- particles that contain FP and SX i.e. mixed due to 
co- association. Table shows % number of particles in each category. 
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DPI_1 250/50. R252654 68 55 67 54 68 0 
DPI_2 250/50. R252237 57 48 57 48 57 0 
DPI_3 250/50. R252265. 68 64 66 63 67 1 
DPI _4 250/50. R252265. 79 66 77 64 79 0 
D P I_5 250/50. R252265. 130 110 128 109 129 1 
DPI_7 500/50. R252323 102 80 96 76 100 0 
DPI_8 500/50. R252238 109 96 104 91 109 0 
DPI_9 500/50 R252238 100 98 98 87 100 0 
DPI_10 500/50 R252238 103 88 103 88 103 0 
DPI_11 500/50 R252400 102 89 100 87 102 0 
Table A5.6. DPI data analysis based on marker ion analysis. (For FP, m /z -74 and 
For SX -188). Category FP - particles that contain FP, Category SX - particles that 
contain SX, Category FPANDSX -particles that contain FP and SX i.e. mixed due to 
co- association. Table shows number of particles in each category. 







DPI_1 250/50. R252654 80.9 98.5 79.4 100.0 0.0 
DPI 2 250/50. R252237 84.2 100.0 84.2 100.0 0.0 
DPI_3 250/50. R252265. 94.1 97.1 92.6 98.5 1.5 
DPI_4 250/50. R252265. 83.5 97.5 81.0 100.0 0.0 
DPI_5 250/50. R252265. 84.6 98.5 83.8 99.2 0.8 
DPI_7 500/50. R252323 78.4 94.1 74.5 98.0 0.0 
DPI_8 500/50. R252238 88.1 95.4 83.5 100.0 0.0 
DPI 9 500/50 R252238 98.0 98.0 87.0 100.0 0.0 
DPI 10 500/50 R252238 85.4 100.0 85.4 100.0 0.0 
DPI 11 500/50 R252400 87.3 98.0 85.3 100.0 0.0 
Table A5.7. DPI data analysis based on marker ion analysis. (For FP, m /z -74 and 
For SX -188). Category FP - particles that contain FP, Category SX - particles that 
contain SX, Category FPANDSX - particles that contain FP and SX i.e. mixed due to 
co- association. Table shows % number of particles in each category. 
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A7 Appendices to Chapter 7 
A7.1 Sample list for AAMS Experiments 
Sample Batch Formulation 
MDI 1* 002/78 FP/SX 50/25 
MDI2 002/78 FP/SX 50/25 
MDI_3 05/97F FP/SX 50/25 
MDI 4 AX7099/23 FP/SX 50/25 
MDI_5 AX7099/23 FP/SX 50/25 
MDI_6 AX7099/23 FP/SX 50/25 
MDI7 1/22 FP/SX 250/25 
MDI_8 1/22 FP/SX 250/25 
MDI_9 AX7102/82 FP/SX 250/25 
MDI 10 DO40861 FP/SX 250/25 
MDI 11 DO40861 FP/SX 250/25 
DPI 1 R15404-20 FP/L 
DPI_2 R25237 FP/SX 250/50 
DPI_3 R25240 FP/SX 500/50 
Table A7.1. List of samples used in the experiments described in Chapter 7. Sample 
MDI 1 was a trial run and no data from this run was used. Sample MDI 11 was run 
with no inlet orifice in place. 
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A7.2 Data Tables 
A7.2.1 Particle size data 
Number of particles 
File Dose >1000 nm 500 to 1000 nm 300 to 500 nm 200 to 300 nm < 200 nm Total particles 
MDI 1 FP/SX 50/25. n/a n/a n/a n/a n/a n/a 
MDI 2 FP/SX 50/25. 4 14 53 47 1 122 
MDI3 FP/SX 50/25. 4 26 44 27 1 102 
MDI__4 FP/SX 50/25. 4 18 54 40 1 120 
MDI_5 FP/SX 50/25. 3 11 42 42 1 102 
MDI 6 FP/SX 50/25. 5 16 73 76 2 122 
MDI_7 FP/SX 250/25. 1 15 9 17 1 46 
MDI_8 FP/SX 250/25. 23 36 22 18 0 102 
MDI_9 FP/SX 250/25. 27 76 14 2 0 122 
MDI_10 FP/SX 250/25. 17 31 28 49 0 122 
MDI 11 FP/SX 250/25. 32 50 13 5 0 103 
MDI 12 FP/SX 250/25. 41 100 11 3 0 155 
Table A7.2. The number of particles in each classification category. 
% Number of particles 
File Dose >1000 nm 500 to 1000 nm 300 to 500 nm 200 to 300 nm < 200 nm Total particles 
MDI_1 FP/SX 50/25. n/a n/a n/a n/a n/a n/a 
MDI_2 FP/SX 50/25. 3.3 11.5 43.4 38.5 0.8 122 
MDI 3 FP/SX 50/25. 3.9 25.5 43.1 26.5 1.0 102 
MDI_4 FP/SX 50/25. 3.3 15.0 45.0 33.3 0.8 120 
MDI_5 FP/SX 50/25. 2.9 10.8 41.2 41.2 1.0 102 
MDI_6 FP/SX 50/25. 4.1 13.1 59.8 62.3 1.6 122 
MDI 7 FP/SX 250/25. 2.2 32.6 19.6 37.0 2.2 46 
MDI_8 FP/SX 250/25. 22.5 35.3 21.6 17.6 0.0 102 
MDI_9 FP/SX 250/25. 22.1 62.3 11.5 1.6 0.0 122 
MDI_10 FP/SX 250/25. 13.9 25.4 23.0 40.2 0.0 122 
MDI_11 FP/SX 250/25. 31.1 48.5 12.6 4.9 0.0 103 
MDI 12 FP/SX 250/25. 26.5 64.5 7.1 1.9 0.0 155 
Table A 7.3. The % number of particles in each classification category. 
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A7.2.2 Analysis of Particle Composition 
A7.2.2.1 Data analysis for pMDI using marker ion analysis 
File Formulation Batch/id Total FP SX Mixed 
MDI_1 FP/SX 50/25. 002/78. n/a n/a n/a n/a 
MDI_2 FP/SX 50/25. 002/78. 122 100 7 15 
MDI_3 FP/SX 50/25. 05/97F 97 74 10 13 
MDI_4 FP/SX 50/25. AX7099/23 120 100 4 16 
MDI_5 FP/SX 50/25. AX7099/23 102 88 3 11 
MDI_6 FP/SX 50/25. AX7099/23 172 139 9 24 
MDI_7 FP/SX 250/25. 1/22. 102 76 5 21 
MDI_8 FP/SX 250/25. 1/22. 169 121 12 36 
MDI_9 FP/SX 250/25. AX7102/82. 126 107 6 13 
MDI_10 FP/SX 250/25. 0040861. 103 80 5 18 
MDI 11 FP/SX 250/25. D040861. 155 118 8 29 
Table A7.4 Particle classification to show the fractional composition for the series of 
pMDL The table shows the number of particles in each category. 
File Formulation Batch/id Total % FP SX Mixed 
MDI_1 FP/SX 50/25. 002/78. n/a n/a n/a n/a 
MDI_2 FP/SX 50/25. 002/78. 100.0 82.0 5.7 12.3 
MDI_3 FP/SX 50/25. 05/97F 100.0 76.3 10.3 13.4 
MDI_4 FP/SX 50/25. AX7099/23 100.0 83.3 3.3 13.3 
MDI_5 FP/SX 50/25. AX7099/23 100.0 86.3 2.9 10.8 
MDI_6 FP/SX 50/25. AX7099/23 100.0 80.8 5.2 14.0 
MDI_7 FP/SX 250/25. 1/22. 100.0 74.5 4.9 20.6 
MDI_8 FP/SX 250/25. 1/22. 100.0 71.6 7.1 21.3 
MDI_9 FP/SX 250/25. AX7102/82. 100.0 84.9 4.8 10.3 
MDI_10 FP/SX 250/25. 0040861. 100.0 77.7 4.9 17.5 
MDI 11 FP/SX 250/25. 0040861. 100.0 76.1 5.2 18.7 
Table A7.5 Particle classification to show the fractional composition for the series of 
pMDL The table shows the % number of particles in each category. 
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Appendix Section 2 
Publications - Anthony New 
Recent posters /presentations 
1. (Oral presentation)- Desorption Electrospray Ionization (DESI) and Direct 
Analysis in Real Time (DART) mass spectrometry. A.P. New. Pharmaceutical 
Analytical Sciences Group (PASG) meeting -New directions: Science and 
Technology. Sept 2007 (Northampton, UK). 
2. (Poster)- Atmospheric Desorption Analysis of Pharmaceutical Solid Dosage 
Forms: Progress over the Past Year. A. Marcus and A.P. New. Proceedings of the 
55th conference on mass spectrometry and allied topics. June 2007 (Denver, CO, 
USA). 
3. (Poster)- An initial assessment of the use of conductivity profiles in process 
manufacturing. A.P. New, D. Elder, D. Rudd, G. Bone and D. Taylor. British 
Pharmaceutical Conference, Sept 2006, ( Manchester, UK). 
4. (Poster)- Evaluation of the use of desorption ionization techniques for the analysis 
of formulated products. A. Marcus and A.P. New. Proceedings of the 54`h 
conference on mass spectrometry and allied topics. June 2006 (Seattle, WA, USA). 
Patent 
1. Temperature controlled membrane interface device. A.P. New, D.G. Lamarca, 
C.S. Creaser. UK Patent Application GB 2392114A, 25 Feb 2004. 
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Research Papers (Chronological order 1988 -present) 
1. Experiments on cyanoguanadino compounds using discharge assisted thermospray 
ionization. N.J. Haskins and A.P. New. Biomed. and Environ. Mass Spectrom. 
17 169 -171, (1988). 
2. A comparison of positive and negative ion FAB -MS data for some sulphonyl 
hydrazones and derivatives. A.P. New, N.J. Haskins and M.J. Frearson. Biomed. 
and Environ. Mass Spectrom. 18, 620 -623, (1989). 
3. Cluster ion formation between solvent and matrix using fast atom bombardment 
mass spectrometry. N.J. Haskins and A.P. New. Rapid Commun. Mass Spectrom. 
3 335 -337, (1989). 
4. A coordinated approach towards the molecular weight determination of peptides 
by gel electrophoresis and fast atom bombardment mass spectrometry. P. 
Camilleri, N.J. Haskins, A.J. Hill and A.P. New. Rapid Commun. Mass Spectrom. 
3 440 -443, (1989). 
5. Fast atom bombardment mass spectrometry (FAB -MS) and fast atom 
bombardment tandem mass spectrometry (FAB MS/MS) of some monosaccharide 
oximes. A.P. New, N.J. Haskins and B. Lee. Rapid Commun. Mass Spectrom. 4 
432 -435, (1990). 
6. The use of tandem mass spectrometry for the differentiation of bile acid isomers 
and for the identification of bile acids in biological extracts. C. Eckers, A.P. New, 
P. East and N.J. Haskins. Rapid Commun. Mass Spectrom. 4 449 -453, (1990). 
7. Deuterated Solvents in High Performance Liquid Chromatography- Fast Atom 
Bombardment Mass Spectrometry. T. McLean, A.P. New, N.J. Haskins and P. 
Camilleri. 'Chem. Soc. Chem. Comm. 24 1773 -1775, (1992). 
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8. An investigation into the stereochemistry of the borate di- esters of some 
monosaccharides using tandem mass spectrometry. A.P. New, N.J. Haskins and 
D.E. Games. Rapid Commun. Mass Spectrom. 7 1099 -1107, (1993). 
9. Analyzing the complexation of amino acids and peptides with cyclodextrin using 
electrospray ionization mass spectrometry. P. Camilleri, N.J. Haskins, A.P. New 
and M.R. Saunders. Rapid Commun. Mass Spectrom. 7 949 -952, (1993). 
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polysporum. A.P. New, C. Eckers, N.J. Haskins, W.A. Neville, S. Elson, J.A. 
Hueso and A. Rivera. Tetrahedron Letters. 37(17), 3039 -3042 (1996). 
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New, M. Gilges and D.G. Lamarca. Trans. IChemE. 77 Part B 43 -46 (1999). 
12. Biodegradation of 2, 3 and 4- iodobenzoic acids and ethyl -4- iodobenzoate. L.M. 
Freitas dos Santos, A.P. New and M. Kingswood. J.Chem Technol. Biotechnol. 
74 815 -820 (1999). 
13. Analytical techniques used for monitoring the biodegradation of fluorinated 
compounds in waste streams from pharmaceutical production. A.P. New, L.M. 
Freitas dos Santos and A. Spicq. Journal of Chromatography A. 889, 177 -184, 
(2000). 
14. Preliminary investigation of the application of on -line membrane extraction of 
trifluoro acetic acid as an aid to improvement of negative ion electrospray mass 
spectrometry data. A.P. New, J -C. Wolff, S. Crabtree, G. Okafo, J. Lee, K. Divan 




15. Aerobic biotransformation of 4- fluorocinnamic acid to 4- fluorobenzoic acid. L.M. 
Freitas dos Santos, A. Spicq, A.P.New, G. LoBiundo, J -C. Wolff and A. Edwards. 
Biodegradation, 12 23 -29, (2001). 
16. Analysis of semi -volatile organic compounds by membrane inlet mass 
spectrometry. C.S. Creaser, D.G. Lamarca, L.M. Freitas dos Santos and A.P. New. 
Advances in Mass Spectrom. 1 S 817 -818, (2001). 
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Lamarca, J. Brum, C. Werner, A.P. New and L. Freitas dos Santos. Anal. Chem. 
74 300 -304, (2002). 
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evaluation of membrane inlet mass spectrometry as an alternative to high 
performance liquid chromatography and ion chromatography. C.S. Creaser, D.G. 
Lamarca, A.P. New, J -C. Wolff and L.M. Freitas dos Santos. Analytica Chimica 
Acta. 454, 13 7 -145, (2002). 
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Santos, G. LoBiondo and A.P. New. Journal of Chemical Technology and 
Biology. 78 1193 -1200, (2003). 
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Aerosol Time -of- Flight Mass Spectrometry (AToFMS) was used to examine co- association between 
two inhaled drugs, ffuticasone propionate (FP) and salmeterol xinofoate (SX), in fine aerosolised 
particles emitted from Seretide'/Advair?' inhaled combination products. Principal Component 
Analysis (PCA) was used to identify fragmentation patterns indicative of either pure or co- associated 
particles (particles containing both drugs). A third component of the particles emitted from dry 
powder inhalers (DPIs), lactose, gave only a very weak mass spectral signal and no interpretable data 
was acquired for this compound; however, it was not found to interfere with the detection of the two 
drug substances. High levels of co- association were found in the emitted doses from both pressurised 
metered dose inhaler (pMDI) and dry powder inhaler (DPI) products. Copyright G 2008 John Wiley 
& Sons, Ltd. 
The two most common chronic respiratory diseases are 
asthma and chronic obstructive pulmonary disease (COPD). 
According to the World Health Organisation (WHO) 
estimates in 2007, 300 million people currently suffer from 
asthma and 210 million suffer from COPD.1 Two classes of 
drugs widely used in the treatment of these diseases are 132- 
agonists and corticosteroids; both being preferably delivered 
directly to the lungs by inhalation. Typically, patients use 
either pressurised metered dose inhaler (pMDI) or dry 
powder inhaler (DPI) devices to administer the drugs. 
In recent years, inhaled products have become available 
which deliver both types of drug within a single dose: e.g. 
Seretide' "' /Advair' which include fluticasone propionate 
(FP), an inhaled corticosteroid (ICS), and salmeterol 
xinofoate (SX), a long- acting ß2- agonist (LABA). Some 
studies have shown that in Seretide "` /Advair" inhalers 
the two drugs provide an enhanced clinical effect beyond 
that achieved when the two drugs are administered 
concurrently from two separate inhalers.2 It has been 
suggested that this increased effect is due to higher levels 
of co- deposition of the two drugs in the lungs when 
delivered from a single inhaler, possibly because the drugs 
are co- associated when emitted from the device. Although it 
has been shown that there is some affinity between FP and SX 
in solution,3 in the past the composition of single particles 
has been difficult to ascertain. Some work using Raman 
"Correspondence to: A. New, Novel Analytical Technologies, 
GlaxoSmithKline, Park Road, Ware SG12 ODP, UK. 
E -mail: apn33849 @googlemail.com 
imaging4 presented statistical evidence of significant co- 
association of FP and SX particles emitted from a Seretide' "' 
inhaler when deposited onto a surface within a cascade 
impactor. 
Conventional analysis of a formulated inhaled product can 
involve highly resource -intensive sample preparation. For 
example, experiments to determine particle size and 
composition using the Andersen Cascade Impactor (ACI)s 
involve washing the plates taken from the impactor followed 
by high- performance liquid chromatography (HPLC) 
analysis. 
The ability of single particle mass spectrometry (SPMS) to 
make near real -time measurements of particle size and 
chemical composition62 is an attractive alternative in the 
field of pharmaceutical aerosol analysis. 
In the work presented here we have employed a 
commercially available single particle mass spectrometer, 
a TSI 3800 aerosol time -of -flight mass spectrometer, to 
analyse particles originating from both pressurised metered 
dose inhalers (pMDI) and dry powder inhalers (DPI). A 
sample introduction apparatus was used in these exper- 
iments to disperse particles appropriately but no manual 
sample preparation was required and the experiments were 
performed directly on the commercial products. 
Although the aerosol time -of -flight mass spectrometry 
(AToFMS) technique was developed mainly for the study of 
environmental aerosols,8'9 it has also been used in a number 
of studies encompassing the analysis of inhaled pharma- 
ceutical products70 -12 and tablets.13 
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EXPERIMENTAL 
sample introduction apparatus 
A schematic diagram of the apparatus used for the introduc- 
tion and dispersion of partides taken from samples is shown in 
Fig. 1. The apparatus is designed for the introduction of 
standard aerosolised powders of active pharmaceutical 
ingredients. It was constructed from glass and allowed 
aerosolised partides to be suspended in Brownian motion 
inthe 5 L settling chamber and sampled through the inlet of the 
AToFMS instrument. 
The liquid impinger stage was the upper stage (stage 1) 
from a twin impinger14 which is designed to separate the 
fine, potentially respirable, fraction of the dose from an 
inhaled delivery device from the coarse, non -respirable 
material. The upper stage is designed to remove the majority 
of partides with an aerodynamic diameter greater than 
approximately 6µm when the air flow rate is 60 L min-1. 
Hence, this stage would be expected to remove the large, 
non -respirable material, such as the coarse lactose carrier 
particles in the dose from a DPI or the larger droplets emitted 
from a pMDI. It would be expected to remove only a small 
percentage of the individual particles of micronised drug or 
small agglomerates of drug particles. 
Sample types 
Three different types of sample were examined in these 
experiments, viz. micronised powders of the pure active 
pharmaceutical ingredients (APIs), and the emitted doses 
from DPIs and pMDIs. Micronised API powders were 
introduced into a flow of air from a large air syringe using a 
Penn- CenturyTM device (Penn -Century, Philadelphia, PA, 
USA) as a powder syringe, as shown in Fig. 1. A flow of air at 
approximately 60 L min-1 was generated using a 3 L air 
syringe and the powder injected into the flow. 
For DPIs a similar apparatus was used except that the DPI 
was actuated and then placed in a box designed to allow a 
flow of air through the device such that the dose was emitted 
horn the mouthpiece into the twin impinger. The flow of air 
was again provided using an air syringe at approximately 
;3L min-1. The apparatus for the introduction of pMDIs was 
similar except that the pMDI was actuated directly into the 
mpinger stage (a flow of air was not required as the 
expansion of the propellant is sufficient to carry the emitted 
particles into the settling chamber). 









Data sets were acquired using the AToFMS instrument on 
clinical grade samples of the pure active pharmaceutical 
ingredients fluticasone propionate (FP) and salmeterol 
xinofoate (SX) and of lactose (the carrier used in the DPI 
samples). The structures of FP and SX are shown in Table 1. 
Data sets from both pure active pharmaceutical ingredients 
(FP and SX) were used as reference standards for comparison 
with the samples from pMDIs and DPIs. Lactose gave only a 
very weak mass spectral signal and no interpretable data was 
acquired for this compound. 
Data sets were then acquired using the AToFMS instru- 
ment to analyse aerosolised powders from Advair Diskus®' 
dry powder inhalers of strengths 5001.1.,g FP /50 µg SX and 
250 FP /50µg SX and from Seretide® pressurised metered 
dose inhalers of strengths 25011g FP/25 SX, 125µg FP/ 
2511g SX and 50 µg FP /2511g SX. Samples from Flovent® 
(10011g FP per dose) and Serevent® (5011g SX per dose), 
which contain only one active pharmaceutical ingredient, 
were also analysed to assess the effect of the matrix. [Samples 
of Advair Diskus®, Seretide®, Flovent® and Serevent® were 
supplied by GSK, Greenford, UK.] 
Sample analysis using the AToFMS instrument 
All experiments were performed using a TSI 3800 AToFMS 
instrument (TSI, Shoreview MN USA). This instrument is 
described in detail elsewhere,"5 and hence only a brief 
description of the operation is provided below. 
The initial configuration of the inlet used a nozzle- 
skimmer design; however, during the course of this work 
the inlet was upgraded to an aerodynamic lens which has the 
capability to give improved transmission efficienciesl6 
especially for smaller particles. 
The measurement of particle size by the AToFMS 
instrument is derived from a measurement of the time taken 
for a particle to pass between two laser beams in the sizing 
region; this yields the aerodynamic diameter of the particle. 
Partide size measurements were calibrated with a range of 
polystyrene beads of known size (Duke Scientific, Palo Alto, 
CA, USA). 
After sizing, the particles are directed into the mass 
spectrometer where they are ablated and ionised using a 
quadrupled Nd:YAG laser (266 nm, 5 ns pulses) which is 
synchronised and triggered by the particle sizing lasers. The 
Penn -Ce turyTM' device 
3 litres @ 
601/minute 





Outlet to ATE 
Figure 1. Left panel: inlets for the dry powder inhalation chamber and metered dose inhaler. Right panel: the 
inlet for the Penn -Century TM device, attached to AToFMS inlet apparatus (settling chamber). 
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Table 1. The structures of fluticasone propionate (FP) and salmeterol xinofoate (SX) 
HO 
Fluticasone propionate (FI') 
Cu H31 F3 05 S 
MW 500 
Salmeterol xinofoate (SX) 
Salmeterol (free base) 
C2e H37 N 04 
MW 415 
Xinofoate 
Cn Ha 03 
MW 188 
AToFMS instrument utilises two separate time -of -flight mass 
spectrometers, of opposite polarity, which allows the 
simultaneous detection of both positive and negative ions 
from the same particle. The vacuum was 6.5 x 10 -6 Torr in 
the sizing region and 3.0 x 10 -Tory in the mass spec- 
trometer. 
Initial experiments (using the nozzle -skimmer inlet) were 
performed to investigate the effect of the laser energy on 
fragmentation and the general quality of mass spectral data 
within the range 0.1 to 1.0 mJ (the power density15 for a 
1.0 mJ, 5 ns pulse, focused on an area of 400 µm2, is 
1 x 108W /cm2; see Figs. 5 and 6). Experiments using the 
aerodynamic lens as the inlet were all performed at the low 
laser energy settings (<0.2 mJ) in an attempt to obtain data 
showing the greatest differentiation between the individual 
FP and SX mass spectra. Data were processed using MS 
Analyze (TSI), collated in MS AccessTM databases, and 
then analysed with multivariate statistical analysis software 
based on MatlabTM (The Mathworks, Natick, MA, USA). 
Application of multivariate analysis to data 
acquired using the AToFMS instrument 
Multivariate statistical analysis can be applied to chemical 
analysis data and can be used as a tool to extract trends from 
large complex data sets.17 A specific application of multi- 
variate chemical analysis (MCA) is principal component 
analysis (PCA).18 This multivariate statistical pattern recog- 
nition method can detect trends in large data sets, by 
mathematically generating a series of fewer new variables 
called principal components (PCs). It is a method of 
identifying patterns in data and highlighting similarities 
and differences between data sets. Once the patterns have 
been identified, the data sets can be compressed to the PCs 
with minimal loss of information. 
Copyright © 2008 John Wiley & Sons, Ltd. 
PCA identifies the axis of maximum variance along which 
to project the data sets. The data matrix that was used here in 
the PCA corresponds to the normalised spectra of FP and SX 
standards stacked along rows. As an additional pre- 
processing step, variables along the matrix columns were 
auto -scaled. From the PCA assessment, two sets of vectors 
were extracted, the scores and the loadings, that can be 
projected into two -dimensional diagrams to inspect the 
major trends that are responsible for most of the variation in 
the data matrix. 
The scores plots shown in the Results section indicate the 
groups of particles that show similar spectra, i.e. those falling 
within the same duster (or confidence ellipse), and this can 
be used to compare datasets. The loadings plots (not shown) 
were used to ascertain the weights ascribed to the original 
variables (m /z values) in projecting the spectra derived from 
each particle onto the scores plot. The most influential m/z 
values are those that cluster furthest away from the origin of 
the loadings plot. 
Principal components are ordered in terms of size, 
indicated by the percentage variation in the dataset that 
they span. In this application it was found that two 
components were sufficient to describe the main trends in 
the data; hence a single scatter plot of the first and second 
principle components (PCI vs. PC2) could be used to 
interpret the main patterns. 
RESULTS 
Particle size effects 
Initial experiments using the instrument fitted with the 
nozzle -skimmer inlet were carried out to examine the 
variation in spectral data as a function of laser energy. From 
these experiments the effect of particle size, in the 0.5 to 
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4.5 p.m range, could be determined. Additional experiments 
were performed, at low laser energy settings (0.2 mJ), in an 
attempt to maximise the difference between the mass spectra 
of the individual active pharmaceutical ingredients (FP and 
SX). For these experiments, using the aerodynamic lens, 
smaller particles, i.e. those in the range 0.5 to 1.5 p.m, were 
detected. 
Mass spectra 
There were some potential difficulties when applying 
AToFMS to drug compounds such as FP and SX. The 
amount of material in each particle is very small - e.g. a 
homogeneous, spherical, 1 µm diameter particle of FP would 
have a mass of approximately 0.7 fg. Also, it is known that 
ablation of particles (especially the larger particles) is 
incomplete with the laser desorption ionization energies 
employed with the AToFMS instrument.19 However, the 
material that is ablated is generally representative of the 
materials present in the particles, so long as the materials are 
homogeneously distributed within the particles 20 
The appearance of the mass spectra acquired using the 
AToFMS instrument depends fundamentally on the ability of 
the analyte molecules, or the matrix, to absorb the laser 
energy at 266 nm and on the laser energy utilised. However, 
it has been reported that both FP and SX absorb energy only 
weakly at 266 nm in solution ;3 lactose absorbs weakly as it 
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Despite these limitations, it was possible to acquire mass 
spectra on single particles of both active pharmaceutical 
ingredients (FP and SX) that showed unique fragment ions 
that may be reasonably interpreted as being deriving from 
the parent active pharmaceutical ingredients. 
For the AToFMS instrument the laser wavelength is fixed 
but the laser energy may be varied and typical positive ion 
spectra for particles taken from standards of pure FP and SX, 
acquired at high and low energy are shown in Fig. 2. At higher 
laser energy (').8 mJ) the mass spectra show many ions at 
lower m/z values. In this case, the ions with lower m/z values 
are difficult to interpret in terms of the FP structure, probably 
because they are formed by secondary, tertiary or further 
fragmentation as the molecule is reduced to hydrocarbon 
cations of the type: C, etc.21 Moreover, 
it was found that spectra acquired at higher laser energy 
showed ions common to both FP and SX. 
At low laser energy ( .'0.2 mJ) the positive ion spectra show 
relatively few ions, many of which are unique to either FP or 
SX. The FP molecule fragments to the ion at m/z 333 by the 
concerted loss of the 17a and 1713 side chains from the D ring 
of the steroid. The ion at m/z 58 probably originates from the 
propionyl group in the 173 side chain. 
We suggest that the ion at m/z 333 then loses HF and water 
to give the ions at m/z 294 and 276, respectively. It is likely 
that these are losses involving trans- elimination of water or 
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Figure 2. Mass spectra acquired using the AToFMS instrument with positive ion detection for (a) a particle of 
FP aerodynamic size 2.09 p.m at high laser energy (0.92 mJ); (b) a particle of FP aerodynamic size 2.03 p.m at 
low laser energy (0.11 mJ); (c) a particle of SX aerodynamic size 1.80 p.m at high laser energy (0.87 mJ); and 
(d) a particle of SX aerodynamic size 0.73 p.m at low laser energy (0.11 mJ) (using nozzle- skimmer inlet). 
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Figure 3. Negative ion AToFMS spectra taken from (a) a 
particle of FP with an aerodynamic size of 1.11 µm and 
(b) a particle of SX with an aerodynamic size of 0.47 p.m, 
showing the mass spectrum for the xinofoate counter -ion 
(data collected using an aerodynamic lens inlet and a laser 
energy 0.2 mJ). 
The spectrum for SX acquired at low laser energy is 
dominated by the ion at m/z 91 due to a tropylium -type 
structure, but also shows fragment ions attributable to the 
alkyl chain and benzyl group at m/z 232 and the 
hydroxylated end of the molecule at in/z 248. 
The negative ion mass spectra obtained from FP and SX 
particles of approximately 1.2 p.m particle size, using low 
laser energy (0.2 mJ), are shown in Fig. 3. For the spectrum of 
FP (Fig. 3(a)), the loss of the SCH,F group gives the ion at 
m/z 436 and a concerted loss of the 17a and 1713 side chains 
from the D ring of the steroid givea the ion at m/z 331 which is 
analogous to what occurs in the positive ion spectrum. The 
negative ion spectrum of SX (Fig. 3(b)) is dominated by 
the ion at m/z 188 which is due to the xinofoate counter -ion 
which shows two sequential losses of water to give the ion at 
m/z 152 and a loss of carbon dioxide to give the ion at m/z 144. 
In addition to the active pharmaceutical ingredients, the 
DPI products also contain lactose, an excipient used as a 
carrier for the drug molecules. The spectra acquired for 
lactose using the AToFMS instrument were extremely weak 
in both positive and negative ion mode (presumably due to 
the lack of a strong chromophore in the lactose molecule 
capable of absorbing radiation at 266 nm), and did not 
interfere with the API mass spectra. 
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Figure 4. Typical negative ion spectra of single particles 
taken from (a) particle of mixed composition of aerodynamic 
diameter 1.2 p.m taken from a DPI (dose of FP /SX 250 ,g/ 
50 µg) and (b) particle of mixed composition of aerodynamic 
diameter 1.2 p,m taken from a pMDI (dose of FP /SX 250 µg/ 
2511,g) aerodynamic lens inlet, laser energy 0.2 mJ. Both 
spectra show fragment ions consistent with FP and SX. 
The particles taken from aerosols originating from DPI and 
pMDI inhalers gave mass spectra which showed good 
evidence for the presence of co- association because of the 
appearance of both sets of fragment ions which were 
previously assigned to either FP or SX. Typical negative 
ion mass spectra obtained from individual particles from 
both DPI and pMDI inhalers are shown in Fig. 4. It can be 
clearly seen that both spectra show ions similar to those 
seen in the spectra taken from pure standards of both FP 
and SX. 
Multivariate analysis of data acquired using 
the AToFMS instrument 
The mass spectral pattern is an important parameter in these 
experiments because it is used to categorise the chemical 
composition (speciation) of each of the particles. Thus ions in 
the mass spectral pattern, originating from the unique 
fragmentation pathways for each of the active pharmaceu- 
tical ingredients, were used to identify and categorise the 
chemical composition of any given particle. 
For a typical data set acquired using the AToFMS 
instrument, there are a large number of individual particles 
(from our work typically in the order of approximately 100 
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Figure 5. Variation in the number of fragment ions per particle for (a) FP and (b) SX (using the nozzle- skimmer 
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Figure 6. PCA charts for FP and SX to show the effect of varying the laser energy 
(LE): (a) PCA chart for the complete data set and (b-f) the PCA charts for the data 
acquired at the given laser energy ranges. This figure is available in colour online at 
www.interscience.wiley.com /journal /rcm. 
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particles per sample) and each is associated with a mass 
spectrum containing many fragment ions. For ease of 
comparison of these large, complex, datasets, multivariate 
statistical analysis in the form of principal component 
analysis (PCA) was utilised. 
The PCA model was based on the pure active pharma- 
ceutical ingredients (FP and SX), taken as reference standards 
and these were compared with samples from the inhaled 
products (pMDI and DPI). During method development the 
PCA model was assessed for robustness caused by changes 
in instrument parameters that could potentially lead to a 
change in the mass spectral fragmentation patterns. Further 
tests were performed to investigate the effect of the matrix for 
DPIs but this was found to be minimal as the lactose carrier 
gives a poor response to laser ablation and ionisation. 
Particles were categorised and counted via PCA scatter plots 
to obtain a semi -quantitative estimate of the amount of co- 
association present. 
The number of fragment ions in each mass spectrum (both 
positive and negative ion), at varying laser energy for each of 
the reference standards (FP and SX), is shown in Fig. 5. As 
expected, at lower laser energies lower numbers of fragment 
ions were observed. 
The individual data sets for each of the active pharma- 
ceutical ingredients which were acquired with the AToFMS 
instrument using the nozzle -skimmer inlet are plotted on 
the same PCA chart (Fig. 6). Each data point represents an 
individual partide and its associated mass spectrum. 
Figure 6(a) shows the entire data set generated to 
investigate the effect of varying the laser energy. The laser 
energy was increased from 0.1 mJ to 0.8 mJ and the PCA 
plots are shown in Figs 6(b) -6(e). The PCA plots show that 
the dusters attributable to either FP or SX converge with 
increasing laser energy. At high laser energy the relatively 
fragile API molecules are mainly fragmented to produce 
significantly greater numbers of lower mass ions that are 
common to both FP and SX. Hence the mass spectral 
patterns become more complex and lose their definition as 
the spectra have many more ions in common. Conversely, 
at lower laser energy there are many more unique fragment 
ions for each API and hence the PCA dusters, based on the 
mass spectral patterns, show greater separation. This 
demonstrates that the PCA model is sensitive to changes 
in the mass spectra. 
The laser energy setting of 0.2 mJ gave the most unique 
ions in the mass spectra of the standards of drug compounds. 
Hence, further data sets were acquired at this laser energy, 
using the AToFMS instrument now equipped with an 
aerodynamic lens to determine the extent of co-association in 
the pMDI and DPI samples. 
Figure 7(a) shows a PCA chart for the standards of FP 
and SX with the standard clusters defined by ellipses. 
These ellipses define an equal distance from the class 
centre using Mahalanobis22 metrics, which take into 
account how particles distribute within the plot. For 
example, because FP particles distribute mainly along the 
vertical axis, this is assumed to be characteristic of this group 
and therefore the distance along this direction is under - 
weighted, resulting in an equidistance ellipse that is tilted 
vertically. 
Copyright U 2008 John Wiley & Sons, Ltd. 
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The standard confidence ellipses have been overlaid onto 
the PCA plot for a DPI sample in Fig. 7(b). This plot shows 
that the majority of the data points for the DPI sample appear 
in the centre of the plot and are not overlaid by the standard 
ellipses, thus showing that there is a difference in the mass 
spectral patterns for these particles compared with the 
reference standards. 
To confirm that the matrix effect of the lactose carrier was 
minimal, additional experiments were performed on Flo- 
vent ® and Serevent® DPIs. The formulated product for 
Flovent® is a blend of FP and lactose and that of Serevent® is 
a blend of SX with lactose, i.e. each device contains only one 
active pharmaceutical ingredient. Approximately 80-85% of 
the PCA components for these DPI products containing a 
single API (either FP or SX) are overlaid by the correspond- 
ing ellipse for FP or SX, as in Fig. 8(a). This confirms that both 
FP and SX can be detected in the presence of lactose and that 
the matrix effect from the carrier is minimal. This is also good 
confirmatory evidence that this PCA approach is valid for 
identifying particles containing either FP or SX alone, and it 
will differentiate these particles from those containing a 
mixture of both FP and SX, i.e. that PCA identifies particles 
where co-association of these active pharmaceutical ingre- 
dients has occurred. 
The presence of co-association is thought to be derived 
from blending during the formulation process and from the 
mixing process that occurs in the aerosol plume following 
actuation. 
There are a number of limitations in using the AToFMS 
instrument for quantitation, mainly originating from shot-to- 
shot intensity differences within the laser beam,23 which can 
lead to variations in vaporisation and ionisation and thus to 
differences in the mass spectral signal intensities. 
The variations in the mass spectral fragmentation patterns 
are shown by the broad dusters on the PCA plots. Therefore, 
if the variation within each experiment is assumed to be 
addressed by the spread of these clusters, an estimate of the 
number of co- associated particles can then be obtained by 
counting the data points that are not overlaid by the reference 
standard confidence ellipses. 
The data in Fig. 8 for Flovent® and Serevent®, which 
contain only a single active pharmaceutical ingredient, 
shows that this is a reasonable model for detecting single 
particles of FP or SX within a lactose blend and, by inference, 
those PCA data points that do not fall within the standard 
confidence ellipses can be assumed to be from particles 
containing both active pharmaceutical ingredients due to co- 
association. 
The PCA model shows some sensitivity to the minimal 
amount of fragmentation used as an input parameter. 
However, whatever value is used for this parameter, the 
amount of mixed particles is always found to be greater than 
the number of particles containing a single API. The data are 
shown in Figs. 9 and 10 and use the PCA model based on a 
minimum of 20 input fragment ions, i.e. only combined 
positive and negative spectra that showed at least 20 
fragment ions were included. 
Figure 9 shows the partide counts taken from the PCA 
charts from a set of experiments performed on two strengths 
of DPI (samples 1 to 5, FP /SX 250 p.g /50 pg and samples 7 to 
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Figure 7. (a) Definition of ellipses using PCA for standards of FP and SX overlaid on the same chart. 
(b) The standard ellipses defined in (a) overlaid onto data from a sample and used to categorize the particles 
in the sample, (i.e. (b) shows data points from the sample only). Example sample shown is FP /SX 25014/ 
50µg. (file DPI 1 ). This figure is available in colour online at www.interscience.wiley.com /journal /rcm. 
1, FP /SX 5001.1,g/50 µg). For each batch the first three runs 
Tere the same sample and the last three runs were three 
ifferent batches of the same strength. Taking the above 
ssumptions into account, these data consistently show that 
t least 80% of the PCA co- ordinates in each sample originate 
om co- associated particles. 
Similarly, Fig. 10 shows the particle counts taken from 
le PCA charts from a set of experiments performed on 
Tree strengths of a pMDI product (samples 1 to 5, FP /SX 
50µg /25µg; samples 6 to 11, FP /SX 125 µg /25 µg; and 
opyright © 2008 John Wiley Sr Sons, Ltd. 
samples 11 to 15, FP /SX 50 µg /25 µg). For each batch the first 
three runs were the same sample and the last three runs were 
three different batches of the same strength of this product. 
Taking the above assumptions into account, these data 
consistently show at least 50% of the PCA co-ordinates in 
each sample originate from co-associated particles. 
The difference in co-association levels between DPIs and 
pMDIs is likely to result from the very different nature of the 
formulations and the mechanisms by which co-association may 
occur. In the pMDI, co-association is believed to occur between 
Rapid Commun. Mass Spectrom. 2008; 22: 3873 -3882 
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Figure 9. Data analysis for DPIs using PCA ellipses. DPI_1 to 5 were 25014/5014 
FP /SX, DPI_7 to 12 were 500 p.g /50 µg FP /SX. This figure is available in colour online at 
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Figure 10. Data analysis for pMDls using PCA ellipses. MDI_1 to 5 were 25014/25 p.g FP /SX, 
MDI_12 to 16 were 125 p.g /25 p.g FP /SX and MDI_17 to 21 were 50 p.g /25 p.g FP /SX. This figure is 
available in colour online at www interscience. wiley.com /journal /rcm. 
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the two types of solid particles (pure FP and SX particles) while 
still in the suspension within the inhaler.24 Furthermore, on 
actuation, it is likely that the droplets emitted from the device 
contain multiple particles of FP and of SX. When a droplet 
collapses through propellant evaporation, these particles can 
remain associated .25 Alternatively, coalescence of droplets 
within the plume could also lead to co-association. 
In DPIs co-association would arise from drug -drug 
interactions as a result of high shear forces during the 
blending process. However, lactose added to the blend as an 
excipient will both reduce the level of co-association by acting 
as a diluent and potentially increase the level of co-association 
by acting as a 'carrier' of both drug types. The dominant 
mechanisms contributing to the levels of co-association 
observed in such combination products require further study. 
CONCLUSIONS 
We have shown that it is possible to detect the active 
pharmaceutical ingredients fluticasone propionate (FP) and 
salmeterol xinofoate (SX) from inhaled drug products using 
an AToFMS instrument. The spectral fragmentation patterns 
are unique and can be recognised using principal component 
analysis (PCA). 
The combination of AToFMS and PCA is a useful approach 
for detecting co-association of different active pharmaceu- 
tical ingredients. An estimate of the number of co-associated 
particles was derived by counting the PCA co-ordinates in 
those specific areas of the PCA plots which were not overlaid 
by the reference standard active pharmaceutical ingredients 
confidence ellipses. 
Using this process it was shown that at least 80% of the 
respirable particles in a DPI product and at least 50% of the 
respirable particles in the pMDI product were comprised of 
co-associated active pharmaceutical ingredients (FP and SX). 
The data suggest that high levels of these co-associated 
particles are emitted from both DPI and pMDI products 
examined after actuation of the devices. 
A mass spectrum could not be obtained for the lactose 
carrier used in DPI products but the carrier lactose appears to 
have minimal interference with these measurements. There is 
potential for association of FP or SX (or both) with lactose and 
RCM 
future work would involve development of techniques that 
could further differentiate and spectate the partides generated. 
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